



(86) Date de dépôt PCT/PCT Filing Date: 2002/01/31
(87) Date publication PCT/PCT Publication Date: 2002/08/08
(85) Entrée phase nationale/National Entry: 2003/07/30
(86) N° demande PCT/PCT Application No.: US 2002/003077
(87) N° publication PCT/PCT Publication No.: 2002/060318
(30) Priorité/Priority: 2001/01/31 (09/775,398) US

(51) Cl.Int.⁷/Int.Cl.⁷ C07H 21/00, C12Q 1/68, C12P 19/34,
C12Q 1/25, C12Q 1/04
(71) Demandeur/Applicant:
THE OHIO STATE UNIVERSITY RESEARCH
FOUNDATION, US
(72) Inventeur/Inventor:
PLASS, CHRISTOPH, US
(74) Agent: OGILVY RENAULT

(54) Titre : DETECTION DE SEQUENCES A FORTE TENEUR EN CPG METHYLE POUR LE DIAGNOSTIC DE
CELLULES MALIGNES

(54) Title: DETECTION OF METHYLATED CPG RICH SEQUENCES DIAGNOSTIC FOR MALIGNANT CELLS

(57) **Abrégé/Abstract:**

The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differently methylated in cancer cells as compared to normal cells.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060318 A2

(51) International Patent Classification⁷: **A61B**
(21) International Application Number: PCT/US02/03077
(22) International Filing Date: 31 January 2002 (31.01.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
09/775,398 31 January 2001 (31.01.2001) US
(71) Applicant (for all designated States except US): **THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION** [US/US]; 1960 Kenny Road, Columbus, OH 43210-1036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


(72) Inventor; and
(75) Inventor/Applicant (for US only): **PLASS, Christoph** [DE/US]; 90 Winthrop Road, Columbus, OH 43214 (US).
(74) Agent: **DOCHERTY, Pamela, A.**; Calfee, Halter & Griswold LLP, 1400 McDonald Investment Center, 800 Superior Avenue, Cleveland, OH 44114 (US).

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DETECTION OF METHYLATED CPG RICH SEQUENCES DIAGNOSTIC FOR MALIGNANT CELLS

(57) Abstract: The present invention provides methods for determining the methylation status of CpG-containing dinucleotides on a genome-wide scale using infrequent cleaving, methylation sensitive restriction endonucleases and two-dimensional gel electrophoretic display of the resulting DNA fragments. Such methods can be used to diagnose cancer, classify tumors and provide prognoses for cancer patients. The present invention also provides isolated polynucleotides and oligonucleotides comprising CpG dinucleotides that are differentially methylated in malignant cells as compared to normal, non-malignant cells. Such polynucleotides and oligonucleotides are useful for diagnosis of cancer. The present invention also provides methods for identifying new DNA clones within a library that contain specific CpG dinucleotides that are differently methylated in cancer cells as compared to normal cells.



WO 02/060318 A2

Detection of Methylated CpG Rich Sequences Diagnostic for Malignant Cells

5 This invention was conducted, at least in part, with government support under National Institutes of Health Grants No: P30 CA16058 and CA80912 awarded by the National Cancer Institute. The U.S. government has certain rights in the invention.

Background of the Invention

10 Diagnosis of cancer, classification of tumors, and cancer-patient prognosis all depend on detection of properties inherent to cancer, or malignant cells, that are absent in normal, nonmalignant cells. Since cancer is largely a genetic disease, resulting from and associated with changes in the DNA of cells, one important method of diagnosis is through detection of related changes within the DNA of cancer cells. Such changes can be of two types. The first
15 type of change is a genetic change that occurs when the sequence of nucleotide bases within the DNA is changed. Base changes, deletions and insertions in the DNA are examples of such genetic changes. The second type of change in the DNA is an epigenetic change. Epigenetic changes do not result in nucleotide sequence changes, but rather, result in modification of nucleotide bases. The most common type of epigenetic change is DNA
20 methylation.

 In mammalian cells, DNA methylation consists exclusively of addition of a methyl group to the 5-carbon position of cytosine nucleotide bases. In the process, cytosine is changed to 5-methylcytosine. Cellular enzymes carry out the methylation events. Only cytosines located 5' to guanosines in CpG dinucleotides are methylated by the enzymes in
25 mammalian cells. Such CpG dinucleotides are not distributed randomly throughout the genome. Instead, there are regions of mammalian genomes which contain many CpG dinucleotides, while other areas of the genome contain few CpG dinucleotides. Such CpG-rich areas of the genome are called "CpG islands." Most often, CpG islands are located in the transcriptional promoter regions of genes.

30 Not all CpG islands are methylated. However, the methylation status of CpG islands (i.e., whether the CpG dinucleotides within a particular CpG island are methylated or not) is relatively constant in cells. Nevertheless, the pattern of CpG island methylation can change and, when it does, often a new, relatively stable methylation pattern is established. Such changes in methylation of CpG islands can be either increases or decreases in methylation.

Methylation of CpG islands in the promoter region of a few specific genes has been observed in some types of human cancer. However, at present it is still uncertain whether the methylation status of multiple CpG islands in the genomic DNA of subjects suspected of having cancer can be used as a diagnostic tool for determining whether or not tissue obtained from such subjects contain malignant cells.

Summary Of The Invention

The present invention relates to methods for identifying CpG islands which are diagnostic of one or more cancers in a subject. The method employs restriction landmark genomic scanning (RLGS) techniques and comprises separately digesting genomic DNA which has been obtained from malignant cells derived from a particular tumor tissue and genomic DNA which has been obtained from control cells derived from healthy tissue with an infrequently cutting restriction enzyme that is not capable of cleaving methylated recognition sites to provide a first set of DNA restriction fragments from the tumor tissue, referred to hereinafter as "malignant cell restriction fragments", and a first set of DNA restriction fragments from the healthy tissue, referred to hereinafter as "control cell restriction fragments"; attaching a detectable label to the ends of the malignant and control cell restriction fragments; digesting the labeled malignant and control cell restriction fragments with a second restriction enzyme; separating each set of restriction fragments on a gel; digesting the restriction fragments in each of the gels with a third more frequently cutting restriction enzyme; electrophoresing each set of restriction fragments in a direction perpendicular to the first direction to provide a first pattern of detectable malignant cell restriction fragments and a second pattern of detectable control cell restriction fragments; and comparing the second pattern to the first pattern to identify control cell restriction fragments, hereinafter referred to as "diagnostic fragments", which are absent, or exhibit an decreased intensity of label in the first pattern. Such fragments comprise CpG islands that are methylated in the malignant cells. Such patterns are useful for characterizing tissue which is suspected of containing malignant cells. Preferably, each of the diagnostic fragments is then isolated and sequenced, at least in part. In one preferred embodiment, the first restriction enzyme is NotI. In another preferred embodiment, the first restriction enzyme is AscI. Advantageously, the present method permits the detection of numerous methylation sites within the entire genome. In accordance with the present method, applicants have determined that particular CpG islands are preferentially methylated in DNA obtained from tumor tissues of subjects diagnosed as having breast cancer, glioma, acute myeloid leukemia,

primitive neuroectodermal tumors of childhood, colon cancer, head and neck cancer, testicular cancer, and lung cancer.

The present invention also provides isolated polynucleotides, referred to hereinafter as “CpG diagnostic polynucleotides”, and isolated oligonucleotides referred to hereinafter as “CpG diagnostic oligonucleotides”, which are useful for characterizing tissue samples obtained from a subject suspected of having gliomas, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, or cancer of the breast, colon, head and neck, testicle or lung. The CpG diagnostic polynucleotides and oligonucleotides both comprise a sequence which contains CpG islands that have been shown to be preferentially methylated in DNA that has been obtained from malignant cells of subjects diagnosed as having breast cancer, glioma, acute myeloid leukemia, primitive neuroectodermal tumor of childhood, colon cancer, head and neck cancer, testicular cancer or lung cancer. The CpG diagnostic polynucleotides are from 35 to 3000, preferably, 35 to 100 nucleotides in length, and comprise from 15 to 34, preferably 18 to 25 of the consecutive nucleotides contained within the sequences depicted in the accompanying DNA sequence listing, or sequences which are complementary thereto. The CpG diagnostic polynucleotides comprise two or, preferably, more CpG dinucleotides or dinucleotides which are complementary thereto. The CpG diagnostic oligonucleotides are from 15 to 34 nucleotides in length and comprise from 15 to 34 consecutive nucleotides contained within the sequences depicted in the sequence listing, or sequences which are complementary thereto. The CpG oligonucleotides comprises two or more CpG dinucleotides, or dinucleotides which are complementary thereto.

The present invention also relates to methods which employ the CpG diagnostic polynucleotides and oligonucleotides of the present invention to characterize tissue from patients suspected of having cancer. Such methods are based on the methylation status of CpG islands that have been shown to be preferentially methylated in DNA that has been obtained from tumor tissues of subjects diagnosed as having breast cancer, glioma, acute myeloid leukemia, primitive neuroectodermal tumor of childhood, colon cancer, head and neck cancer, testicular cancer and lung cancer. In one method, DNA which is isolated from suspected tumor tissue from a subject is digested into smaller fragments and reacted with a CpG diagnostic polynucleotide under stringent hybridization conditions. The reaction products are then assayed to determine the size or the sequence of the DNA fragment with which the CpG diagnostic polynucleotide has hybridized. The size or the sequence of the DNA fragment to which the CpG diagnostic polynucleotide has hybridized, hereinafter referred to as the “target DNA fragment”, indicates whether the target DNA fragment

comprises methylated or non-methylated CpG islands. The presence of methylated CpG islands in the target DNA fragment indicates that the DNA has been obtained from a tumor or neoplasm for which the diagnostic CpG polynucleotide serves as a diagnostic marker.

5 In another method the DNA from the suspected tumor tissue is treated with a chemical compound which converts non-methylated cytosines to a different nucleotide base. An example of such a compound is sodium bisulfite which converts non-methylated cytosines to uracil. The DNA is then reacted with at CpG diagnostic oligonucleotides under conditions which permit the CpG diagnostic oligonucleotide to hybridize with a complementary sequence in the DNA, referred to hereinafter as the "target sequence". The
10 DNA is also reacted with a modified CpG diagnostic oligonucleotide. The modified CpG diagnostic oligonucleotide comprises a sequence that is complementary to a modified target sequence, i.e., a sequence in which the non-methylated cytosines in the target sequence are converted to a different nucleotide base, e.g. uracil, when treated with a chemical compound. The reaction products are then assayed to determine whether the DNA contains sequences
15 which have hybridized with the CpG diagnostic oligonucleotide or with the modified CpG diagnostic oligonucleotide. Hybridization of the sample DNA with the CpG diagnostic oligonucleotide, as opposed to the modified CpG diagnostic oligonucleotide, indicates that the cytosines in the target sequence are methylated and that the DNA sample has been obtained from a tumor or neoplasm for which the CpG oligonucleotide has been shown to
20 serve as a diagnostic marker.

The present invention also relates to a method of identifying genes whose expression is increased or decreased in cancer cells.

Brief Description of the Figures

25 Fig. 1. Methylation detection in restriction landmark genomic scanning (RLGS) profiles. A, Diagram of the RLGS procedure showing the quantitative nature of methylation detection on NotI fragments displayed on RLGS profiles. Methylation detection in RLGS profiles depends on the methylation sensitivity of the endonuclease activity of NotI. Differences in digestion are assessed by radiolabelling the DNA at cleaved NotI sites. Following further
30 endonuclease digestion, two-dimensional electrophoretic separation and autoradiography, the intensity of a DNA fragment on the resultant RLGS profile quantitatively reflects the copy number and methylation status of the NotI fragment. A priori, this allows NotI fragments containing single-copy CpG islands to be distinguished from the abundant NotI fragments present in repeat elements and rDNA sequences. B, A portion of an RLGS profile from

normal peripheral blood lymphocyte DNA displaying nearly 2,000 single-copy NotI fragments and 15-20 high copy-number fragments. First-dimension separation of labeled NotI/EcoRV fragments extends from right to left horizontally. Following in-gel digestion with HinfI, the fragments are separated vertically downward into a polyacrylamide gel and autoradiographed. To allow uniform comparisons of RLGS profiles from different samples and different laboratories, each fragment is given a three-variable designation (Y coordinate, X coordinate, fragment number). The central region of the RLGS profile used for all comparisons described in this invention has 28 sections (1-5 vertically and B-G horizontally; the 4G and 5G sections were excluded due to high density and lower resolution of fragments). C, Enlarged view of profile section 2D, showing the numbers assigned to each NotI fragment. D, Analysis of the GC content and CpG ratio $\{(\text{number of CpGs})/(\text{number of guanines})(\text{number of cytosines})\}(\text{number of nucleotides analyzed})$ of 210 non-redundant NotI/EcoRV clones containing the NotI/HinfI fragments seen in B and in other portions of the RLGS profile. Of 210 clones, 184 clones were randomly chosen and 26 corresponded to fragments which were frequently lost from tumor profiles. CpG islands have a GC content of greater than 50% and a CpG value of 0.6 or greater, relative to bulk DNA (average CG content of 40% and CpG ratio of 0.2). Nucleotide sequences were determined with greater than 99% accuracy overall. An average of 377nt/clone were analyzed (not indicative of actual CpG island size). The average NotI/EcoRV clone size was approximately 2 kb.

20

Fig. 2. Fragment loss from RLGS profiles is due to methylation. Top, portions of the RLGS profiles obtained from normal tissue and from two tumors having NotI fragments with either decreased intensity or no change in intensity. Bottom, Southern-blot analysis of EcoRV (NotI: -) and EcoRV/NotI (NotI: +) restriction digested DNAs from a larger number of samples, including the samples at top. In samples without methylation in the NotI site, the probe detects a smaller fragment on double digestion with NotI and EcoRV. The quantitation from multiple Southern blots using a phosphorimager allowed the determination of a lower limit of reliable detection in RLGS profiles of 30% decreased intensity of the diploid NotI/EcoRV fragments. Presence (+) or absence (-) of the corresponding NotI fragment is indicated. N, normal tissue DNA; T, tumor tissue DNA. A, CpG-island locus 3C1 methylation in low-grade gliomas. B, CpG island locus 2C40 methylation in leukemias. C, CpG-island locus 3E24 methylation in PNETs of childhood. *, EcoRV fragment of approximately 13 kb with homology to the probe. BLAST searches using the NotI-EcoRV clone sequence identified a homologous BAC clone sequence lacking an internal NotI site,

30

which accounts for the 13-kb fragment on the Southern blot.

Fig. 3. Heterogeneity in CpG-island methylation across tumors. RLGS profiles were generated from 98 primary human tumors and compared with profiles of either matched
 5 normal DNA (58 of 98 cases) or to multiple profiles of tissue type-matched normal DNA from unrelated individuals. Loss or decreased intensity of single-copy fragments in the tumors, relative to several neighboring unaltered NotI fragments, were detected by visual inspection of overlaid autoradiographs and confirmed in many cases by independent profiles of the same DNA samples. For each tumor type, the dot plots display the total number of
 10 methylated CpG islands (of 1,184 CpG islands analyzed) observed in each tumor. Under the assumption that the tumors are drawn from a homogeneous distribution, with all tumors having the same frequency of methylation, the loss distributions should be approximately Poisson. The colored curve represents the expected distribution. BRE, breast tumors; CLN, colon tumors; GLI, gliomas; HN, head and neck tumors; LEU, acute myeloid leukemias;
 15 PNET, primitive neuroectodermal tumors of childhood; TST, testicular tumors.

Fig. 4. Subsets of CpG islands are preferentially methylated. For each tumor type, the histograms display the number of tumors in which the particular CpG islands were methylated. Most of the 1,184 CpG islands were not methylated in any of the tumors
 20 (histogram bar at 0 is not shown), but several CpG islands were methylated in multiple tumors. The black line shows the expected distribution under the null hypothesis that the CpG islands have equal frequencies of methylation. Most of the tumor types show significant preferential methylation.

25 Detailed Description Of The Invention

In one aspect, the present invention relates to methods for identifying clones within a DNA library that can be used for cancer diagnosis and tumor classification, based on the methylation status of CpG dinucleotides contained within or closely adjacent to the specific clones. Such method employs methylation-sensitive restriction endonucleases (MSREs) and
 30 restriction landmark genomic scanning (RLGS) gels to identify new, differentially-methylated CpG islands within malignant cells obtained from patients diagnosed as having cancer. In accordance with the present invention, Applicants have identified 93 clones which can be used to determine whether a tumor biopsy from a patient contains benign or malignant cells.

To carry out such method, tissue (referred to hereinafter as "tumor tissue") which contains a tumor or neoplasm is obtained from a patient known to have a cancer. In some cases, the tumor tissue is obtained from a particular type of solid tumor which has been surgically removed from the patient. In some cases, the tumor tissue is obtained from the hematopoietic system, such as for example, bone marrow or blood, of the patient. The tumor tissue will have been determined to be from either a benign or malignant tumor or neoplasm.

Separately, tissue (referred to hereinafter as "healthy tissue") which does not contain a tumor or neoplasm is obtained from a subject. The healthy tissue, may be obtained by surgically removing normal tissue from the patient or by surgically removing normal tissue from a healthy control subject who does not have cancer. The healthy tissue may also come from the hematopoietic system, such as for example, bone marrow or blood, of a healthy control subject. The healthy tissue will have been determined to be non-tumorigenic or non-neoplastic.

DNA is then isolated from both the tumor tissue and healthy tissue. If the tumor tissue is a solid tissue sample, such procedure may first comprise separating the individual cells contained within the tissue from each other. For example, if the tissue samples were frozen after surgical removal from a patient, cells may be separated from one another by grinding the frozen tissue with a mortar and pestle. DNA is then isolated from the individual cells using procedures well known to those skilled in the art. Commonly, such DNA isolation procedures comprise lysis of the individual cells using detergents, for example. After cell lysis, proteins are commonly removed from the DNA using various proteases. The DNA is then commonly extracted with phenol, precipitated in alcohol and dissolved in an aqueous solution.

In the procedures which follow, the DNA obtained from the tumor tissue is treated separately from the DNA obtained from healthy tissue (i.e., the two DNAs are not mixed). The DNAs are separately analyzed using a method called restriction landmark genomic scanning (RLGS). The purpose is to analyze both DNAs separately. The two analyses are then compared in order to identify CpG islands that distinguish cancer cells from normal cells.

Both DNA samples are treated with restriction enzymes and the free ends that result from the restriction enzyme cleavage are labeled. However, since the isolated DNA is in linear pieces, there are free ends that exist before the DNA is cleaved with the restriction enzymes. To prevent these ends from being labeled, the ends, preferably, are blocked before restriction enzyme treatment. Such blocking can be done by addition of dideoxynucleotides

and sulfur-substituted nucleotides to the free ends before treatment with restriction enzymes. Subsequently, when the DNA is cleaved by restriction enzymes and labeled, only the ends resulting from the restriction enzyme cleavage will be labeled.

After the reaction to block free ends, the DNA samples are cleaved with a first
5 restriction enzyme that can be characterized as an infrequently cleaving, methylation-sensitive restriction enzyme. Examples of suitable first restriction enzymes are NotI, AscI, BssHII and EagI. As used herein the term "infrequently cleaving" refers to a restriction enzyme that is expected to cleave genomic DNA at intervals greater than 10 kilobases. For example, NotI is an infrequently cleaving restriction enzyme. NotI recognizes a nucleotide
10 sequence of 8 base pairs (bp) in the genome (i.e., 5'GCGGCCGC3') and cleaves the DNA at this site. There are an estimated 4000-5000 of such NotI recognition sequences within the human genome. It is estimated that such recognition sequences are spaced at approximately 1 megabase (Mb) intervals within the genome. In contrast, a frequently cleaving restriction enzyme is expected to cleave the human genome at from 5-10 kb intervals. Such an enzyme
15 will have approximately 100-times more cleavage sites within the human genome than infrequently-cleaving enzymes. Such frequently cleaving enzymes usually recognize a nucleotide sequence of less than 8 bp in the genome and cleave the DNA at that site. However, not all restriction enzymes that have nucleotide recognition sequences of less than 8 bp are frequently cleaving enzymes. BssHII and EagI both have 6 bp recognition
20 sequences but the recognition sequences for these two enzymes are spaced at intervals within the genome that are greater than 10 kb. "Methylation sensitive" as used herein refers to any enzyme that is unable to cleave DNA at its normal restriction site if one or more nucleotides within the recognition sequence is methylated. For example, the restriction enzyme NotI will cleave the 5'GCGGCCGC3' recognition sequence if the sequence does not contain a 5-
25 methylcytosine. However, the NotI enzyme will not cleave this sequence if any of the cytosines have been methylated to become 5-methylcytosine.

Following digestion of the DNA with the first restriction enzyme, the ends of the DNA fragments are labeled. This can be done, for example, by attachment of nucleotides carrying a detectable label, such as a radiolabel, to the ends of the DNA sample. Typically,
30 attachment is accomplished by filling in the recessed DNA ends left by cleavage with the first restriction enzyme such that the ends become blunt (i.e., non-recessed). Such end-filling reaction may employ deoxynucleoside triphosphates having a radiolabeled phosphate at the α phosphate position. Such labeled phosphate is preferably ^{32}P .

The labeled fragments from each sample are then cleaved with a second restriction

enzyme. Such second restriction enzyme preferably cleaves human DNA at average intervals of between 5-10 kb. Such enzymes normally have a 6 bp recognition sequence. Preferably, the second restriction enzyme is not methylation sensitive. Examples of suitable second restriction enzymes are PstI, PvuI, EcoRV or BamHI. Cleavage of the DNA fragments with the second restriction enzyme provides a second set of fragments, labeled at the ends left by cleavage with the first enzyme. Many of such second fragments are smaller than the fragments resulting from cleavage with the first restriction enzyme.

The DNA fragments are then separated from one another. Preferably this separation is based on size. Preferably this separation is performed by first-dimension electrophoresis through an agarose tube-shaped gel of approximately 60 cm in length.

After electrophoresis through the tube-shaped gel, the DNA is digested within the gel with a third restriction enzyme.¹ Such third restriction enzymes preferably have recognition sequences of 4 or 6 bp. Such third restriction enzymes also have the property of being able to cleave DNA which is embedded within agarose. One such enzyme is HinfI.

After cleavage by the third restriction enzyme, the DNA is again separated based on size, preferably by electrophoresis through a polyacrylamide gel. Subsequently, the separated DNA fragments are detected based on the labeled ends of the DNA fragments. In those cases where the fragments are radiolabeled, detection is by autoradiography of the two-dimensional gel. Such autoradiography provides a pattern of DNA fragments or "spots." Such pattern is called an RLGS profile.

Each fragment on the RLGS profile obtained from using the DNA from healthy tissues is uniquely identified by its location on the autoradiograph (Y coordinate, X coordinate, fragment number). For each fragment location on the RLGS profile obtained from healthy tissue DNA, the identical location is observed on the RLGS profile obtained from tumor tissue DNA.

In a fragment by fragment comparison of RLGS profiles obtained from tumor tissue DNA with healthy tissue DNA, three different patterns are possible. First, for a given fragment on the healthy tissue RLGS profile, there may be a corresponding fragment at the same location, and of the same intensity, on the tumor tissue RLGS profile. This indicates that the first restriction enzyme cleaved both DNAs at the same sequences (Fig. 1A). This indicates that there were no differences in methylation of the NotI nucleotide recognition sequence of that fragment between the tumor tissue DNA and the healthy tissue DNA.

Second, for a given fragment on the healthy tissue RLGS profile, there may be no fragment at the same location on the tumor tissue RLGS profile. Such a pattern indicates that

the first restriction enzyme did not cleave the tumor tissue DNA at the recognition sequence required to produce that specific fragment, but did cleave at such sequence within the healthy tissue DNA (Fig. 1A). This indicates that there was methylation within the NotI recognition sequence in the tumor tissue DNA but not in the healthy tissue DNA.

5 Third, for a given fragment on the healthy tissue RLGS profile, there may be a corresponding fragment at the same location on the tumor tissue RLGS profile, but the intensity of the fragment may be of decreased intensity. Such a pattern indicates that the first restriction enzyme cleaved one of two copies (i.e., the genome is diploid) of the tumor tissue DNA at the recognition sequence required to produce that specific fragment (Fig. 1A). In
10 healthy tissue DNA, the first restriction enzyme cleaved both copies of the recognition sequence. This indicates that there was methylation within one of two NotI recognition sequences in the tumor tissue DNA.

Through comparisons of RLGS profiles obtained from healthy tissue DNA with profiles obtained from a large number of different tumor tissue DNAs, loss of specific
15 fragments in multiple tumors can be associated with a specific type of cancer. Loss of such fragments from RLGS profiles, therefore, can be diagnostic for cancer in a subject. For example, loss of a specific fragment (i.e., methylation of the first restriction enzyme site at the end of said fragment) in a high percentage of tumor tissue DNAs from women known to have breast cancer can be diagnostic for breast cancer in subjects suspected of having the
20 disease. To perform such a diagnostic analysis, DNA isolated from a patient suspected of having breast cancer would be analyzed by RLGS, as described above, to determine whether there was loss of one or more fragments in RLGS profiles that are known to be lost at high frequency in women known to have breast cancer. Similarly, loss of other specific fragments can be diagnostic for other cancers, such as for example, colon cancer, head and neck cancer,
25 lung cancer, testicular cancer, neuroectodermal cancer, gliomas, acute myeloid leukemias, and others.

Loss of a specific fragment in RLGS profiles from multiple tumors can also be diagnostic of several types of cancer, rather than a single type of cancer. For example, loss of a specific fragment can occur in a high percentage of tumor tissue DNAs obtained from
30 individuals with either breast, colon or lung cancer. Loss of such a spot from RLGS profiles using DNA obtained from a patient suspected of having cancer would be diagnostic for either breast, colon or lung cancer in that patient.

Isolated Polynucleotides and Oligonucleotides Diagnostic for Cancer

Individual DNA clones that contain the DNA present in each spot or fragment that

makes up an RLGS profile can be obtained. This is done by constructing a DNA library of healthy tissue DNA that has been cleaved with the same first and second enzymes used to perform the RLGS gel analysis. Such DNA library will contain individual clones, each clone comprising DNA that is present in a single spot of the RLGS profile. The totality of clones within the library is representative of the combined DNA spots in the RLGS profile.

Individual clones within the library can be identified that contain the DNA of each spot on the RLGS profile. This can be done by taking DNA from one or a few individual clones of the DNA library and mixing it with healthy tissue DNA, before RLGS analysis is begun. When this mixture of DNAs is used to produce an RLGS profile, the intensity of the spots that contain the same DNA as the individual clones added to the mixture will be increased. By performing multiple analyses of this type, each spot on an RLGS profile can be matched up with a DNA clone within the library. The result of such an analysis is an ordered human genomic library of restriction fragments containing the same subset of genomic fragments as those displayed on RLGS profiles. In such ordered genomic libraries, an individual library clone corresponding to any spot or fragment in an RLGS profile can be rapidly located.

To design diagnostic CpG polynucleotides and oligonucleotides, the sequence of the DNA within each clone (referred to hereinafter as a "diagnostic clone") that corresponds to a spot that is absent or exhibits decreased intensity on the RLGS profile of the DNA from malignant tumor tissue is sequenced using standard techniques. Once sequence information is obtained, regions comprising multiple CpG dinucleotides are located. Such regions serve as the target sequence for the CpG polynucleotides and oligonucleotides.

The CpG polynucleotides are from 35 to 3000 , preferably from 35 to 1500 nucleotides in length and comprise two or, preferably, more CpG dinucleotides or dinucleotides which are complementary thereto. The CpG diagnostic oligonucleotides are from 15 to 34 nucleotides, preferably from 18 to 25 nucleotides, in length and comprise at least two CpG dinucleotides or dinucleotides which are complementary thereto. The CpG diagnostic polynucleotides and oligonucleotides each comprise a sequence which is substantially complementary to target sequences containing CpG islands that are known to be preferentially methylated in the DNA from one or more types of cancer cells. "Substantially complementary" means that there is enough complementarity between the CpG diagnostic polynucleotides or oligonucleotides and the target sequence so that hybridization occurs between the CpG diagnostic polynucleotides and oligonucleotides under stringent conditions, preferably under highly stringent conditions. Such assays include hybridization assays, such as for example Southern

analysis, where the sample DNA is reacted with the CpG diagnostic polynucleotide under stringent hybridization conditions.

The term "stringent conditions, as used herein, is the "stringency" which occurs within a range from about $T_m - 5$ (5 below the melting temperature of the probe) to about 20 C below T_m . "Highly Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.2x SSC at about 65 degree C. As recognized in the art, stringency conditions can be attained by varying a number of factors such as the length and nature, i.e., DNA or RNA, of the probe; the length and nature of the target sequence, the concentration of the salts and other components, such as formamide, dextran sulfate, and polyethylene glycol, of the hybridization solution. All of these factors may be varied to generate conditions of stringency which are equivalent to the conditions listed above.

Changes in the stringency of hybridization and signal detection are primarily accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lower stringency); salt conditions, or temperature. For example, moderately high stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2 M NaH_2PO_4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

Such assays also include polymerase chain reactions (PCR) where the sample DNA and the diagnostic CpG oligonucleotides are reacted, preferably under conditions which result in the synthesis of a single PCR product. Computer programs, such as for example, the "Primer3" program that can be accessed at "<http://genome.wi.mit.edu/cgi->

bin/primer/primer_3www.cgi" can be used to determine the size and sequence of the CpG diagnostic oligonucleotides. Optimum conditions are determined empirically.

The CpG diagnostic polynucleotides and oligonucleotides are made using standard techniques. For example, these polynucleotides and oligonucleotides may be made using
5 commercially available synthesizers.

Diagnostic Methods

In another aspect, the present invention relates to methods which use the CpG diagnostic polynucleotides and oligonucleotides to characterize tissue samples from a subject suspected of having cancer, referred to hereinafter as test sample DNA. To do this, DNA is
10 isolated from the cells of the tissue sample of the patient. Preferably, DNA that serves as a control is also obtained from healthy tissue of the test subject or a control subject as described previously. The diagnostic methods comprise reacting the test sample DNA with the diagnostic CpG polynucleotide or oligonucleotide and assaying the products that are formed as the result of the reaction. In some cases, the sample DNA is digested into smaller
15 fragments prior to reaction with the CpG diagnostic polynucleotides or oligonucleotides. In some cases, a portion of the test sample DNA is first reacted with a chemical compound, such as for example sodium bisulfite, which converts methylated cytosines to a different nucleotide base.

Southern Blot Analysis

One such method for diagnosing cancer in a patient involves cleavage of the test
20 sample DNA with a methylation sensitive enzyme, then Southern blot analysis of said cleaved DNA using a CpG diagnostic polynucleotide or oligonucleotide as a probe. For example, the DNA from the patient and the control, healthy tissue DNA are separately cleaved with a methylation-sensitive restriction endonuclease, such nuclease being the same
25 first restriction enzyme used to identify the diagnostic spot in the RLGS profile that corresponds to the CpG diagnostic polynucleotide or oligonucleotide. After cleavage, the test sample and control DNAs are electrophoretically separated by size in different lanes of the same agarose gel and blotted to a membrane that can be used in hybridization, such as for example, nitrocellulose or nylon. The membrane is then used in a hybridization reaction with
30 a labeled CpG diagnostic polynucleotide or oligonucleotide. The labeled CpG diagnostic polynucleotide or oligonucleotide will hybridize to complementary DNA sequences on the membrane. After hybridization, the location on the membrane where the probe hybridized to the control and patient DNAs is visualized. Such locations will identify DNA fragments or bands within the control and patient DNAs containing the same sequence as the CpG

diagnostic polynucleotide or oligonucleotide. Hybridization of the probe to a fragment within the patient DNA that is of higher molecular weight than that of the fragment within the control DNA to which the probe hybridized, indicates that a restriction endonuclease cleavage site flanking the target sequence of the CpG diagnostic polynucleotide or oligonucleotide was not cleaved due to methylation. Such result indicates that the tissue is from a cancer for which the CpG diagnostic polynucleotide or oligonucleotide serves as a diagnostic tool.

A second method for diagnosing cancer in a patient involves cleavage of patient DNA with a methylation-sensitive restriction endonuclease, such nuclease being the same first restriction enzyme used to identify the diagnostic spot in the RLGS profile that corresponds to the fragment. Such nuclease will cleave the patient DNA at the diagnostic recognition sequence only if the DNA is unmethylated. Using nucleotide information derived from sequencing of the library clone corresponding to the diagnostic spot on the RLGS gel, primers for PCR are selected that span the diagnostic recognition sequence. Using the primers, PCR is performed on the DNA. PCR amplification of the sequences will be successful only if the diagnostic nucleotide sequence in the patient DNA had been methylated and was not cleaved by the enzyme. Successful PCR amplification, therefore, is indicative of cancer in the patient.

Methods Employing a Chemically-Modified DNA Test Sample

Another group of methods for diagnosing cancer in a patient using CpG diagnostic polynucleotides and oligonucleotides are based on treatment of patient DNA with sodium bisulfite which converts all cytosines, but not methylated cytosines, to uracil. The bisulfite converted patient DNA can then be analyzed in a number of different ways. One method of analysis is direct sequencing of the DNA to determine whether the sequence contains cytosine or uracil. Such DNA sequencing requires primers adjacent to the sequenced region to be made. Such primers would be based on DNA sequence information obtained from the diagnostic RLGS spots.

Another method of analyzing bisulfite converted patient DNA is a method called "methylation sensitive PCR" (MSR). In MSR, primers are designed to comprise a sequence which is substantially complementary to the CpG islands which are known to be preferentially methylated in DNA of cells found in one or more type of tumor tissues. Two sets of PCR primers are made to encompass this region. One set of primers is designed to be complementary to the sequence that was changed by bisulfite (i.e., cytosines that were originally unmethylated and changed to uracil). As discussed above, these are the modified

CpG diagnostic oligonucleotides. A second set of primers is designed to be complementary to the same sequence that was not changed by bisulfite (i.e., cytosines that were methylated and not changed to uracil). As discussed above these are the unmodified CpG diagnostic oligonucleotides, i.e the oligonucleotides which contain at least two CpG dinucleotides or
5 dinucleotides which are complementary thereto. Two sets of PCR reactions are then run, one reaction with each set of primers, using DNA from the subject as the template. In the case where cytosines within the target sequence of the subject DNA are not methylated, the target sequence will be modified by the chemical reaction and the primers complementary to the modified sequence, i.e., the modified CpG diagnostic oligonucleotides, will produce a PCR
10 reaction product while the primers complementary to the methylated sequence, i.e., the unmodified CpG diagnostic oligonucleotides, will not produce a PCR product. In the case where cytosines within the target sequence of the subject DNA are methylated, the target sequence will not be altered by the reaction with the sodium bisulfite, and the primers complementary to the unaltered sequence, i.e., the unmodified CpG diagnostic
15 oligonucleotides, will produce a PCR reaction product while the modified CpG diagnostic oligonucleotides, which are complementary to the modified target sequence (i.e., unmethylated sequence) will not produce a PCR product

A modification of MSR is bisulfite treatment of patient DNA and PCR amplification of said DNA using primers designed to amplify either methylated or unmethylated sequences.
20 The PCR product is then digested with a restriction enzyme that will cleave or not depending on whether said product contains uracil (rather, thymidine, the complement of uracil; found in PCR product if original patient DNA contained unmethylated cytosine) or cytosine (found in PCR product if original patient DNA contained methylated cytosine).

Another technique referred to as MS-SnuPE, uses bisulfite/PCR followed by primer
25 extension, where incorporation of C (vs. T) denotes methylation.

Methods of Identifying Genes

In another aspect of the invention, the CpG diagnostic polynucleotides and oligonucleotides can be used as probes to identify genes whose expression is increased or
30 decreased in cancerous tissues. To do this, CpG diagnostic polynucleotides are reacted with individual clones of the DNA library. The clones which hybridize with the CpG diagnostic polynucleotide can then be analyzed to determine if they contain an open reading frame that could encode proteins. To determine if the CpG diagnostic polynucleotide hybridizes with the promoter region of a known gene, the open reading frame sequence is analyzed by

searching existing DNA databases. For example, GenBank databases can be searched using the BLAST algorithm. If no known genes that correspond to a library clone is found, the sequence can be searched for open reading frames that could encode a protein. Such searching can be performed using commercially available sequence analysis programs
5 commonly known to those skilled in the art. GCG is an example of one such program.

Sequences from clones of the DNA library that contain either known genes or open reading frames can be used as probes to determine whether genes encoded by the sequences are expressed in tumor tissues as compared to control, healthy tissues. To do this, RNA, preferably messenger RNA (mRNA) is isolated from healthy tissue and from tumor tissue
10 from which it is desired to test expression. Such RNA is examined for the presence of expressed transcripts encoded by the sequences obtained from the library. Examination for the presence of expressed transcripts can be performed using a number of methods. One method is Northern blotting where the isolated RNA is separated by size using gel electrophoresis and then blotted to a hybridization membrane. A fragment, polynucleotide or
15 oligonucleotide from the sequence obtained from a library clone is labeled and then used to probe the hybridization membrane containing the size-separated RNA. Detection of hybridization of the probe to the membrane indicates presence of a transcript encoded by the sequence and indicates expression of the gene encoded by that sequence.

Another method to examine isolated RNA for the presence of expressed transcripts is
20 to use RT-PCR analysis. In such analysis, primers are designed and made that span a region of the gene whose expression is to be tested. The isolated RNA is reverse transcribed into DNA using reverse transcriptase. Such DNA is then amplified with the designed primers using PCR. PCR products are visualized after electrophoresis. The presence of PCR products on the gel indicates that the gene encompassed by the designed primers was
25 expressing RNA transcripts. Such analysis can identify and determine genes whose expression is changed in cancer cells as compared to normal, non-cancerous cells.

The following examples are for purposes of illustration only and are not intended to limit the scope of the invention as defined in the claims which are appended hereto.

30

Examples

Example 1. Identification of diagnostic markers using NotI and RLGSA. Isolation and enzymatic processing of genomic DNA

Tissue from solid tumors was obtained as surgical tissue samples. Where possible, surrounding non-tumor tissue was taken and used as a control. Where it was not possible to obtain patient-matched normal tissue, normal tissue from multiple patients was used. Tissue samples from patients with acute myelogenous leukemias (AML) consisted of either bone marrow aspirates or peripheral blood. Normal samples were obtained from the same patients who were in remission after chemotherapy.

The surgically removed tissues were quickly frozen in liquid nitrogen and stored at -80°C prior to isolation of DNA. When DNA was ready to be isolated, 2 ml of lysis buffer (10 mM Tris, pH 8.0; 150 mM EDTA, 1% sarkosyl) was added to 100-300 mg of tissue in a 50 ml Falcon tube and frozen in liquid nitrogen. The frozen mixture was then removed from the tube, wrapped in aluminum foil, and quickly broken into pieces with a hammer. The broken pieces of cells were transferred to a chilled mortar and ground to a powder with a chilled pestle. For peripheral blood samples, cells were separated on a sterile Histopaque-1077 (SIGMA) gradient and stored at -80°C before DNA isolation.

Cells were transferred to a 50 ml tube and 15-25 ml of lysis buffer containing 0.1 mg proteinase K per ml of lysis buffer was added and mixed using a glass rod. The mixture was incubated at 55°C for 20 min with gentle mixing every 5 min. The mixture was then placed on ice for 10 min. Subsequently, an equal volume of PCI (phenol:chloroform:isoamylalcohol in a ratio of 50:49:1) was added and the tubes containing the mixture were gently rotated for 30-60 min. The tubes were then centrifuged for 30 min at 2500 rpm and the separated, aqueous phase was transferred to a new 50 ml tube using a wide-bore pipette. The PCI extraction was repeated one time. The collected aqueous phase containing the DNA was transferred to dialysis tubing and dialyzed against 4 L of 10 mM Tris, pH 8 for 2 hr. The dialysis tubing was then transferred into fresh 10 mM Tris and dialyzed overnight at room temperature. One additional dialysis was performed in fresh 10 mM Tris for an additional 2 hr. The DNA was then transferred from the dialysis tubing to 50 ml tubes and RNase A was added to a final concentration of 1 µg/ml. The mixture was incubated at 37°C for 2 hr. Subsequently, 2.5 volumes of 100% ethanol were added to the DNA and the mixture was gently rotated. The insoluble DNA was transferred to a microfuge tube, centrifuged briefly, and the remaining alcohol removed. The pellet was briefly dried in air. The DNA in the pellet was resuspended to a final concentration of 1 µg/µl. Such isolated DNA had an

average size of 200-300 kb.

The isolated genomic DNA was blocked at ends where the DNA had been sheared. Blocking was done by addition of dideoxynucleotides and sulfur-substituted nucleotides. In a 1.5 ml tube, 7 μ l of genomic DNA solution was added along with 2.5 μ l of blocking buffer (1 μ l 10X buffer 1, 0.1 μ l 1 M DTT, 0.4 μ l each of 10 μ M dGTP α S, 10 μ M ddATP, 10 μ M ddTTP, and 0.2 μ l 10 μ M dCTP α S; buffer 1 consists of 500 mM Tris, pH 7.4, 100 mM MgCl₂, 1 M NaCl, 10mM DTT) and 0.5 μ l DNA polymerase I. The mixture was mixed thoroughly and incubated at 37°C for 20 min. The mixture was then incubated at 65°C for 30 min to inactivate the polymerase. The reaction was then cooled on ice for 2 min. The DNA was digested with NotI by adding to the sample, 8 μ l of 2.5X buffer 2 (20X buffer 2 is 3 M NaCl, 0.2% Triton X-100, 0.2%BSA) and 2 μ l (10 U/ μ l) of NotI. The sample was incubated at 37°C for 2 hr. The DNA was then radioactively labeled. This was done by adding to the sample 0.3 μ l 1 M DTT, 1 μ l [α -³²P]-GTP, 1 μ l [α -³²P]-dCTP and 0.1 μ l [α -³²P]-GTP Sequenase ver 2.0 (13 U/ μ l). The mixture was incubated at 37°C for 30 min. The DNA was then digested with EcoRV by adding to the sample 7.6 μ l second enzyme digestion buffer (1 μ l 1 mM ddGTP, 1 μ l 1 mM ddCTP, 4.4 μ l ddH₂O, 1.2 μ l 100 mM MgCl₂) and 2 μ l EcoRV (10 U/ μ l). The mixture was incubated at 37°C for 1 hr. Then, 7 μ l of 6X first-dimension loading dye (0.25% Bromophenol Blue, 0.25% Xylene Cyanol, 15% Ficoll type 400) was added.

20

B. First dimension gel set-up and electrophoresis

To make the 60 cm long agarose tube-shaped gel, a gel holder was made. To do this, a sharp razor was used to cut one end of PFA-grade teflon tubing (PFA 11 thin wall, natural; American Plastic, Columbus, Ohio) at an angle to make a bevel. The beveled end of the tubing was fed into glass tubes (4 mm inner diameter, 5 mm outer diameter, 60 cm long). Using a hemostat, the beveled end was pulled up through the tapered end of the glass rod until it protruded 2 to 4 cm. The tubing was cut horizontally at the same end, leaving a 2 mm protrusion (this is the top of the gel holder). The opposite end was cut horizontally, leaving a 5 to 6 cm protrusion from the glass tube. The gel holder was inverted and the top protruding end was pressed firmly against a hot metal surface (metal spatula heated by a Bunsen burner) to fold the edges of the teflon outward onto the rim of the glass support. A rubber stopper with cored center was pulled over the top end of the gel holder until it was just past the taper of the glass rod. A two-way stopcock was attached to a 10 ml syringe and then to the gel

30

holder via 2 to 3 cm of flexible tubing. The stopcock valve was adjusted to the open position.

Then, to a clean 200 ml glass bottle was added, 60 ml 2X Boyer's buffer (20X is 1 M Tris, 360 mM NaCl, 400 mM sodium acetate, 40 mM EDTA) and 0.48 g Seakem GTG agarose (0.8%). The mixture was heated in a microwave oven until the agarose was dissolved. The mixture was then equilibrated to 55°C in a water bath. With the stopcock valve in the open position, the protruding teflon tube was lowered into the molten agarose solution. The gel solution was suctioned into the gel holder until the gel solution reached 1-2 cm from the top of the gel holder. The stopcock valve was then closed. Keeping the gel upright, the gel was suspended from a ring stand. The gel was allowed to solidify for 20 min.

The stopcock valve was then opened and the syringe and connecting tubes were removed from each gel. After adding 2X Boyer's buffer to the bottom of the first dimension gel apparatus (C.B.S. Scientific), the gels were lowered into the first dimension gel apparatus, seating the rubber stopper firmly into the appropriate holes in the top portion of the apparatus. The top chamber was filled with 2X Boyer's buffer.

Between 1.0-1.5 µg of DNA was loaded onto each gel. The sample was electrophoresed at 110 V for 2 hr, and then 230 V for 24 hr.

C. In-gel digest

After the DNA was electrophoresed in the first dimension in the agarose tube gel, the DNA was further digested with an additional restriction endonuclease so it could be electrophoresed in the second dimension. In order to perform this additional endonuclease digestion, the buffer and gel holders were removed from the first dimension apparatus. The gel was extruded into a pan containing 1X buffer K (10X buffer K is 200 mM Tris, pH 7.4, 100 mM MgCl₂, 1 M NaCl) by forcing the gel out through the bottom of the gel holder. This was accomplished using a 1 ml syringe fitted with a pipet tip and filled with buffer K. The tip was firmly inserted into the top of the gel holder and the plunger depressed until the gel began to come out through the bottom of the gel holder. The 1 ml syringe was replaced with a 5 ml syringe, and the plunger was depressed until the entire gel was expelled. With a razor, a bevel was cut in the low molecular weight end of the gel and a horizontal cut was made at the high molecular weight end so that the gel was approximately 43 cm in length. The gel length was now the same as the width of the second dimension gel.

The gel was placed into a separate 50 ml tube containing 40 ml of 1X buffer K. The tube was incubated for 10 min at room temperature. The buffer was poured off and the gel incubated in 1X buffer K for an additional 10 min. The buffer K and gel was poured into a

pan containing fresh buffer K. Using a 10 ml syringe attached to restriction digest tubing (PFA grade teflon, 9, thin wall, natural; 2.7 mm inner diameter and approximately 3.3 mm outer diameter; American Plastic, Columbus, Ohio), via a 1 to 2 cm segment of flexible tubing, the gel was suctioned into the digest tubing, low molecular weight (beveled) end first.

5 The gel was suctioned into the digest tubing by placing the end of the tubing in line with the beveled end of the gel and pulling the syringe plunger. The tubing was positioned vertically, with the syringe at the bottom and remaining buffer from the tubing was suctioned into the syringe.

In a clean tube, a 1.6 ml mix of 1X HinfI restriction enzyme buffer (50 mM NaCl, 10 mM Tris pH 7.9, 1 mM DTT), 0.1 % BSA, and 750 U of HinfI restriction enzyme was made. The open end of the digest tubing was placed into the tube containing restriction digestion solution. Holding the syringe end up, suction was applied until a small amount of digestion solution appeared in the syringe. The digest tubing was removed and both ends were oriented upward in a U-shape. The syringe was removed and the two ends of the tubing were attached to form a closed circle. This was placed in a moist chamber and incubated at 37°C for 2 hr.

D. Second dimension electrophoresis

The digested DNA was now run in the second dimension using a 5% non-denaturing acrylamide gel with a 0.8% agarose spacer. To do this, the second dimension gel apparatus (C.B.S. Scientific) was first assembled. All glass plates were cleaned thoroughly and the non-beveled face of each plate was coated with Gelslick or Sigmacote (only once every 10 uses). The back half of the apparatus was laid horizontally on a table top with the upper buffer chamber hanging over the table edge. The two small clear plastic blocks were inserted at the bottom corners of each apparatus. A glass plate was placed in the apparatus, beveled edge facing upward and near the upper buffer chamber, followed by two spacers, one along each side. Glass plates and spacers were added in this manner until the fifth plate had been added. After the third plate, flexible Tygon tubing was slid down the side channel of the apparatus, with a bevel cut in the leading end of the tubing. The other end was cut, leaving approximately 10 cm protruding from the apparatus. The Plexiglas "filler" sheet was placed over the fifth glass plate. The front half of the apparatus was positioned by aligning the screw holes of the front and back half. These were secured with the teflon screws. The oblong oval "windows" at the lower, front face were sealed with Plastic tape (Scotch brand). The apparatus was stood upright in the lower buffer chamber.

Using a three-way stopcock, the gel apparatus tubing was attached in series with a 2 L

reservoir and a 60 ml syringe was attached to the remaining stopcock outlet. The tubing was attached to the 2 L reservoir through a bottom drain (a 2 L graduated cylinder was used). The reservoir was secured above the gel apparatus to allow for gravity flow. The stopcock valve was adjusted to allow liquid to flow between the 2 L reservoir and the 60 ml syringe. Once the TEMED was added, the acrylamide solution (1X TBE, pH 8.3, 96.9 g acrylamide, 3.3 g bis-acrylamide, 1.3 g ammonium persulfate and 700 µl TEMED in a total volume of 2 L) was poured into the 2 L reservoir. The syringe plunger was pulled down to the 50 ml mark. The plunger was depressed to push the air out of the upper tubing. Once all air was removed, the valve was adjusted so that all three ports were open. Acrylamide flowed into the apparatus, filling all four gels simultaneously from the bottom upward. The flow was stopped when the level reached 3 mm from the top edge of the glass plates. The solution was allowed to settle for 2 to 3 minutes. After the valve leading to the gel apparatus had been closed, the syringe and reservoir were detached.

The ends of the in-gel digest tubing were separated and the first dimension gel was extruded into a pan containing 1X TBE, pH 8.3. The gel was transferred to a 50 ml tube containing 40 ml 1X TBE, pH 8.3. This was incubated for 10 min at room temperature, replaced with fresh TBE, and incubated for an additional 10 min. The first dimension gel was placed in a horizontal position across the beveled edge of each glass plate. Once all gels were in place, the space between the agarose gel and the top of each polyacrylamide gel was filled with molten 0.8% agarose (equilibrated to 55°C). This connecting agarose was allowed to solidify for 10 to 15 min and then 250 µl second dimension loading dye (1X TE, pH 8.3, 0.25% Bromophenol Blue, 0.25% Xylene Cyanol) was added along the length of each gel. Then 1X TBE, pH 8.3 was added to the upper and lower buffer chambers and electrophoresis was carried out at 100 V for 2 hr and then at 150 V for approximately 24 hr.

Buffers were then removed and the apparatus was disassembled. Each gel was lifted from the plates by overlaying with Whatmann paper cut to size for autoradiographic or phosphorimager cassettes. The perimeter of the paper was traced with the edge of a plastic ruler, removing any excess gel. The Whatmann paper and gel were lifted and placed, gel side up, on a second piece of Whatmann paper. This was overlaid with saran wrap and a third piece of Whatmann paper was added to the top and saran wrap was folded over the top of the Whatmann paper. This was placed in a gel drier, in the same orientation, for 1 hr at 80°C while applying a vacuum. The lower and upper Whatman paper was then removed, saran wrap folded under the remaining paper and exposed to X-ray film (BioMax MS).

E. RLGS spots resulting from methylation-sensitive restriction enzymes identify CpG islands

Using this methodology, an RLGS profile of DNA from human cells produces a pattern displaying approximately 2,000 spots. Fig. 1B, for example, shows such an RLGS profile from normal peripheral blood lymphocyte DNA. First-dimension separation of labeled NotI/EcoRV fragments extends from right to left horizontally. Following in-gel digestion with HinfI, the fragments were separated vertically downward into a polyacrylamide gel and autoradiographed. To allow uniform comparisons of RLGS profiles, spots were defined based on their location in the gel by assigning each spot a three-variable designation (Y coordinate, X coordinate, fragment number). This can be more easily seen in the enlarged portion of section 2D of the RLGS profile (Fig. 1C) showing the numbers assigned to each spot.

From a set of 1,567 NotI spots comprising the central portion of the RLGS profile of normal DNA, 392 spots were eliminated from all analyses on the basis of having more than diploid intensity, less than diploid intensity, or a degree of positional overlap with neighboring fragments. In addition, a small fraction of loci in individual tumor profiles was not able to be analyzed due to poor local gel quality. In normal DNA profiles, the less-than-diploid copy-number intensities can result from polymorphism, partial methylation or spots derived from sex chromosomes. Thus, the analyzed spots were of diploid copy number in most samples. Tumor tissue and healthy tissue DNA profiles were compared by visual inspection of overlaid autoradiographs. In those cases in which matched normal tissue was not available, tumor profiles were compared with profiles matched for tissue type of four to five unrelated individuals. Each CpG island was defined as unmethylated or methylated (a visually apparent decrease in intensity on the RLGS profile, which, through corroboration with Southern-blot data for 26 CpG island loci and more than 100 loss events, corresponded to a 30% or greater level of methylation).

To determine if the NotI restriction sites which produced the RLGS spots, had characteristics of authentic CpG islands, DNA from 210 of the NotI/EcoRV RLGS spots was partially sequenced. This was possible because each spot on the human NotI/EcoRV RLGS profile had previously been assigned to a clone from a NotI/EcoRV genomic plasmid library (see description earlier in the specification). Of the 210 spots, 184 were randomly chosen. Another 26 spots were chosen because they were frequently lost from RLGS profiles from human tumors, suggesting that cytosine nucleotides within the NotI sequence of that spot were methylated in the tumor. From the sequences derived from these clones, the GC content (%GC) was plotted against the CpG ratio for each clone (Fig. 1D; CpG ratio = [(number of

CpGs)/(number of guanines)(number of cytosines)(number of nucleotides analyzed)]). CpG islands have a GC content of greater than 50% and a CpG value of at least 0.6. Fig. 1D shows that, of 210 clones sequenced, 197 (94%) had sequence characteristics consistent with CpG-island DNA.

5

F. Tumor tissue samples analyzed

DNA used to perform the RLGS analyses was obtained from 98 primary human tumors and, where possible, matched normal samples. These samples were from 8 broad tumor types; breast, colon, gliomas, head and neck, acute myeloid leukemias, primitive neuroectodermal tumors (PNETs) and testicular.

Fourteen breast cancers included 2 adenocarcinomas, 2 lobular carcinomas and 10 ductal carcinomas. The samples were from obtained the Cooperative Human Tissue Network (CHTN). All tumors were from females, 38-89 years of age (average of 54 years). Breast tissue adjacent to the tumor was available for 6 of 14 cases, and 8 tumor profiles were compared with 4 breast samples from the matched sets.

Colon tumors were obtained from Roswell Park Cancer Institute and classified according the American Joint Committee on Cancer staging manual. The 8 primary tumors included 1 stage I tumor, 2 stage II tumors, 2 stage III tumors and 3 stage IV tumors. Patient ages ranged from 49 to 77 years (average of 63 years). Normal adjacent colon mucosa samples were obtained for all tumors.

Fourteen gliomas, including 12 World Health Organization (WHO) grade II astrocytomas and 2 WHO grade III anaplastic astrocytomas, from Saitama Medical School, the University of Tokyo, Teikyo University School of Medicine, Komagome Metropolitan Hospital and the University of Washington, Seattle. Patients included 10 females and 4 males with an age range of 7-57 years (average of 34 years). Brain tissue adjacent to the tumor was also obtained for 1 WHO grade II and 1 WHO grade III tumor. Twelve cases were compared with 3 unmatched normal brain samples and with the 2 brain samples from the matched sets.

Fourteen head and neck squamous cell carcinomas were obtained through the CHTN. Tumors were from 11 males and 3 females. Patients were 42-77 years of age (average of 57 years). Tissue adjacent to the tumor was available for 12 of 14 cases, and 2 tumors were compared with 4 samples from the matched sets.

Nineteen acute myelogenous leukemia samples (3 bone marrow aspirates and 14 peripheral blood) from the Cancer and Leukemia Group B Tissue Bank. Samples were

classified according to the French-American-British system. Samples were obtained from patients at the time of initial diagnosis with AML and again at complete remission (24-154 days, average 45 days) after induction chemotherapy. Samples were from 14 males and 3 females. Patients were 22-61 years of age (average 40 years). All cases were compared with
5 matched samples (either peripheral blood lymphocytes or bone marrow, but always matched with the origin of the cancer sample) obtained at remission.

Twenty-two PNETs, including 17 medulloblastomas and 5 supratentorial PNETs, through the CHTN, Pediatric Division. Tumors were from 15 males and 7 females. Patients were 2-26 years of age, with peak ages between 3 and 6 years. All tumors were WHO grade
10 IV. Matched peripheral blood lymphocytes were available for 6 of 22 cases, and 18 samples were compared with unmatched normal cerebellum DNA.

Nine testicular tumors included 6 seminomas and three nonseminomas. Samples were obtained from the Norwegian Radium Hospital and from the Helsinki University Central Hospital. Patients were 21-77 years (average of 41 years). Adjacent testicular tissue was
15 available for 7 of 9 cases, and 2 samples were compared with 4 samples of testicular DNA used in the matched sets.

G. Loss of spots from RLGS profiles is due to methylation

In comparing RLGS profiles of DNAs from different tumors with control, healthy
20 tissue DNAs, loss of a fragment or spot from an RLGS profile (Fig. 1A) was frequently detected. Loss of such a spot could be due to either methylation of DNA sequences at the NotI site giving rise to that spot, or to deletion of DNA surrounding that NotI site from the genome of the tumor. The relative contribution of each mechanism was assessed by using clones from the NotI/EcoRV genomic library, specific for lost spots, as probes in Southern
25 blotting studies. In Fig. 2A, a section of an RLGS profile, from normal, healthy tissue was compared with tumor tissue from two gliomas, J7 and J16. This RLGS section contains spot 3C1. In tumor J16, spot 3C1 is absent from the RLGS profile. If there was a deletion of DNA surrounding the NotI site, however, the expected result in the Southern blot would be
30 either no hybridization of the probe to the J16 genomic DNA or hybridization to a band of a size different from those detected in the lane containing normal, healthy tissue DNA digested with NotI plus EcoRV, and tumor tissue DNA digested with EcoRV alone. This result is not seen. These results show, therefore, that DNA corresponding to a missing 3C1 spot in J16 glioma DNA is present in the genome, as shown by the Southern hybridization result.

Likewise, DNA corresponding to specific RLGS spots missing in certain leukemias

(Fig. 2B) and neuroectodermal tumors of childhood (Fig. 2C) are found to be present when these DNA are analyzed by Southern blotting. Overall, in 26 tumors where specific spots in RLGS profiles were missing DNA corresponding to the spot, was found to be present in the genome by Southern blotting. These results show that loss of spots on RLGS profiles is due to methylation of the corresponding NotI site and not deletion from the genome of DNA representing that spot. Therefore, methylation is the predominant mechanism underlying loss of spots from RLGS profiles.

H. Heterogeneity in CpG-island methylation across tumors.

To compare the overall pattern of methylated CpG islands among different tumors of the same tumor type, 1,184 spots in each of 98 tumors (and their non-tumorigenic controls) were analyzed by RLGS. The analysis was performed by determining the number of RLGS spots lost, or of decreased intensity, as compared to the controls. Each lost spot or spot of decreased intensity is equivalent to one methylated CpG island. For each tumor type, the number of methylated CpG islands in each individual tumor, as compared to controls, was plotted (Fig. 3). These data showed that breast, head and neck, and testicular tumors had relatively low levels of methylation, with many such tumors showing no methylation. Colon tumors, gliomas, acute myeloid leukemias and primitive neuroectodermal tumors (PNETs) had a much higher frequency of methylation. Nonparametric comparison (Kruskal-Wallis procedure) of the methylation frequencies of the various tumor types showed significant differences between them ($\chi^2=56.9$, $P<0.0001$).

Within a tumor type, the range of methylated CpG islands in individual tumors was variable. The data (Fig. 3) are not consistent with chance variation between tumors because, in the absence of heterogeneity, the variance of the methylation frequency would not be expected to be greater than the mean¹. A formal test of this overdispersion was performed for each tumor type and the results are shown in Fig. 3 as a superimposition of the expected Poisson distribution on the dot plots. These data showed that aberrant methylation of CpG islands can be quantitatively different in individual tumors within a tumor type and more pronounced overall in particular tumor types.

¹Heterogeneity of methylation frequencies across samples was assessed within each tumor type by a standard test for evidence that the variance in methylation frequency exceeds the mean. This test is motivated by the Poisson approximation, which applies even if the frequencies of methylation vary across CpG islands. Moreover, a simple result from the binomial distribution shows that the test is conservative, because under homogeneity the population variance cannot exceed the mean.

I. Subsets of CpG islands were preferentially methylated in tumors

Through analysis of the RLGS spots lost in different tumors, it was determined that certain spots on the RLGS gels were lost in multiple tumors. This means that specific CpG dinucleotides were methylated in more than one tumor. This is shown in Fig. 4 where the number of tumors within a specific tumor type that had a particular CpG island methylated are shown.

To test the hypothesis that methylation of these common CpG islands was not random, a standard goodness-of-fit test was used.² This can be seen in the plots of Fig. 4 where the black line of each plot shows the expected distributions if methylation of specific CpG islands in multiple tumors was random. It can be seen from Fig. 4 that for breast tumors, colon tumors, gliomas, acute myeloid leukemias and childhood PNETs, the actual distributions were significantly different ($P < 0.0001$) from the theoretical distributions indicative of randomness. Similarly, the results for head and neck tumors were significant ($P < 0.025$). The results for testicular tumors ($P = 0.365$) were not significant. However, tumors of this type have a low overall methylation frequency and larger sample sizes are needed. Overall, the data indicate that the patterns of CpG island methylation in tumors is not random.

20 J. Frequencies of aberrant CpG-island methylation of shared and tumor-type-specific targets

Because the data have shown that they are methylated in a nonrandom fashion, CpG islands that are methylated at a high frequency in one or more tumor types can be used for diagnosis of tumors. From analysis of 98 tumors using NotI/EcoRV RLGS analysis, a number of spots that are absent or of decreased intensity, as compared to control healthy tissue DNA, have been found. Table I lists these spots. Each fragment (CpG island) is identified in three ways in the table. First, the location of each CpG island is designated as the distance (in cm) migrated during electrophoresis, from the gel origin, in both the first dimension and the second dimension. Second, each CpG island is given a three-variable designation (Y coordinate, X coordinate, fragment number). The X coordinate indicates horizontal direction on the two-dimensional RLGS profile and is a letter from B-G. The Y coordinate indicates vertical direction and is a number from 1-5. Together, an X and Y

²Under the null hypothesis of equal methylation frequencies for each CpG island, a goodness-of-fit test (χ^2) was applied to the observed versus expected frequencies of islands exhibiting methylation in multiple tumors within each tumor type.

designation divide the RLGS profile into 28 sections. Within each section, the spots/fragments are given a number. Such a profile is available at: <http://pandora.med.ohio-state.edu/masterRLGS/>. Third, the partial DNA sequence of individual spots has been determined by sequencing of library clones corresponding to each spot. These sequences are shown in the attached Sequence Listing and have been assigned SEQ ID NOS. from 1 to 82.

The diagnostic NotI/EcoRV spots are of two types (Fig. 1). The first type of spot is absent or of decreased intensity in a single tumor type. For example, the NotI site that is part of the CpG island designated 2.B.53, is methylated only in head and neck tumors. Similarly, the NotI site of CpG island 2.F.2 is methylated only in breast tumors.

The second type of spot is absent or of decreased intensity in more than one type of tumor. For example, the NotI/EcoRV spot designated 2.C.24 is missing in gliomas and AMLs. Similarly, the NotI/EcoRV spot designated 3.B.55 is methylated in breast, colon and PNETs.

Table I. Diagnostic CpG islands in tumors.

CpG Island¹	1st-D (cm)²	2nd-D (cm)²	Type³	Methylated In⁴:
2.B.53	36.85	9.25	t	HN
2.C.24	30.3	5.32	s	Abt/Leu
2.C.29	27.8	5.45	s	Leu/Hn
2.C.35	29.45	6.9	s	Abt/Bre/Cln/Leu/Pbt
2.C.54	32.38	9.42	s	Leu/Hn
2.C.57	30.9	8.5	ND	Tst
2.C.58	31.2	9.2	s	Abt/Leu
2.C.59	30.4	9.35	ND	Hn
2.D.10	27.55	5.3	s	Leu/Pbt
2.D.14	24.25	4.47	t	Leu
2.D.20	26.3	5.3	t	Cln
2.D.25	27.15	6.4	ND	Bre
2.D.27	25.65	5.82	ND	Hn
2.D.34	23.62	6.6	s	Leu/Pbt
2.D.40	23.95	7.25	ND	Pbt
2.D.48	26.1	8.1	ND	Leu
2.D.55	24.2	8.3	s	Cln/Leu
2.D.74	23.95	9.35	s	Abt/Bre/Cln/Leu
2.E.20	20.6	5.95	ND	Pbt
2.E.24	19.35	5.7	s	Abt/Leu
2.E.25	18.27	5.65	t	Bre
2.E.30	20.35	6.4	s	Abt/Bre/Leu
2.E.37	21.42	7.1	ND	Bre
2.E.4	21.1	4.48	s	Leu/Pbt

2.E.40	NA	NA	ND	Tst
2.E.61	19.4	8.08	s	Abt/Pbt
2.E.64	20.5	8.35	s	Abt/Cln
2.F.2	17.27	4.72	t	Bre
2.F.41	NA	NA	t	Tst
2.F.50	15.23	7	s	Abt/Leu
2.F.59	17.49	8	ND	Bre
2.F.70	15.88	13.3	s	Pbt/Tst
2.G.10	10.29	4.49	s	Leu/Tst
2.G.108	7.68	7.44	ND	Bre
3.B.30	35.4	12.55	ND	Tst
3.B.36	34.2	11.8	s	Abt/Cln/Leu/Pbt
3.B.55	NA	NA	s	Bre/Cln/Pbt
3.C.01	31.6	9.7	s	Abt/Cln/Leu
3.C.16	27.9	11.8	t	Pbt
3.C.17	29.2	10.57	t	Cln
3.C.30	31.61	10.37	t	Bre
3.C.35	31.6	11.5	t	Pbt
3.C.64	29.1	14.05	ND	Bre
3.D.21	24.2	10.75	t	Leu
3.D.24	23.2	11.03	s	Abt/Leu
3.D.35	26.1	11.65	s	Abt/Cln/Leu/Pbt
3.D.40	23.4	12.26	s	Abt/Cln/Leu
3.D.44	24.45	12.82	t	Leu
3.D.60	27.2	12.4	s	Abt/Cln/Leu
3.E.04	20.4	14.2	s	Hn/Pbt
3.E.50	20.55	10.7	s	Hn/Tst
3.E.55	18.78	10.55	s	Cln/Leu
3.E.57	18.09	10.9	s	Cln/Hn
3.E.59	18.4	9.72	s	Abt/Tst
3.F.16	16.6	9.75	ND	Leu
3.F.2	16.73	9.35	s	Leu/Tst
3.F.50	16.25	11.6	s	Cln/Leu/Tst
3.F.72	16.9	13.7	t	Leu
3.F.82	13.8	13.12	s	Abt/Cln/Leu
3.G.46	9.88	11.5	ND	Bre
3.G.78	10	12.93	ND	Leu/Pbt
4.B.44	33.7	18.53	s	Cln/Hn
4.B.56	33.2	19.45	s	Bre/Leu
4.C.05	30	14.9	ND	Bre
4.C.25	28.62	17	ND	Bre
4.C.42	NA	NA	ND	Tst
4.C.9	30.3	15.3	ND	Bre
4.D.07	22.9	14.5	s	Leu/Tst
4.D.08	23.5	15	s	Abt/Tst
4.D.12	25	14.85	s	Abt/Leu/Tst
4.D.13	24.95	15.3	s	Abt/Bre

4.D.47	27.6	18.25	s	Abt/Leu/Pbt
4.E.53	19.39	18.43	t	Leu
4.F.15	13.25	15.45	t	Cln
4.F.17	14.1	15.6	s	Abt/Bre/Cln
4.F.22	17.56	16.2	s	Cln/Hn/Leu
4.F.6	14.85	14.59	ND	Bre
4.F.69	12.58	18.86	t	Abt
5.D.9	25.17	23.4	t	Hn
5.E.2	20.58	19.5	t	Bre
5.E.25	18.7	21.3	t	Cln
5.E.4	18.45	19.75	s	Abt/Bre/Leu
¹ Y coordinate, X coordinate, fragment number				
² NA, spots too close to analyze.				
³ T, tumor-type specific target of methylation; s, shared target of methylation; ND, not determined.				
⁴ Types of tumor in which CpG island is methylated: Abt, gliomas; Bre, breast; Cln, colon; Hn, head and neck; Leu, acute myeloid leukemia; Pbt, pediatric brain tumors; Tst, testicular germ cell tumors.				

Example 2. Identification of diagnostic markers for lung cancer using AscI and RLGS

Tissue from lung tumors was obtained as surgical tissue samples. Where possible, surrounding non-tumor tissue from the same patient was obtained and used as a control. DNA was isolated from the tissue as described in Example 1. In preparation for RLGS analysis, the ends of the DNA were blocked as described in Example 1. The DNA was then digested with AscI followed by digestion with EcoRV. The AscI restriction enzyme recognizes the sequence 5'GGCGCGCC3' and does not cleave said sequence if cytosines within the sequence are methylated. First dimension gel electrophoresis, in-gel digestion with HinfI, second dimension gel electrophoresis and autoradiography were performed as described in Example 1.

RLGS profiles from lung tumor DNA were compared with RLGS profiles obtained from healthy, non-tumor tissue DNA. Spots which were lost or present at reduced intensity in tumor tissue RLGS profiles as compared to profiles obtained from healthy tissue were noted. Eight spots were lost or altered in the RLGS profiles from multiple lung tumor samples. A compilation of such spots is shown in Table II (lung tumors).

DNA sequence information was obtained from the lung cancer-specific spots. This was done by sequencing individual clones of an AscI/EcoRV library that was made from DNA from healthy tissue. Individual clones of this library that corresponded to spots on the AscI/EcoRV RLGS profile were identified by overloading an RLGS gel with DNA from

various groups of library clones, as was described earlier in the specification of this application for the NotI/EcoRV library. After individual clones were matched with spots in the AscI/EcoRV profile, the DNA from the spots that were missing in profiles from the lung tumor DNAs were sequenced. Such sequence information is shown in the attached DNA

5 Sequence Listing.

Table II. Diagnostic CpG islands grouped by tumor type.

Library	Tumor type	Tumor type specific (+), shared (-), or not determined (ND) ¹	CpG island designation
NotI/EcoRV	Breast	+	2.E.25, 2.F.2, 3.C.30, 5.E.2
		-	3.B.55, 4.B.56, 4.D.13, 4.F.17, 2.D.74, 2.C.35, 2.E.30, 5.E.4
		ND	2.D.25, 2.E.37, 2.F.59, 2.G.108, 3.C.64, 3.G.46, 4.C.05, 4.C.25, 4.C.9, 4.F.6
NotI/EcoRV	Colon	+	2.D.20, 3.C.17, 4.F.15, 5.E.25
		-	3.E.57, 4.B.44, 4.F.22, 2.D.55, 3.E.55, 3.F.50, 3.B.55, 4.F.17, 2.D.74, 2.C.35, 2.E.64, 3.C.01, 3.D.40, 3.D.60, 3.F.82, 3.B.36, 3.D.35
		ND	---
NotI/EcoRV	Glioma	+	4.F.69
		-	4.D.13, 4.F.17, 2.D.74, 2.C.35, 2.E.30, 5.E.4, 2.E.64, 3.C.01, 3.D.40, 3.D.60, 3.F.82, 3.B.36, 3.D.35, 2.C.24, 2.C.58, 2.E.24, 2.F.50, 3.D.24, 4.D.47, 4.D.12, 2.E.61, 3.E.59, 4.D.08
		ND	---
NotI/EcoRV	Head & neck	+	2.B.53, 5.D.9
		-	2.C.29, 2.C.54, 3.E.04, 3.E.50, 3.E.57, 4.B.44, 4.F.22

		ND	2.C.59, 2.D.27
NotI/EcoRV	Acute myelogenous Leukemia	+	2.D.14, 3.D.21, 3.D.44, 3.F.72, 4.E.53, 2.C.29, 2.C.54
		-	2.D.10, 2.D.34, 2.E.4, 2.G.10, 3.F.2, 4.D.07, 4.F.22, 2.D.55, 3.E.55, 3.F.50, 2.E.64, 3.C.01, 3.D.40, 3.D.60, 3.F.82, 3.B.36, 3.D.35, 3.C.01, 3.D.40, 3.D.60, 3.F.82, 3.B.36, 3.D.35, 2.C.24, 2.C.58, 2.E.24, 2.F.50, 3.D.24, 4.D.47, 4.D.12
		ND	2.D.48, 3.F.16, 3.G.78, 4.B.56
NotI/EcoRV	Pediatric neuroectodermal tumor of childhood	+	3.C.16, 3.C.35, 3.E.04
		-	2.D.10, 2.D.34, 2.E.4, 3.B.55, 2.C.35, 3.B.36, 3.D.35, 4.D.47, 2.E.61
		ND	2.D.40, 2.E.20, 3.G.78
NotI/EcoRV	Testicular	+	2.F.41
		-	2.G.10, 3.F.2, 4.D.07, 3.E.50, 3.F.50, 4.D.12, 3.E.59, 4.D.08
		ND	2.C.57, 2.E.40, 3.B.30, 4.C.42
AscI/EcoRV	Lung	+	
		-	
		ND	A.2.F.45, A.2.F.50, A.2.F.67, A.3.F.38, A.4.D.30, A.4.D.36, A.4.E.32, A.5.E.28 ²

¹ND, not determined. Indicates that the designated CpG island was methylated in the indicated tumor type but its methylation in other tumor types was not determined.

²The "A" preceding the X, Y, number designation for the CpG islands indicates that these islands are from the AscI/EcoRV RLGS profile.

Example 3. Design of primers for cancer diagnosis

Primers are designed for diagnosis of cancer using methylation-specific PCR (MSR). The primers are designed to amplify regions of the human genome whose sequences are contained within the library clones disclosed in this application. Two sets of primers are needed for each library clone whose DNA sequence is to be used for diagnosis of cancer.

Each primer set is designed to amplify the same region of the genome, said region beginning at the end of a library clone containing the methylation-sensitive restriction enzyme recognition site (i.e., the NotI site for the library described in Example 1; the AscI site for the library described in Example 2) and ending at a region contained within the clone up to 200
5 nucleotides from the methylation-sensitive restriction enzyme recognition site.

The first set of primers is designed to amplify template genome DNA whose cytosine residues are not methylated and, after bisulfite treatment, the cytosines of said genome DNA are converted to uracil. The second set of primers is designed to amplify template genome DNA which is methylated on cytosines that comprise CpG dinucleotides. Such methylated
10 cytosines are unaffected by bisulfite treatment. Therefore, by using two sets of primers, one set that will amplify only unmethylated DNA and another set that will amplify only methylated DNA, methylation state of the template DNA can be determined. Such methylation state can be diagnostic for cancer.

The primers used for MSR are designed to be from 15 to 34 nucleotides in length and
15 contain within their sequence either CpG dinucleotides or dinucleotides complementary to CpG dinucleotides that have been treated with bisulfite. It is preferred that the 3' ends of primers used to amplify unmethylated DNA are CpA dinucleotides. It is preferred that the 3' ends of primers used to amplify methylated DNA are CpG dinucleotides.

For each library clone to be used diagnostically, the first set of primers are designed to
20 amplify genome DNA that is not methylated. After treatment of such genome DNA with bisulfite, all such unmethylated cytosines are converted to uracil. PCR primers that will use such DNA as a template and amplify it, will have adenine residues which are complimentary to these uracils.

For the first set of primers, the 5' end of one of the primers begins at the end of the
25 library clone containing the methylation-sensitive restriction enzyme recognition site. The sequence of this primer is identical in sequence to the strand of the template which has its 5' end as part of the methylation-sensitive restriction enzyme site, except that guanine residues are replaced with adenine residues. The adenines allow the primer to hybridize with the template strand in which cytosines have been converted to uracils by bisulfite. This primer
30 extends to a length of between 15 and 32 total nucleotides. Preferably, the 3' end of said primer ends with a CpA dinucleotide, the adenine of said dinucleotide hybridizing to a uracil which, before bisulfite treatment, had been a cytosine that comprised a CpG dinucleotide.

The diagram below shows implementation of these rules to select a primer that can be used to amplify clone 2.B.53 of the NotI/EcoRV library (Table I and attached sequence

listing). In the diagram, I shows the end of the 2.B.53 clone containing the methylation-sensitive NotI site (NotI recognition sequence is shown in bold letters). CpG dinucleotides are shaded. To amplify a region of this clone rightward of the NotI site, the first primer is identical to the top strand of the duplex shown in I. However, since bisulfite treatment of the DNA in I converts cytosines to uracils, guanines within the PCR primer must be replaced with adenines. II shows the sequence of the bottom strand of I after bisulfite treatment converts cytosines to uracils. A primer complementary to the bisulfite-treated bottom strand has the sequence shown in III.

10 **I**
 5' **GCGGC****CGCG**TTAGCTTCTCCTGTC**CGAA****CG**CAGGG-----
 3' **CGCG****CGCG**CAATCGAAGAGGACAG**CGTT****CG**GTCCC-----

15 **II**
 3' UGUUGGUGUUAATUGAAGAGGAUAGGUTTGUGTUUU-----

III
 5' ACAACCACAATTA ACTTCTCCTATCCAAACA 3'

20 III shows the entire sequence of one of the two primers used to amplify unmethylated genome DNA corresponding to library clone 2.B.53. This primer encompasses 5 CpG dinucleotides, as shown by the shading in I above. Encompassment of 2 or more such CpG dinucleotides is preferred so that this primer will not hybridize to a bisulfite-treated template which contains methylated cytosines. The 3' end of the primer shown in III ends in a CpA
 25 dinucleotide. This is also preferred in order to provide maximal discrimination of the primer between methylated and unmethylated template DNA in MSR. The primer shown in III has a length of 31 nucleotides.

The second primer is designed to work with the first primer in PCR amplification such that a fragment of less than about 200 base pairs is amplified. Therefore, this primer is
 30 made to a sequence rightward of the sequence shown in I. The sequence of this primer is complementary in sequence to the strand of the template which has its 5' end as part of the methylation-sensitive restriction enzyme site, except that guanine residues are replaced with adenine residues. This primer is preferably between 15 and 32 nucleotides in length. This primer is also designed to preferably encompass 2 or more CpG dinucleotides. Preferably,
 35 the 3' end of said primer ends with a CpA dinucleotide.

The diagram below shows implementation of these rules to select a primer that can be used to amplify unmethylated genome DNA corresponding to clone 2.B.53 of the

5

10

VI

15

20

25

30

primers, however, the primers of the second set are preferably between 15 and 32 nucleotides in length. Preferably the 3' ends of such primers contain CpG dinucleotides.

The diagram below shows implementation of these rules to select the first of two primers that can be used to amplify methylated genomic DNA corresponding to clone 2.B.53 of the NotI/EcoRV library. In the diagram below, VII shows the end of the 2.B.53 clone containing the NotI site (NotI recognition sequence is bolded). CpG dinucleotides are shaded. Cytosines within said CpG dinucleotides are methylated and are underlined in VII to indicate methylation to 5-methylcytosine. Treatment of the DNA in VII with bisulfite produces a bottom strand with the sequence shown in VIII. In VIII, only unmethylated cytosines are converted to uracil by bisulfite.

VII

5' **GCGGC****CGCG**GTTAGCTTCTCCTGT**C**GAAG**C**CAGGG-----
 3' **CGCGC****CGCG**CAATCGAAGAGGACAG**C**TT**C**GTCCC-----

VIII

3' UGCUGGCGCUAATUGAAGAGGAUAGGCTTGCGTUUU-----

IX

5' ACGACCGCGATTAACTTCTCCTATCCGAACG 3'

A primer complementary to the bisulfite-treated bottom strand shown in VIII is shown in IX. Said primer will prime PCR amplification of sequences rightward of those shown in VII. The primer shown in IX encompasses 5 CpG dinucleotides. Encompassment of 2 or more such CpG dinucleotides is preferred. The 3' end of the primer shown in IX ends in CpG. This is also preferred. The primer shown in IX has a length of 31 nucleotides.

A second primer is designed to work with the primer shown in IX to amplify methylated genome template DNA. Design of such a primer is shown below. In the diagram, X shows the same region of clone 2.B.53 (approximately 70 nucleotides rightward of the sequences shown in VII) that is shown in IV. Treatment of the DNA in X with bisulfite produces a top strand with the sequence shown in XI. In XI, only unmethylated cytosines are converted to uracil by bisulfite.

X

5' -----GGAGT**CGCG**GT**CGCG**GGAGGCTG**CGCG****CGCG**CAC**CGA**-----3'
 3' -----CCTCAG**CGCG**CA**CGCG**CCTCCGAC**CGCG****CGCG**GTG**CGT**-----5'

XI

5' -----GGAGTCGCGGT**CGCG**GGAGGUTGCGUCGCGUAUCGA-----3'

XII

3' GCGCCAGCGCCCTCCAACGCAGCGCATAGCT 5'

5 A primer complementary to the bisulfite-treated top strand (XI) has the sequence shown in XII. Said primer will prime PCR amplification of sequences leftward of those shown in X. The primer shown in XII encompasses 8 CpG dinucleotides. Encompassment of 2 or more such CpG dinucleotides is preferred. The 3' end of the primer shown in XII ends in a CpG dinucleotide. This is also preferred. The primer shown in XII has a length of
10 31 nucleotides. Together, the first (IX) and second primers (XII) of the second set amplify a PCR fragment of 128 base pairs in length.

Example 4. Use of oligonucleotides to diagnose cancer

The library clones, and DNA sequences within, can be used to detect DNA
15 methylation in a genome at the specific sequences identified by the sequences within the clone. Such detection can be diagnostic for cancer. Various methods can be used for such diagnosis.

A. Diagnosis of cancer using methylation-sensitive restriction enzymes followed by
20 Southern blot

Cleavage or lack of cleavage by a methylation-sensitive restriction enzyme at a specific restriction enzyme recognition site can be detected by a probe for the specific recognition site, using Southern blotting. Genomic DNAs were isolated (as described in Example 1) from tumor tissue from a patient with acute myelogenous leukemia (AML).
25 Cells from the same patient after chemotherapy and remission of the disease served as a source of control, healthy tissue DNA. The AML and control DNAs were designated as 26T and 26N, respectively. The DNAs were digested with NotI and EcoRV for 4 hours and then electrophoresed through a 0.8% agarose gel. DNA within the gel was depurinated by soaking the gel in 0.2 N HCl for 10 min. The gel was equilibrated in transfer solution (0.5 N NaOH, 1
30 M NaCl) for 10 min. and then blotted to Zeta Bind-GT nylon membranes (Bio-Rad). Blots were crosslinked with UV light, baked in a vacuum oven and then prehybridized for 1 hour at 65°C in a solution of 7% SDS, 500 mM sodium phosphate buffer (pH 7.2) and 1 mM EDTA. The blot was hybridized overnight at 65°C in prehybridization solution with 10 ng of α -³²P-labeled probe at a specific activity of 10⁸-10⁹ dpm/ μ g. The DNA probe used was the 2.C.40
35 clone from the NotI/EcoRV 2.C.40library. The purified NotI/EcoRV fragment (50 ng) was

labeled with [α - ^{32} P]dCTP by random priming using the Prime-It II random-prime labeling kit (Stratagene). The blot was washed with two quick rinses at 65°C in wash solution 1 (100 mM sodium phosphate buffer, pH 7.2, 0.1% SDS), followed by one 30 min. wash at 65°C in wash solution 1. The blot was next washed for 30 min. at 65°C in wash solution 2 (40 mM sodium phosphate buffer, pH 7.2, 0.1% SDS). Bands were visualized by autoradiography using Kodak X-OMAT AR film.

Fig. 2B shows the data. The first 2 lanes of the autoradiograph are relevant. The first lane, labeled 26N is the normal, healthy tissue DNA cleaved with both NotI and EcoRV. The 26N lane shows a band near the bottom of the autoradiograph labeled "NotI/EcoRV." This is fragment resulting when the NotI site present in the 2.C.40 clone is unmethylated. The adjacent lane, labeled "26T," is the tumor tissue DNA cleaved with both NotI and EcoRV. It is seen that this band, labeled "EcoRV," does not migrate as fast as did the 26N band. The reason is that the NotI site present in the 2.C.40 clone is methylated and the NotI enzyme was unable to cleave at this site.

B. Diagnosis of cancer using methylation-specific PCR (MSR)

MSR is a technique whereby DNA is amplified by PCR dependent upon the methylation state of the DNA. In this example, the specific areas of the genome whose methylation status is to be determined are the regions at the ends of the CpG islands that are demarcated by the methylation-sensitive restriction enzyme recognition sequence. In the case of the NotI/EcoRV RLGS profiles, this is the NotI site. In the case of the AscI/EcoRV RLGS profiles, this is the AscI site, at the end of each clone.

For the purposes of this example, the methylation status of genomic sequences corresponding to the NotI site of clone 2.B.53 of the NotI/EcoRV library is examined. Genomic DNA is first isolated from normal tissue and from tumor tissue, as described in Example 1. This DNA is then treated with bisulfite. This is done by taking 1 μ g of genomic DNA in a volume of 50 μ l and denaturing said DNA in a final concentration of 0.2 M NaOH. Thirty microliters of 10 mM hydroquinone and 520 μ l of 3 M sodium bisulfite, at pH 5.0, are added, mixed and incubated under mineral oil at 50°C for 16 hours. The modified DNA is then purified using the Wizard DNA purification resin (Promega) and eluted into 50 μ l of water. Modification is completed by NaOH (final concentration, 0.3 M) treatment for 5 min. at room temperature, followed by ethanol precipitation. DNA is resuspended in water.

Each genomic DNA is then used in two PCR reactions. One PCR reaction will amplify DNA that is not methylated and has, therefore, been modified by bisulfite. The

second PCR reaction will amplify DNA that is methylated. Separate primers are used for each reaction. To determine the methylation status of the NotI site in the genomic DNA which corresponds to the 2.B.53 clone, the two sets of primers described in Example 3 are used. Each PCR reaction contains 1X PCR buffer (16.6 mM ammonium sulfate, 67 mM Tris, pH 8.8, 6.7 mM MgCl₂, 10 mM 2-mercaptoethanol), dNTPs (each at 1.25 mM), primers (300 ng each per reaction), and 50 ng bisulfite-modified DNA in a final volume of 50 µl. Separate control reactions are run which contain DNA that has not been modified by bisulfite. Reactions are hot-started at 95°C for 5 min. before the addition of 1.25 units of *Taq* polymerase. Amplification is carried out for 35 cycles (30 sec at 95°C, 30 sec at the annealing temperature, and 30 sec at 72°C), followed by a final 4 min. extension at 72°C. Each PCR reaction is directly loaded onto nondenaturing 6-8% polyacrylamide gels and electrophoresed. Gels are stained with ethidium bromide and visualized under UV illumination.

If input genomic DNA is not methylated at cytosines within CpG dinucleotides at the NotI site corresponding to the end of the 2.B.53 CpG island clone, the PCR reaction using the primers specific for nonmethylated DNA (primers III and VI in Example 3) will produce an amplification product of 128 base pairs in length. Using the same input genomic DNA, the PCR reaction using the primers specific for methylated DNA (primers IX and XII in Example 3) will not produce an amplification product.

If input genomic DNA is methylated at cytosines within CpG dinucleotides at the NotI site corresponding to the end of the 2.B.53 CpG island clone, the PCR reaction using the nonmethylation-specific primers will not produce an amplification product. Using the same input genomic DNA, the PCR reaction using the methylation-specific primers will produce an amplification product of 128 base pairs in length.

Example 5. Detection of gene expression

The library clones (Tables I and II) and DNA sequences (attached sequence listing) are useful for determining whether genes encoded within said clones are being transcribed in tumor tissue or cultured cells. To determine transcription, RNA was isolated from five different human glioma cell lines (U87MG, U178, T98G, U251 and LN235) using Trizol (Gibco BRL). Such RNA isolation reagent is known to those skilled in the art. RNAs were quantified using a spectrophotometer and then treated with amplification grade Dnase I (Gibco). The RNA (2 µg) was reverse transcribed by incubation with oligo-dT and random

primers in a 20 μ l reaction, heated to 70°C for 10 min. and placed on ice. A mix containing 1X reaction buffer (Gibco), DTT (10 mM), dNTPs (0.5 mM each), and RNAsin (80 U, Promega) was added to each sample. The samples were divided into two tubes, each containing 19 μ l, and incubated at 37°C for 2 min. M-MLV reverse transcriptase (RT, 200 U) was added to one of the two tubes and each was incubated at 37°C for 1 h. DEPC-treated water (30 μ l) was added to each sample and heated in boiling water for 5 min.

PCR amplification of the reverse transcribed RNA was then performed. In this study, transcripts encoded by sequences within the 2.C.24 library clone (Table I) were looked for. A computer search using the BLAST program had identified an open reading frame within the sequence of this library clone. PCR primers were made to this region. Primer 1 was 5' TGGTGCTGAAGTCGGTGAA 3'. Primer 2 was 5' GGGCCATCTTCACCATCTG 3'.

These primers (10 pmol of each) were used in 10 μ l PCR reactions which contained 1.5 μ l of the reverse transcription reaction, 1X reaction buffer, Taq polymerase (0.5 U, Boehringer), and dNTPs (250 μ M each). For each gene, separate amplification reactions were carried out using RT-positive and RT-negative reactions as template. Amplification was not detected from the RT-negative reactions. The PCR reactions were carried out by heating the samples to 94°C for 5 min and then amplifying for 35 cycles, each cycle consisting of 94°C for 30 sec., a 30 sec. annealing step at 56°C, and 72°C for 45 sec. The reactions were then incubated at 72°C for 7 min and cooled to 4. The sample was then electrophoresed through an agarose gel containing ethidium bromide and PCR products were visualized using an Eagle Eye gel documentation system (Stratagene). The correct identity of the PCR products was confirmed by nucleotide sequencing of both strands.

The data showed that no transcripts encoded by this region of the 2.C.24 clone were found in any of the 5 glioma cell lines. Such expressed transcripts are present in RNA obtained from human fetal brain and adult brain.

In addition to examination of cell lines, tumor tissue obtained from patient samples can be similarly tested for the presence of transcripts by one skilled in the art. Other techniques to detect transcripts can also be used. Such techniques include, for example, Northern blot hybridization, RNase protection and primer extension assays.

SEQUENCE LISTING

<110> The Ohio State University Research Foundation
Plass, Christoph

<120> Detection of Methylated CpG Rich Sequences Diagnostic for Malignant Cells

<130> 22727/04110

<150> US 09/775,398

<151> 2001-01-31

<160> 90

<170> PatentIn version 3.0

<210> 1

<211> 677

<212> DNA

<213> Homo sapiens 2.B.53

<220>

<221> n

<222> (578) .. (578)

<223> a or g or c or t

<400> 1

```

gcgggccgcgg ttagcttctc ctgtccgaac gcaggggttc actggggcgc cgctacggtt      60
cctatggcaa cgcggctcct cgacgcagcc caggagtcgc ggtcgcggga ggctgcgccg      120
cgcaccgagc tcttccctgt ggccgccgca gccgccagcc tcttccctgt catgcttttc      180
ctcatcttca tctcgggtctg agtgggctct ggacctctcc accagcctct gccccagAAC      240
tgttaactgc ggggggggaaa aaaggaattt gtcgtcgcaa cgcgcgttcc gatggagccg      300
cacgccacaa aggaagactc atgctgcacc ccgcggggca gatgcggcga cactggacat      360
cgctgcacag ctgggtctgc ccgtttccag agctgcttag cgcgcagcc cataaatgag      420
gaggactccc tgtgtattaa aaggggggatc cgcaggggtt aatttgataa ggattatagc      480
cttcataaag gcatttttaa caaaaagatg taggtggcat ggtaatcgag tattatttac      540
gcatctctcc gcacacgcac tcatacctga aaacgttntg gcaggcacia aatgattttt      600
ttgtgtataa aagaatgtgt gtaactcgtg gatgggtgggg ttcagcagga caagatagtg      660
acattagata aattaca                                         677

```

<210> 2

<211> 380

<212> DNA

<213> Homo sapiens 2.C.24

<220>

<221> n

<222> (246) .. (246)

<223> a or g or c or t

<220>

WO 02/060318

PCT/US02/03077

<221> n
 <222> (297) .. (297)
 <223> a or g or c or t

<220>
 <221> n
 <222> (318) .. (318)
 <223> a or g or c or t

<220>
 <221> n
 <222> (325) .. (325)
 <223> a or g or c or t

<220>
 <221> n
 <222> (327) .. (327)
 <223> a or g or c or t

<220>
 <221> n
 <222> (345) .. (345)
 <223> a or g or c or t

<400> 2
 gcggccgcct tgaaggcgct ggacgggatg gtgctgaagt cgggtgaagga gccccggcag 60
 gtgagctcgc ggcccgccag cccgctgccc acgcagtagt ggaagaggcc gaagtagcca 120
 ggcttggggg tgctcacgct gtcgcccacc cagtagggct ggatgaagac caccacgttg 180
 atgatggcga agcagatggt gaagatggcc cacagcacgc cgatggcccc cgagttccgc 240
 atgtantgct cgtggtagag cttggaacct cctgcgaggg cagcatgggtg cccggangcg 300
 gggccggcgg cggctgtngc tggcnngngc cgtcggcccc ggacngacgc ctggctgccg 360
 ggcgggaact ggggactcac 380

<210> 3
 <211> 566
 <212> DNA
 <213> Homo sapiens 2.C.29

<400> 3
 gcggccgcgc cgctagtgaac tacttccctc tactccttct cctcctgctc cggcctcctg 60
 gcgccctgct ccaggctctc cggcgccctg ctccaggctc tccggcgccc tccagccagg 120
 caccggccga accgggtagt gccgcaagggt gtaattactg ctttgaaact ttaaaggcat 180
 ttggaaagaa actacggggt atgcttactt tttttgtttt tgattattat tttgtaggag 240
 acacaaagtt taaaaataga aagcaaaaag tgtgacacat ttaaagagtt aaaggaaata 300
 aacgtttcca atttacctta taacatgatt ttcatacact ggatttggtt aaaacagact 360
 gactacatgg ataacttttc taggaattgt tcttaactct gatagctggc tcaactgatg 420
 taggcattaa aataacgtca tattaccatc tttcctccac gaattgatga tatttgacta 480

tagctttgtc agggttatgt ccaactattg tataatatgt gtcagtttcc tattgctacc 540
gtaacaaatt accccaaatt tactgg 566

<210> 4
<211> 1297
<212> DNA
<213> Homo sapiens 2.C.35

<220>
<221> n
<222> (1046)..(1046)
<223> a or g or c or t

<400> 4
gttcacttct cgctgcgccg cgggttctgt agaagcgcaa gaatggggct gattattccg 60
gtgcccacat gccgccccca cagccccca ccccgctccg gcgcaagact tcccttggcc 120
aaaagaggcg tttaattagt tctggggccg cggagagcca gcgtggccga caaagcccgg 180
ctccccaggt aaccggggtt ccctgcggac ccgggagggg gcgcgcgggg ccggagcacc 240
ggccttgggc tgcgcgctcc ctccggcgac actgccgtcc ccctggcctc cggcccggtc 300
ccccgcaggc caaaggctca tctgccgggc ttgggtggcc cgggccagcg ccgcctgcgg 360
tccccgagtg cggctggctc taaggccggc gccctctccc cggctttcag tgctcagagc 420
caggccagcg ggaaagaagg cagcatggtc cgcaaaagac aggtggcagt ggcagtcttg 480
catgatactt gtccttcttc cctgttcccc attttgggga aacactggaa acacttttct 540
ctttatgcgc attcgcgtct cagcaccgag tgctccaagc cctgcgcgca gcgccgggct 600
tggaaggcgg cgaatggctg cctagccgcc gccctacta gtgacactcg gccgccagcc 660
ccgcccagg atgtgcacat ctgctggcag cactggcccc ggtggcagtc accgggccac 720
ccactccaca ggtacaaccg cacccaatcc aacctggaac tcggagggct gtgcgcgccg 780
agctgggatc gcgccccaac gagccgggccc tttggctgcg ccagggccca ggccgagtca 840
tccccccgct cgcgtcgccg cgaggcggga caccgtgtaa tacctttgcc gtgggctggg 900
cgtcggccgc gggccggaga gcgggtgtcc cacctcgcct catcatttga tttccgccag 960
cgtctgagga cggcgcaccc aattcgttcc actcgcctgcg ctctgtgaac cagcggcggg 1020
cagggcgggg gaggccgggc tggggnaggg caggggtggc ccaatcccc gcccccggcc 1080
cgccggcctc gcggagcaca agtgttggga ttcccacggg caggcgtgct ctgcggctgg 1140
aggcccagc gcccagggcc caggagacgt ggcggacaca gaggggtttg taggcacggc 1200
gacctccgtg ctctgctct gaaagggcct gaaaggagcg gtttatggcg cattaccagt 1260
caagggctca ggtaccagcg cctgtgtcgg gaaccgg 1297

<210> 5
<211> 651
<212> DNA

<213> Homo sapiens 2.C.54

<400> 5
 gcggccgccc cgggggacgc tcagatctcg cgagaagagg gcgagcgcgc tgccccctg 60
 gtgggcgggg cgaagcccgg gagagggtgg gcgccaccgg aggggaggag gggaacaggg 120
 aactgaagga agtgggaggg gccggcgggg cggggaagcg gaaagggggc gtggctgagg 180
 gcgggaggat taagctgcct ttttgaaagt ggagcgccag gtcccgggtt ctgggtggag 240
 gtggttgctg attggtggag ctggagcgg cggttgggag ggtcctggtc acatggtggg 300
 gagtgggagg ggggaagtgc ggagagcggg agcgggatgg tagtgggctg ggccccactg 360
 ggctgggaca gcaggaggat agtcttgagg aggagcgtgg ggtgctagat gtgtaactac 420
 gtcccgaact ggttcctgtg tttttctagg gcatgtggac tagggatggg tacttgagta 480
 gaagcctgca acttgaagag tttgtgcagg agttagctgc agtgtcggaa attagtgtcc 540
 tgtatgctca acaagggtatt cggactgggt gtgcacacca cagctctcag gactggaagg 600
 tggaaattta atctacgaag ttcccttaaa ctgcataagc ttcgggacct c 651

<210> 6
 <211> 710
 <212> DNA
 <213> Homo sapiens 2.C.57

<220>
 <221> n
 <222> (652) .. (652)
 <223> a or g or c or t

<220>
 <221> n
 <222> (690) .. (690)
 <223> a or g or c or t

<220>
 <221> n
 <222> (695) .. (695)
 <223> a or g or c or t

<220>
 <221> n
 <222> (710) .. (710)
 <223> a or g or c or t

<400> 6
 gcggccgcac ggagttgaag acactaacc agctaagcca catacagacc ctcacggccg 60
 cctggtctac acaggccgcc acagctacac aggtcaggc ctcagcctgg tcacaatggt 120
 cacaccaca ctctcgggtc ccacagtttt gcgggagcgg tgacacacac ccgctcccaa 180
 ctgaccacgc ccacacacgc tggcttcagc cgcacacgca cacagtagcc acgccccctt 240
 atgctccagc cttgccagca cccgccctcg ccacgctggt cagcccaca cacacacaca 300

cacacacaca cacacgcacg caggcctggg gcacgcccct ccccccacacg caggcgtgcg 360
 gcacgccttc ccatacacac acacacgcgc gcgggcctgg ggcacgcctt ccacacacat 420
 gcaggggtag ggcacgcccc cacacacaca cacgccggcc tggggcacgc tcgcgcgcac 480
 atgcacacac atacacacgc acaggcctgg ggcaggcccc acccccacac acgcaggcct 540
 ggggcacgcc ccccccacaca tgcaggcctg gagcatgcgc aactcgcag gccttgggca 600
 cacgcgcaca cactcatgca cagacacgca cgcacacatc gagccccgcc cncggaagca 660
 catgagaggc acttgctttc actgactgan ggcanggctt tgggcccgc 710

<210> 7
 <211> 1204
 <212> DNA
 <213> Homo sapiens 2.C.58

<400> 7
 gcggccgctc ctctttattc tactctcacc cgaggccgc gcccgctccg gggagcggct 60
 ctgccaggaa aacggcccga ccagtgcctg gcgcctgggc tgcgtccgag cccaccttct 120
 tccctcgctc tgcgtctcca gactaaatcc cggaaaggga aagcgggatg tttgcgcca 180
 ccgcgctgta gctggtcctg acacttgcaa aatggtcagt ggctcctgct cggccaggct 240
 gagtgtgtgc gtgtgtgtga gcaaggagc gaggggtgtc ggtgtgcagg ggggtgcgctg 300
 tgtgtgcgcg cgtctccggg aaggtctcgc ggcggtgga gccgggactg acagcccggg 360
 cggagcgcag gcagctccac acgctaaacc tctgcctct cccctcacc ccaccccttc 420
 cactcccctc tccttcccc accctccccg gcccttcca agctctctga ttggccaatg 480
 ggacaaaagt ttctgtggag acggctgggc gctgacgtca cgggcagaat tgtcccattt 540
 agggatcccs ggggcagtgc gcatgctgca ggctgcagg tagaggcaga aggaggtagc 600
 agcgggcccg gcggcagcca ggtggcagaa aggagcacgc agcatccagg tggggggacg 660
 actccagcag ggtttccatg gagattcctc tgggtctagc ctaaaaacag cagatcagct 720
 gacaccatta gctcaggacc taattactgc ttattggagc aacaaatgag ggaaagggcc 780
 agctgcaaag gaagagtttt tatccccca cccattccc ccatctcctt tctccccctc 840
 tctccatccc tcttgagtcc cgggtgaatt ctcatctact tgcaagattc ctgcaacaac 900
 agctcccctt ctccagaggc caccocgact gcttttattc ttttatttcc ttcttttgta 960
 ttaaaaagaa atgctaaaat aatcagttg ttgagtcctt gaatttttgt tcaatacgta 1020
 ttagaccata gagctcagag aagacactgt ccaatgaagt cacaagtga tctaatacaa 1080
 gggactcagg ggaaaaatat cactttcaat ttattgaggt gaatctttag atatttcaca 1140
 ttaaaaaaat cttaatatct taaatacata aatatttgaa acacgcaatt ggacagaaga 1200
 tatc 1204

<210> 8
 <211> 687

WO 02/060318

PCT/US02/03077

<212> DNA
 <213> Homo sapiens 2.C.59

<220>
 <221> n
 <222> (650)..(650)
 <223> a or g or c or t

<400> 8
 gcggccgcac aagcgcacac gcacacgtcc agggcggagg aacactacta gtaacacccg 60
 cctccttcta gcctccctat cccaaagtta tgggtgccgat tttgtccgcg gcaggggctc 120
 caggggcaca ctcataaatt cgggtgcggag gaacacaact agcagcacca ccccccgcc 180
 actgccagaa ccaaagtgac ggtgccgaca cccctccgca agcgcaaggc cgacttccat 240
 aagtaattag ccagagcacc gtcccgttcc tgtcagcacc gagccccagc caggacaccg 300
 gtattcccag caccatacaa gaactacttt ttcgatgaag caacccaaaa gctgcgagcg 360
 gttcccgggtg aggccgcccc ctcacctggc cggcgcagac aagctccgtg cgtcaagaca 420
 taacagcgta agtgtacgac gttgcgcgag gacgcggggg ccttcgggaa atgtagtcta 480
 caactggaaa ccggccggat cgtgtctgcg caggcccagc agctaagatc ggggtccggcg 540
 ctccagaaca gaacgatccc tgaggctccc ttgctcgaac tgtgggactt accctactat 600
 ggtccgagcc taccctatctt cattatactc aagtaacgcc ccagaaattn cagagaatct 660
 acacaaagag gttgagtctt gccgtgg 687

<210> 9
 <211> 1520
 <212> DNA
 <213> Homo sapiens 2.D.10

<400> 9
 gcggccgcga ggacagctcg gacgggggag agaaaggagg tttccagtaa aaataataac 60
 gccagagaga aaaccgtaac tcgcgtgaca cagacagaaa tttccagtaa taatcatcag 120
 gtgatagaga aggaaggctt ccaaaatgaa gaacaagtga aataaagggt ttagtcatga 180
 attacagcac gtgcgatgga tgagtgggtga tttctcatca taaatggtaa ctcgggagat 240
 agagaaacgt gtccagccct aaactacaac agggtttggt ttgaaagaga ggtgctgtca 300
 taaagcggaa ctcaagggat ggggaagacg gcctccgtcc caaatgacaa ctcaatgaca 360
 gagaacaaaa gatccaaact aaagtgatgg agaaaaaggg tttccaacca ccacacaaat 420
 gaagagaaag actgatcaca taatgaagta ttcagtcatt aatacatgat aaaccgggtg 480
 atagagaaag aggcttagtc acaaattact cagataatgg agaaaaaagc cttattcatg 540
 tatcactcag gtagatacat caaggcagggt ttcctgccat aaaggataac acagctaaaa 600
 gagaaataaa ggttttagta ataagtgaca attcatataa cagagaaaga aggcttctgg 660
 ccataaggat aactcatgta ataaagaaaa gtttttagtca taaataatag agaaagaaag 720
 gtttccgata gaaaatggta gagatagaaa ggttctaggt aacaaacggt aactgaagtg 780

```

atagagcaag gtcacaaata ataactcagg taatagagaa agatttctag tcataaataa      840
tacatctgct acagaaataa gggttttgat tcataaagtt atgtcataag tgataagtgg      900
tagaaaagga aaggtttttag ttataaatta tgattcaagg gatagaaaaa caaagggttc      960
aagttataaa tatcatttca atgggtcaaga aaggttttca gtcataaatg aaaactgggt    1020
gaagttttcc agtcacaggt tataactcag gcaatggaca gagaaggaaa gatttttgtc    1080
atcaatcaac tcagggtggag aaggaaaggt ttttcaataa gaaataactc agttgagtga    1140
aagaaggctt gaggtcatga atgataatta ggtgatagag aaagaaatgt tccagtcata    1200
agggttaaat cagatgctag agaaagaaag gtttttagtc ataaataaaa ctcagctgct    1260
agaaagaata gggctaccag tcataattga taactcaggt gagagaaaga ttgctgggtca    1320
taaattgtaa cccagggtgac agaaaagaag gtgtcactca cacatgataa ttcgggttat    1380
gaggaagggt tccagccaca gtggtaactc aggtgctagg gaaagaaggt ttgggcaata    1440
atgacaactc aggtaataca gaaaaacgat tacagtcata aatgacagag aaggaaaggc    1500
ttttattcat aaaggatatc                                         1520

```

```

<210> 10
<211> 575
<212> DNA
<213> Homo sapiens 2.D.14

```

```

<400> 10
gcggccgcgg ctgtggctcc tcttggccgc gcagctgaca ggtaaggcgg cggcgcgcgg      60
gctaccaag ggtctgcgct cccggggcct gagcggggag gtgataagt gctgtcctgg    120
ccctggtcct ggcagggtgc agcgtcgagc ccgcggtggc ggggcgcccg ggaggcagct    180
tggcaggcac ggtccctaag ggtggaaata aaataccccc atatcgcat accccggggg    240
accggagagc ccctggactg aggccacctc ccctcaaaag cctggacgca ggagaagggg    300
aggcagtga aaggggagcg agtgaggga ggaaagagag ggtcgctgga ggtcaccagg    360
ggaaggaaac aggtccctgc ccagggtccc cgcaggatgt gctcggagga aggttggcca    420
ggccatgggt cctgtggaca catttttatt acttccgggg aagtgtttgt agtacaatca    480
gacaaacatc gggcgttctc agttctcgga gggctagggc agggatgatcc ctctggctcc    540
cgttctccct gatgtcgctg gtgttgggtg tcatg                                         575

```

```

<210> 11
<211> 741
<212> DNA
<213> Homo sapiens 2.D.20

```

```

<220>
<221> n
<222> (691)..(691)
<223> a or g or c or t

```

WO 02/060318

PCT/US02/03077

<220>
 <221> n
 <222> (732) .. (732)
 <223> a or g or c or t

<400> 11
 gcggccgcgt cgtcgtgag tacaccagct gcctcatcta tctggagccc ggccctccatc 60
 tcgccaggct cagcgcccgc gtccgtgtcg gtgccggagc cattggccgc gcctagcaac 120
 acctcgtgta tgcagcgctc cgtagctgca ggcgccgcca ccgcagcagc ctcttatccc 180
 atgtcctaag gccagggcgg cagctacggc caaggctacc ctacgccctc ctcttcctac 240
 tttggcggcg tggactgcag ctcatacctt gcgcccattg actcacatca ccaccgcac 300
 cagctgagcc ccatggcacc ctctccatg gcggggcacc atcatcacca cccacatgcg 360
 caccaccgct tgagccagtc ctgaggccac caccaccacc atcaccacca ccaccaccaa 420
 ggctacgggtg gctctgggct tgccttcaac tctgccgact gcttggatta caaggagcct 480
 ggcgccgctg ctgcttcctc cgcctggaaa ctcaacttca actccccga ctgtctggac 540
 tataaggacc aagcctcatg gcggttccag gtcttgtgag cccaggaatg aaagaggaga 600
 agaaacgcaa ctacctgcgc cctccgtggc cccgatcctg ttgctgctgc tgcaccgccc 660
 gcctttgcct cgtcttctcc aaaaactgat tntcaccccc caaaagatgt ccattgcctg 720
 cactgccgcc cncatttttg t 741

<210> 12
 <211> 458
 <212> DNA
 <213> Homo sapiens 2.D.25

<220>
 <221> n
 <222> (333) .. (333)
 <223> a or g or c or t.

<220>
 <221> n
 <222> (372) .. (372)
 <223> a or g or c or t

<220>
 <221> n
 <222> (426) .. (426)
 <223> a or g or c or t

<400> 12
 gcggccgcca gtagcagagc ccagcacatt gcgggtgccc agttcatctt cgtgggggta 60
 aacctgcggg aagagaggga aagggccctt agtttccatg gagatcgggt gccagggggc 120
 ggagggctca aggctggaga gcagagggac ccccatcttt tgtgggatca gggtgcccc 180
 agcatcttgg aggccactg aggcctgggg gggcgcggtt taacttctag catcagggac 240

ttaggcctgg gggaggcgct gggaagtggc aggtggggca ggaggggtct gcacctgaag 300
 gttgtgcacc tggattgggg gtgtagaagc gnggcaggag cgccgcggtg ggggcgtcca 360
 ggccccgggcg gnggagcaag cctgggggag ggagctctgc acgcgttgct gggatgtggg 420
 gggcgngggg aggcggcatg gggggagggg cgttgtgt 458

<210> 13
 <211> 615
 <212> DNA
 <213> Homo sapiens 2.D.27

<400> 13
 gcggccgccc ggcgtcccgc tctggggggc cgggaccgaa gcgctcacgg cccggggacg 60
 cggggttggt ccaggctgcg gcctgtggcg cgtgcaggcc tgaaggaggc gagatgccga 120
 tgccgccacc gctgggtccg tggaccaggc cccttggtcc agcctcccct cccgcagccg 180
 cccgtctggg ggtgttcgca gccccgggct cccccggccc gcccgccggg gagtgggagg 240
 gcgatggcgc cccgcctccg gctcttacgg agagcgcgcc tccccctcaa ctccggcggc 300
 ggtgagccgg ggtgcgatgc gcggccgagg cctcgcccgg accgcgggtc cccatcgcgt 360
 ccctggggcga gggagggggc gttggccgga gatggcggag gggcgtacct gccccgcctg 420
 cccgccgtcc ccagccctca gcgcctgggg aagcccctgc tgtggcagtg ctccggcgct 480
 atccggagga agaggagcag ttctcttttc ttggctgcgg cagggtgct tgggcccggaa 540
 aactaacttg tgtcggcgcc cagccgcccc gcgcgggctg ccggctagct caggccgacg 600
 ccgaggggag cggcg 615

<210> 14
 <211> 669
 <212> DNA
 <213> Homo sapiens 2.D.34

<400> 14
 gcggccgcgc ggggcagcgc gaggaactgt tgatttgctt gcgccttggg cccctgcgtc 60
 tctcccaggc ggcggctccc gctttcctca aaggccgtgt cgggtttggt gtttggtgtg 120
 ggtgccggga aagggcgctt ctccccagtg aggtggggaa cttgggtgat gggaccacgg 180
 aggcgcgggt tcgtgcccgg tggggacggg tgaggcaggg gagagtgaga ttttattctc 240
 cccaaggaa ggagtgtccc cttctcctta ttttgagggc tattcaagct tattgaaacc 300
 agaaagcggg gtttcttgtc aatctctcag ccccttcttc caaccaagaa caattgtcga 360
 tgagtttcca tcacaggcgc ttgtgagaga accggtaaacc ccagtacagc aaaatccaag 420
 cccttggttt ccacatgcat ttgtctagca gtttttgga ttgaccctcg ccctcccgtg 480
 tttccactcg acatcattta gcgtttgagg ttttttccc tcctcaaaat tgcaaatgag 540
 aaaaaagag gaaaccagga aaagggggtg gggggtagca tttaaattgg atgtgagttt 600
 ctgctgagaa ttctagcgaa gtcccctgta cactgaagcg ccgagagatt tttccgtttg 660

tgtatcttc

669

<210> 15
 <211> 998
 <212> DNA
 <213> Homo sapiens 2.D.40

<220>
 <221> n
 <222> (929) .. (929)
 <223> a or g or c or t

<400> 15
 gatatccatt ataatactat ttgacctcaa agtgaatttt attgttccac acaagcaaca 60
 gattacacca atttcacaac tcccagaatc caaacctaca aagacccttc ccaccaagca 120
 ctttaccaaa aacgggcttc atctccatct tcctttcttt cacagttgaa aaactgccct 180
 tcctaattaa gccaaccaac ttcttacctc aataaaatcc ttgtttttca gtagcatgta 240
 cagtatttcc agtgatgaac agtgaactgt ctttcgtctc acacagtaac ctccgtgaag 300
 aagatccacc ttgttcttta ctgtatatcc ctggcatgct aactgcatcc tcagacaatt 360
 ttaagtgact gaaaactcag gcaaagaaag gcaagagggc aaatagaagg gcacaggaga 420
 caacgctttt caaatttttc tcactgcgac ctacagaaac aactgtaga acacctccta 480
 gtacactcac acgtgtgtgt acacctgaag tgtcaagaaa caatacccta agtgcaacac 540
 cctctgatat tttctatttc aagtggcgt gatctactaa actgatttcc aactcaccaa 600
 taggattcag ttgaaaaaac actgcaataa atcaaacctt acagttgcat tccacaagct 660
 actaatgaac tcttgaaaat ccagcataca gcagagacgc tgaccaacta caagatccaa 720
 acccccaggg tgggcagtgt ccttctgttc agcagtggca gttccccacc accaccagcc 780
 ctgagagtta attatctccc aaactcccag agtttcccaa gtagcctgag gtgtctgtca 840
 tatgcccttt taacctcttt ataaattcag tcccgctcgt ctcttacggt ggcaaagttc 900
 atttatcgtc ggctgtggaa agcaatacnt tctttttgtc cccttcagga acccagaatt 960
 aatgaccagg ttgggtgcccg gtgtgccttt atgatcta 998

<210> 16
 <211> 797
 <212> DNA
 <213> Homo sapiens 2.D.48

<220>
 <221> n
 <222> (679) .. (679)
 <223> a or g or c or t

<220>
 <221> n
 <222> (687) .. (687)
 <223> a or g or c or t

<400> 16
 gcccctctga gttacgggga gccctgcaga caccagccc ctggggatcc tctccccgac 60
 ctgcccttcc cctccgacac ttgccagtac tccccggcct ggtattcctt tcgagacccc 120
 ctcacctatt ccaggctgtc ctccactgag gcgaagctct atgaagtagc ccaatttcaa 180
 tataattcac gttgtgtaaa agaactttga agacggacta catcgtgcaa ggacaccgtc 240
 acccgaaaac cattgggtgga acgttaaaac aaacaaaaaa caaacgggca aaaccttttt 300
 gaaggcaatt ttgacattta tgaatttaca gttattattc ggtttgtccc tgaaatgtca 360
 cttctgaaaa tttgcatagt tttcattatc actaaaataa tctagtaa atattcccgaat 420
 gaatgcattc aagaatattc actaaattat tttagtata aggaaaaagt ggaaatagct 480
 gacagtcattc aatttataaa taaaatgatg gttaaataaa atgatgaaca ttcatataaa 540
 ggaatactct atattcagac gagatctgtg tgctcacagg caaacaggtc taagcttact 600
 ttaaataaaa aaggataaat tgcaaaaaga atagtgtgtg taatatgatt ccacatttgt 660
 aaaaatggag aaagaaatng taagcanatg tctgcaagca atcagatatg attagtgact 720
 taatttcatg gatagttata taggaaatat atgtatatat tatatgcaca tagatatgga 780
 ggaatatact ttcactg 797

<210> 17
 <211> 1024
 <212> DNA
 <213> Homo sapiens 2.D.55

<220>
 <221> n
 <222> (499)..(499)
 <223> a or g or c or t

<220>
 <221> n
 <222> (768)..(768)
 <223> a or g or c or t

<220>
 <221> n
 <222> (846)..(846)
 <223> a or g or c or t

<220>
 <221> n
 <222> (847)..(847)
 <223> a or g or c or t

<400> 17
 gcggccgcgg cgctgcacgg gcgtgacgtc atggcgccgc ggagccgcgt cctccccgcc 60
 ccgcccccg ccgggggtcac ccaccgctg ccgggggtga cagagaccct ggcccgcggt 120
 ctgcagcctc ctcagtcgtg cgtgcgttca ttccgctcat agcttctgtc actcagcaag 180

```

cgctcaacac agacgcatga gataccctgg ctggaaggcc ctgaaaggta gtcgtccatt 240
caacacgtgc ttagcgcgct gctgatctgt gccaggcact gggccagggc cccgacacgc 300
gtcagggtag aagcaagcag aagcctggcc ctgttgagc ttacattggg aaataaccaa 360
gataatttca ggtaaattatt aggtcctatt aaaaatatgc gtcttcgcca ggcgcggtgg 420
atcacgcctg taatctcagc actttgagag gtcgagcacg ggcggatctc ctgagggtcaa 480
gagttcgaga ccaacctgng taaatgggtga aaccgcatct ctacaaacat acaaaaaaaaa 540
aaattagcag tgagctgtga gcttgcacca ctgcactcca gtctgggcaa caggacgaga 600
tcttctaaca acaacaaaaa aaaagtatgg gccacctagt ccagccaaaa aaacaaagtg 660
cttttttttt gctttttttt tttttttttt tttttgagat ggagtctcgc tgtgtcgccc 720
aggctggagt gcagggggcg gatctcagct cactggaagc tccacctncc gggtttacgc 780
cattctcctg gctcagcctc ccgagtagct gggactacag gcacatgcca ccatgcctgg 840
ctaatnnttt gatttttttg ttgggtgttt agtagagacg ggttcacgtg gtagccagat 900
ggctaactct gactgtgatc tgcacttgcc tccagtgtgg atacagggga ccacttgag 960
caaagctcta ttcctgtagg aggggtgttg tgaatcagac ccaatttgga aatcaaattc 1020
tagt 1024

```

```

<210> 18
<211> 1854
<212> DNA
<213> Homo sapiens 2.D.74

```

```

<220>
<221> n
<222> (258) .. (258)
<223> a or g or c or t

```

```

<400> 18
gcggccgctg cagaccctgc tccaggcgcc gtagccttgc aggaagagca gacaaagaca 60
ggagagaggg aaagcgccgc ttgcccagag atgcagtcgg ctcaagtcaat agaggggaaat 120
cgcctccaaa cccaggctgg gaatgagggg ggagggggcg ggcggctggg gactagaaaa 180
agcagcaggg aattaacgtg acagtcagag cccagccagt gcctcgccgg cgctgctctc 240
tcgcctcgcg gttgcggngt ccggaatgga gagaggaggc gggggctgag ccgttggtg 300
ccggagacca gctgaggtag gagtattaac tccctctgct gctctcgctt gccttcctcg 360
caccctcta cacagctcta cttgcagcag gctatggccc cattctttct cctatttttc 420
taactactga gatcagagct gaattaagct ggtgaaagga gcaaacgtg caagggattg 480
attgccctcc ttgggggaaa agcggaggct taaaatcaat tcgacaaatg agtgtttact 540
gggtgctgag tactgtgctc cgctattgtg agggagggtt atgaataagg taccctctc 600
ccgccccagg gtccgttgct agatctcaga atcagtttcc cctgcagttc tggaagccca 660

```

aagtttcggg gttgagttgt ggtccctgat cccgatcctc aaccaatcta gcttttctaaa 720
tcagaagaag gtggaattca attttccttt ctccttcctg ggatgacttt aacctgcagc 780
cgaaatggag tctataggcc ccttaaaaaa gcgcgcgcac gccagtgtgt gtgtgtgcga 840
gcgcgctcgc gtgcgcgcgt gtgttttaag agtaagtcaa attaatgggt ttagtgatgt 900
tcttatttca tgattttaat tatttaccat atctgcagta gacaccagtt tggggcagag 960
gaacccgcct ctccagactc tacaaatacc accttttttt cttaaagcttt tttccgctac 1020
cccagtcctc tgactcgagg cagaaatcct tcccctctct ttgccctctc agaattttat 1080
ttgccaatca cttgcggaac ttatatatatt atagatttat ctcttcactc acatatgagt 1140
attccctgtg ctttttggtt gtttggttct actgcaacat ccagcagtggt tttgtatcta 1200
atgggtactc aaggaaagct tatccagttg aaggtcattt tctccttctg tatgagctaa 1260
atctcagtggt ctctagaatt aaagagactc cagggatgga acttttgatt taggggtgtgg 1320
tgaagggacc cacacataca gttagactca cagccccttt actggaaagg taataaagta 1380
tttaattcat tttggtctct agacaatcaa ccttctccca ctgaccaccc acctctgttt 1440
cctgaattcc caaaagcaaa agaaaaccaa actgctaagc aactgcctag agcaagacat 1500
gtatgttcag ctgccaacac ctagagcaaa cccattccaa gtggagaatg accaaaaaat 1560
cttgattatt tcttgacctg tgtcaagtat gttgaaagcc tgccaaagtt tcctcatttc 1620
tattgaagca ctcttattct ggatgcattt tagaacagtt tgaacagtggt tacattgctc 1680
agaggtgaag aaaattgctt tgtagtttaa ggatatttaa gatttgtttg tttgtttgtt 1740
tgttttctgt cccaccttct acaaattgca cgatagatac ctcagatcag gaatgctgca 1800
tgaaaaagta tgtccataat gcaggagatt agactaaatg actcttaaga tate 1854

<210> 19
<211> 674
<212> DNA
<213> Homo sapiens 2.E.20

<400> 19
gcggccgcct tcccttccca ttcactgggt gcctcctttg tgaactaatg actgtaatta 60
ttacctccca gagctctttt gttatctcca accccaagcc ccggagaggg ggaatgggct 120
ctttagtga atgaaagtca ttacaaagca aattaccgtc tagggagggg cagccttcag 180
gaaagacaaa tcagatctcc atctgcattc gaagtaggggt gtgttttaaat aaaaaatgta 240
aatatcacca ttagatccaa agtactccag agctgtggga tttaatggag tttaaacgggt 300
agcacttgaa gccattgctt taccaaaaag aaaaaaaaaat cagttaaatt cagggtgtttt 360
aatccgtttc ttctttgggg gttttgtgtg atttaaagc ttgcttttaa gaacctttat 420
gttttcaacc actcatccat agtagaaaag ttctgcaacc ctagactgct ggcttgaagg 480
aaaacctttg caggatttga tatggatttc aacaaagaac cagcctctgc gaggctggag 540
agagctgcgg agctgccatg cctgaagtgc agatggctga accacaagtc tttagggttc 600

cggagttggtt attgtggtga cctagagtgt cagagccagg agagcaagaa agaggagcca 660
aactgagccc tgag 674

<210> 20
<211> 676
<212> DNA
<213> Homo sapiens 2.E.24

<220>
<221> n
<222> (493) .. (493)
<223> a or g or c or t

<220>
<221> n
<222> (505) .. (505)
<223> a or g or c or t

<220>
<221> n
<222> (508) .. (508)
<223> a or g or c or t

<220>
<221> n
<222> (533) .. (533)
<223> a or g or c or t

<400> 20
gcggccgcag acgcgccagg cccgccaggg cgccgcacgc cgggcgcgcc acgatgtcca 60
cgaagcccac gatggacagc aggaaggcgg cgtcgggtgc gggcacgccc gcgtccttgg 120
cgtagttcac cagcaggatg gcggggacga agagcccagc cgccatcagg aacttgggtga 180
cggcgtacac ggcgaaggcg cggtcgggtgc aactgccaa gtccagcagg cgccggcggg 240
gccggaccct gggggatgcc tcgcgcagct gcagccccgc accgtcagcc tccgcctcgc 300
ccggagcgtc cccggcgcgg tcgccggcgc tgtccctgcg cggtcgcggg cccggcccgg 360
gcggcggcct catgacagcc ccgcaggcgc agcagtgcag caggagcccg ccgagcagca 420
ggaagccgcc gcgccagccg aagcgtcca gcagctgctg gccgagcggc gacagcgcgg 480
acaggaacac ggngctgccc gccgncgnca gcccgttggc cagaggccgc cgnccgtcga 540
agtacagccc cagcatgatg agcgacggct ggaagttgag ggccaggccc aggcctgcgg 600
gcgaggcggg gctgtgccgg ggtccccgga gagcccctcc ttgggccccca caggaggag 660
gggccaggcc ccggaa 676

<210> 21
<211> 455
<212> DNA
<213> Homo sapiens 2.E.25

WO 02/060318

PCT/US02/03077

```

<400> 21
gcggccgcg g ctggggggcgg ggagggggggc gcaggacccc aagtgggggt cccggagcca      60
gaggcaagtg tcctgggggtg ctggggggcgc cgtgccggcc gggccgctgc cctggcctag      120
gctgggtccgg gggctagcgc gccggggggct gcggccgatg ggcggggcga ggggcccgcgg      180
gggtggcgag ccggggggggc acgggggtcg ggggtgcccg agggggcgcg gccgggcggg      240
ggtggccagg gatgggggtc actgggggca aaggggatcc agtggggggg tcccgatgga      300
ggcgtgcagg gccagggggcg cccgaggcgt gcgggggtcg ggtgccccag actggtggcg      360
tcagacaggc gtgggtcgtt gggggcctgg gtcgcggctt gactgagggc ccggccgggg      420
ctgtggggcg tcaggagagc gtggggtgtt atggg                                     455

```

```

<210> 22
<211> 156
<212> DNA
<213> Homo sapiens 2.E.30

```

```

<400> 22
gcggccgcgc ttcgacgacg acgacgactc cttgcaggag gccgccgtag tggccgccgc      60
cagcctctcg gccgcagccg ccagcctctc tgtggctgct gcttcggggc gcgcggggac      120
tggtgggggc ggcgctgggg gtggctgtgt ggccgg                                     156

```

```

<210> 23
<211> 978
<212> DNA
<213> Homo sapiens 2.E.37

```

```

<220>
<221> n
<222> (712)..(712)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (819)..(819)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (938)..(938)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (956)..(956)
<223> a or g or c or t

```

```

<400> 23
gcggccgcta cagtgcgtca acaggcgtg taatccgagc gcataaacga ggggtccggg      60
ggtggggggc cggggcgggc gtggcagtgg cccggggctg gcagcccgt ttgaaaatct      120
ggcgaagtcg gggagcctgc gtttgctttg gcagctgcga aggcgcacag gtgcacgggg      180

```

```

gcgggggggct ggctggcggc gccaccaccg accgtcactg acagagcctc gccatgggcg      240
cccaaattcg ttcaacttgcg aattgcgtaa gcggccctcc ggtacccaac ctctgggaat      300
tacgcgggct tgtgcctgtg gccaccttgc tagggcccac cgctccagcc tgaactccca      360
ccgctccctg ccttgcgctt gatgttccag caacttcgaa ctgtttttat ctctgtataa      420
ccaagccgct tctctccttg acgctggcct tcctgcctgg cttgccctcc cgccttcttt      480
tgccttttaa gaccgggcag ctatcccacc ccgccagtat atgcccctct tctgggctcc      540
ttggcttcct gtttatacct acgtgactgt gcttactttt ttgcacatgg tttttcttat      600
ccttctgtaa gtttcttgaa ggtaggagcc atgtcttacc ctgccaagca cattgtctgg      660
cacgtagtag ctgttcagta gaggaagtgg tccctttccc taaagggctt tncgtctcac      720
tggagagaaa ggctagcctg gtaccaggga ctgccgagat caagtgatgg cagtacgtgc      780
gattcgatgg tgccgaaagt gacctagaga ggcagctgng agtgctctgg tgctcgcgga      840
tagagctttg gcgatattgt catttacaat gaggactgta ctctgagacg tggaccttct      900
aacagaccat tataaccttt gctctggagg agtgagcnag caacggactc tgacancatg      960
ttttgacaat ggggtattg                                     978

```

```

<210> 24
<211> 321
<212> DNA
<213> Homo sapiens 2.E.4

```

```

<400> 24
gcggccgcac cggctcgggc tctgccaagg gacccggcct gcccgaatgc cgcgggcggg      60
cgggtgcccg tgaccctgc acctgactgc gaggcgcggg aaatgaccgg gtctgtcagc      120
ctcccatcgc ggcttccgtc tacaggtaact acctgtgctc tgtccagcct cagccactgg      180
acgatccttc ccgtagccgt aggaaggggc ggcgcttcct tggaggggat attagaggcc      240
cgaattcgcc cgggaagcgg cgggagggcg ggggtgccgg gaaggaggga ggggagaagg      300
agtgagggaa gtgggtgtat g                                     321

```

```

<210> 25
<211> 1023
<212> DNA
<213> Homo sapiens 2.E.40

```

```

<220>
<221> n
<222> (628) .. (628)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (651) .. (651)
<223> a or g or c or t

```

WO 02/060318

PCT/US02/03077

<220>
 <221> n
 <222> (830)..(830)
 <223> a or g or c or t

<220>
 <221> n
 <222> (837)..(837)
 <223> a or g or c or t

<400> 25
 gcggccgcgg gctggggggcg agcgcacacc ccgcgccgct ggagttcact gccgggcgcc 60
 ggcattgggcc tgggggaggg gtgcacaggg cccggagggt gcgtgggtgt ggggtgcgcc 120
 cggaggagag cgaggctgcc agagtgcgtg tgccgactga gccagtgtga gtgtgcaggg 180
 gctggcggag agactgggag cgagtgtgtg tgcattctaac cgggaggttg tgagtttgtg 240
 tgcgcgcacg cccgcagaga agttgtgagc ctgtgtgtgc acctaacaca gaggttctaa 300
 gtgtgtgcac ttgtatgtgt gtgtgcacac gcggacagag tgattgtaag gatattgtgtg 360
 cacctcacag agaggttgtg agattgtaag ggtttgcgca cctaaccggag atgttgtgag 420
 tgcttttttt cctgacaggg tgtgagtttg tgttgtgtgt attagagggt tgtatggacc 480
 tgactgaggg gttgtggaat gtgtgtgcgt gagcatgagc ctggagaggt tctatgcctg 540
 ttcactcctg acagagtttg tgagtgtgta tgattgtgtg actacaccac ccaactggcg 600
 gattgaatgt gttgtataca tctactgnga gggcgtgtgt gtgtgtaaat tgtatacaat 660
 gaggtgtgtg gcatcagtgc acctaacac gaacctgtgt gtacagatgt gtgtgccttt 720
 ctgtgtatca gacatgaggg catgtgtctg nggtgtgtta gttgggtgtg caagtgtgg 780
 agtctggggg ggagagaggg agttcggagc cttcccgctt tctccttctn cactctntgc 840
 ttgtctcggc caccagcatg ttggaggact acaaggctgc ccttcaggcc ctttagaccc 900
 gcttaaggca cttgtgatcc tatatgccag atgccctccc aaagtgccag gctaccacat 960
 ggcttggctg attgattggc attgaccacc catttgttct ttgcttcctg ggccgggtcat 1020
 aaa 1023

<210> 26
 <211> 964
 <212> DNA
 <213> Homo sapiens 2.E.61

<400> 26
 agccacatgt gtacccatct tcctcctctg tggaaggcgg aaggaaacag atgccctcca 60
 aatatggaca gctgaaatga tgaagtgtg aagccctggc ccagaccctc agagagatgt 120
 actcaaccac ctccccaccc ttggacaagc acaaaaccag agaaaacaaa ggccagcaac 180
 tgtggctcag cccgcataaa tttcttctgg acactggcct gtctatttga atatctgtaa 240
 tgtttggtgg agtcaggggt gagggctctc gcctttggct gctgcattct cagacaccaa 300

tcatgggggtt cttttctttt ttttaatttt tttttttttt ttggaaccgg attccaaggg 360
 gccaatttaa gttaacttcg gcttccaagg ttcaaggcaa ttcttctggc ttaaccttcc 420
 aaagtggctg ggaataccag gattgcacma cmatgccsgg ytaatttkgw attttwagka 480
 raracarggt ttytccatgt kggtwaggyt ggyctmaaac tytsgacctm aggwgatcca 540
 cccgcytsgg cctccmaaag tgctggratt acagsswtga sccaccgkgc csggcccatc 600
 atgggtcttac taatgggtat tttcccctta acatgtcatt tgagccccctg cctgctcatc 660
 agtaaactgg gctaattaat aataccctcc tgtagggctg ttgtaagaat aaaatggact 720
 atttgagaaa agggcttaac aacagggtat agtgacagag gactcggtaa ctgctttttt 780
 gtgcttatta agagagaata ctacagcaac ctatgggaag atttgaggctc acgaaaacct 840
 gttctccgtc cttggagcca cagctggact acatttccca gccttccttg cagctgggca 900
 tggtcacatg actgtgctcc agccaatgga atgtgaatgc aagtgatatc aagcttatcg 960
 atac 964

<210> 27
 <211> 748
 <212> DNA
 <213> Homo sapiens 2.E.64

<400> 27
 gcggccgctc cgttgactgc agggccccgg cggctcttct ccgctgttcc gagggcgttg 60
 agggctgatg tgctccatcc tcccacttgt ggtttggcaa gccatccagc cgactacaaa 120
 cccacgtttg tgagttacct gctggctgtg acgcttccgt caaatctgag taacagtttc 180
 ctcatctcta agatgggtaa catagtatct acctcacagg atcgtgtggg cagtacatgc 240
 atagaaagga tttaacacgc agtgtactca gctagtttta ttatttatcc gtaatgatca 300
 tttgttcttt tcccctaact gtgcctcaca agcatgaaac agaatccacc aaacatttag 360
 gtctgggtag tggttggatg gaaacccatc gcgggttaac gcttccaaca ccagtccctt 420
 gacactctcc cgccgaggag gctgatttgt aaacttgctg agaagagaat acccagcaga 480
 tctttcaggt ttcaaatacca cgttctttac aagttgtgtt aattgtttgt atatgcttcc 540
 gatatagagt ctctaggaag taatactagt acatgtttta aaattcaaata actgccaaac 600
 agtgagatgt aagtctccct cctaacttct gtttcccaaa tcccatgtcg tttcttctga 660
 tgcaatagac attgtatgtg tgtgtgtcta gatagatata tatgtgtatc tctcggcttt 720
 ttttttttct tttaaagagt aaaccaag 748

<210> 28
 <211> 250
 <212> DNA
 <213> Homo sapiens 2.F.2

<400> 28
 gcggccgccc gggaagggcc ctggaagagc aggaccaggc agagcgggcg ctgggggtctg 60

WO 02/060318

PCT/US02/03077

cgctggagct tgcgctgagg ccgggggtctg gccaggagcc gcagttgcag ccgctgctgc 120
 cgcaggggtct gaggatgagg ctggagccgc agcgggaacc ggagccgcag ccggtgctgg 180
 cgttggcgct ggaactgagg ctggggccgc cgcgggact ggggttggcg tggccggagg 240
 agcacttact 250

<210> 29
 <211> 657
 <212> DNA
 <213> Homo sapiens 2.F.41

<400> 29
 gcggccgcgt acggacagcc agtgcattag gcagggctcc cctacgcgcc cggagagcgc 60
 ggaccgctgc ctcgggcccgg cgcgcctcc tgccgcctgc cgcgcctcgc ggagcccag 120
 ccccagcccc agccgcgcc taccacaggc cggggcgctc agcagccggc ggctgtcca 180
 tgtggggcta gccctcgcgc ctggcctgca tcaggaccag caacatggag gcggccgttt 240
 gcgacccccga cacgcgagga ccagggcggg gcggagcccc gcgaggacgc gacgcccattg 300
 gacgcctgtc tgcggaaact gggcttgtat tggaaactgg tcgacaagga cgggtcgtgc 360
 ctgtttctgg cccgggcccga gcaggtattg cactctcagt ttcgccatgt ggaagtcaga 420
 atggcctgta ttcactcgtc tcgagagaac agagagaaac ttgaagcgat tatagaacga 480
 ccatttgaag gaattttaaa gcgcttcgga aattcacagg aatgggtatg acaaattgaa 540
 aaaagagccc tttctcttat gtacaggaaa gattttattc ctaaactgga gccaaagggt 600
 ctttctcaca agtaactgaa aatattttcc tgaaaggggt tactgggtgtt tttaaat 657

<210> 30
 <211> 318
 <212> DNA
 <213> Homo sapiens 2.F.50

<220>
 <221> n
 <222> (39) .. (39)
 <223> a or g or c or t

<220>
 <221> n
 <222> (84) .. (84)
 <223> a or g or c or t

<220>
 <221> n
 <222> (189) .. (189)
 <223> a or g or c or t

<220>
 <221> n
 <222> (223) .. (223)
 <223> a or g or c or t

<220>
 <221> n
 <222> (256) .. (256)
 <223> a or g or c or t

<220>
 <221> n
 <222> (260) .. (260)
 <223> a or g or c or t

<220>
 <221> n
 <222> (261) .. (261)
 <223> a or g or c or t

<220>
 <221> n
 <222> (279) .. (279)
 <223> a or g or c or t

<220>
 <221> n
 <222> (296) .. (296)
 <223> a or g or c or t

<220>
 <221> n
 <222> (297) .. (297)
 <223> a or g or c or t

<220>
 <221> n
 <222> (305) .. (305)
 <223> a or g or c or t

<220>
 <221> n
 <222> (317) .. (317)
 <223> a or g or c or t

<400> 30
 gcggccgcgg agcgattgca tgcaggggcc gcgtaccgng aagtgcagaa gctgatgcac 60
 cacgagtggc tgggcgcggg cgcnngccac cccgtgggcc tagcgcaccc ccagtggcta 120
 cccacgggag gaggcggcgg cggcgattgg gccggcggcc cgcacctaga acacggcaag 180
 gcaggcgng gcggcaccgg ccgagccgac gacggcggcg gcngcggagg tttccacgcg 240
 cgcctggtgc accagnnggn ntgcccacgc ggtcgcagna tgggcgcagg gcaatnncaa 300
 aacancactt gggcccng 318

<210> 31
 <211> 525
 <212> DNA

<213> Homo Sapiens 2.F.59

<400> 31

```

gcgggccgcct cccgccagga aggggtggcgg gcccggaagg ccagagatgc cccagtgcct      60
cccgcgcgcgc tacgcaacta gctgcccgcg ggtcccacat ggctgcggcc ggaggggtccg      120
caccaggacc gccgccgcct ggggaagcgc ttccctgtgg gcagggcgcg gcgggcagtg      180
cggaagcccc aaagctaccg gagccccggg caggggcggc gcgatgcaga ggccggcgctc      240
gggggcccc agctgcctgc ggctcggcta cccagccgcg atcagagggg gcgggggacg      300
caggaacccc ggcgtccggg cgggtgtgcag ccgcagacct attccaagtt tccacgtagt      360
tgcgagagcc caaaaactgt cacgtgcacg tcgctgctga gtgggaggag gtgtttgtca      420
tcgcgttcaa aaggggcgtt tcggtgtctc ccgtcatgca agcaaattgg atggctctcg      480
gccgcctttg aataaacgag tgcttcgaac cctttaccag gaggg      525

```

<210> 32

<211> 1032

<212> DNA

<213> Homo sapiens 2.F.70

<220>

<221> n

<222> (687) .. (687)

<223> a or g or c or t

<220>

<221> n

<222> (689) .. (689)

<223> a or g or c or t

<220>

<221> n

<222> (885) .. (885)

<223> a or g or c or t

<400> 32

```

gcgggccgcgg ccgggggggct gagaagggcc tgggtgcctg tcgcccggga gccgaggttt      60
cccggcctcc cccgaccccc ggccccaaga gcagtcggtc cccccggcct cccgccggca      120
aaggggcccct ggggcccagg cgcgcggccc ctgcgtggcg gcaggcggcc caggccagcg      180
ccggcggcta gagaaggcct ccagtccagg cctcatggaa gggcctgcct cgagcggccc      240
ctcaacgccc cgcagtgtgg cactggaagg gacctaaaaa cccacctggc tttctccttt      300
ccccttcccc acgcttccca gggcccaatg cccgcctctc agtttcgctt tccggcaggg      360
tcaggggtga gagggaggaa ttctcaggtg tcacctctc acccgcttg aggcggaggc      420
tagaaagacg tcggggcact ctggagggga ggaagagggt tgcctagaat tctctctctt      480
aaacgctcgc gttatcacgg aggagacttt ataaacactt taaacacaac accaaccatt      540
ttatcagcaa aagcgagggg agggggggcgt acagtaaatt ctgagagatg ttcgagaagc      600

```

cccaagacgt tccctgcgga aggagaacgg aagaaagaaa ttacggggcgg aaaaagagta 660
 aatattagct ccacacctaa ccacttnonc agccccaac taggagagaa tctgctaaga 720
 ttcgctttat atttatatag tctatgtgat gttaacaata ggggttgcaa atattgcatg 780
 ggggcattct tagagtaaaa aattgggtatc tacctgaaat tcaaaaattt aactgggcat 840
 cctgtattttt tattggctaa tcctgcaatt ctaactaaaa aacancctgt gaagaaatca 900
 tatagaagga agctaattgc tgatgaatac agtattggga actgttatgg aactggctgg 960
 aaagaaatga ttctctacga tactttgagc catgtaggtg agagagatga tgagcactgg 1020
 atgtctacta tt 1032

<210> 33
 <211> 708
 <212> DNA
 <213> Homo sapiens 2.G.10

<400> 33
 gcggccgcgc ccaggcgccc ctccccctgt ggggcaaccc aagccgggga cgcgtgaacc 60
 acctccgtag ccgccccgcc agcaccccca gccgtgcgcc cctgcaccac gcagctgccc 120
 tgcgcatgga gccagagagg acagcaggcc cggccccag caccaccggc ctgccgggag 180
 gttcgggaaa ctggcgtcgc agcggagagg gcatcaggcc aacgcctccc ccgaggctca 240
 gctgcgggct ccaggcgta ggcaccacg gcccttacgc tgaccgtagc ttggacgccg 300
 ctgccgccgg ggtccaatgc cggtcatgcc catcccgcgg gggttgtgct ccttccatgg 360
 tccacacacc acctgcctgc atgcggtctg tgggcccgtg ggcgcctccc acctggcccg 420
 caccaagtac aacagcttcg aggtgtgcat caagacgcgc tggctgtagg gcttcatcca 480
 cttcctgctc tacttcagct gcagcctgtc actggggcac gctggccgcc ttcttctgcc 540
 tgcagtactt gggcgttagc gtcctcctgt gcttccaaca caagctgtgg gtgctgctgc 600
 tgctgcttgg cccgctggcg cgttgaaatt tcgctgttga acgagctgct catctacagc 660
 atccacgtca acatgcttgt tgtatggggg cctgggctgg atgcctaa 708

<210> 34
 <211> 569
 <212> DNA
 <213> Homo sapiens 2.G.108

<400> 34
 gcggccgcac acgtgtccag gcgtcacgtc cgcgcgcgcc cccggggctt gcgtcagcgg 60
 ctgttccaga agcgggtggg ccagggtctt gcgcaccgct ggggttcggg gcccgggacg 120
 ccgccgggag gagggcaccg cgcgggggtcc gacgcggagg cgtgctcgga acgcggggg 180
 ctgcggagtg catcagcgcg gtccagccct ccgcctgccg ggcgccgagc gtctccgccg 240
 cccggacctg ggctgggcgc cgtggcggtt cctcggagct cgctgccgcg ggggcgcgca 300
 ccgccttgac ccgggcggcc ccgcggcagg caggcgcgcc cagttccatg gttgggttcgg 360

agcgcgatga gccgcccgtc ctccaccggc cccagcgcta ataaaccctg cagcaagcag 420
 ccgcgcgcgc agccccagca cactccgtcc ccggctgcgc ccccggcgcg cgccaccatc 480
 tcggctgcgg gccccggctc gtccgcgggtg ccgcccgcgg cggcggtgat ctggggcccc 540
 ggcggcggcg gcggggccggc ccggtgtcc 569

<210> 35
 <211> 916
 <212> DNA
 <213> Homo sapiens 3.B.30

<400> 35
 gcggccgcgc tgagctcact ccgggccctg cggaaagaat tcgtaccgtt cctgttgaac 60
 ttcttgaggg agcagagcag ccgcgtcctc ccgcaggggc ccccgacccc cgccaagacc 120
 ccgggcgcct cggcagcctt gccagggagg ccgggaggcc cgccgcgggg tagccgcggg 180
 gcgcgcagcc agcttttccc tccgaccgag gccctgagca ccgctgccga ggccccctctg 240
 gcccgcgcgc ggggcaggag gcggggcccg gggccggccc gcgagcgtgg aggccgcggc 300
 ctggaggagg gggtcagcgg ggagagcctg cccggagccg ggggccggag gcttaggggc 360
 tctggcagcc ctagccgccc cagcctcacg ctgtctgata cgccaaacct cagcaacctg 420
 gaggagtccc ctccgtagg ctcggttccc cccggcccta cagggtgaga ctgagctctc 480
 atgcaggaga tgggtaccac gaaggctctg gggagtcagt cattcgagct cggcgctccg 540
 cagtggagcg ccaggatggg tagaaggctg ggggtgatgg tgagggtttt tgtggggttt 600
 ctccgcagcg gccatgctct gcccgtggg ccgtcatttt gtcgtttcgt tttctctata 660
 atgtaataac taactaggca aaaagtgtta aaattaataa ctactaaata tccgatgtca 720
 ttacaacatt tataatatat aacaatatta aaacatataa ttaataataa aaaaaacctt 780
 attttaatct ttttcttttt gttaatttat atcaccttat ataccatttt tctcaatacc 840
 attcgataca atcataaatt tattttattgt atattgtcaa aataaaatat tcctctatat 900
 aaaaataact ctcccta 916

<210> 36
 <211> 998
 <212> DNA
 <213> Homo sapiens 3.B.36

<400> 36
 gcggccgcag catggctttc ggccactact cggagcactg gaagggtgcag cggcgcgag 60
 cccacagcat gatgcgcaac ttcttcacgc gccagccgcg cagccgcaa gtcctcgagg 120
 gccacgtgct gagcgaggcg cgcgagctgg tggcgctgct ggtgcgcggc agcgcgagc 180
 gcgccttcct cgacccgagg ccgctgaccg tcgtggccgt ggccaacgtc atgagtgccg 240
 tgtgtttcgg ctgccgtac agccacgacg accccgagtt ccgtgagctg ctgagccaca 300
 acgaagagtt cgggcgcacg gtgggcgcgg gcagcctggg ggacgtgatg ccctggctgc 360

agtacttccc caacccggtg cgcaccgttt tccgcgaatt cgagcagctc aaccgcaact 420
 tcagcaactt catcctggac aagttcttga ggcactgcga aagccttcgg cccggggccg 480
 cccccgcga catgatggac gcctttatcc tctctgcgga aaagaaggcg gccggggact 540
 cgcacggttg tggcgcgcggt ctggatttgg agaacgtacc ggccactatc actgacatct 600
 tcggcgccag ccaggacacc ctgtccaccg cgctgcagtg gctgctccct ctctttcacc 660
 aggtaaagcg ctctgggagg cgtggggccag gtctttttctc ctctgaaaar ggcggagtag 720
 agacagaata tgctgagttt gcaagcaggg ccccsggttt ggggtttcgc tccaggtccc 780
 caccctcaa aaccaagaat cgcgtcggta arggractca cagtgagggc tgcgacacgc 840
 gcacgcgccc caccagcgg tgccccgaac cctccggtc yyctatctkg yytctatcgt 900
 cccctcmcyt gcttkcgagt gagaacacat ttgcaaagac cctccaccc cccggaaaaa 960
 caagagtttt taaatgcttg gagatgagcc ctgatatc 998

<210> 37
 <211> 514
 <212> DNA
 <213> Homo sapiens 3.B.55

<400> 37
 gcggccgcgg cgctgttggg ccagcagggc agcaccgagc ccgacttggg gccgcagtac 60
 tgccgggggac tgccggcgcc ccagcccagc gggtcggcgt agtagccgag cgggcggcca 120
 gtgcagcctg cagcctgcag cggcagcgcc ttcaagcccg ccgcccgcga agagagcagc 180
 gtggccgcgt tgcccgcgaa gtccgtggcc gtgtcatagg ccgaggdcgc gaagtccagc 240
 cggttgttgg ccggcgtcac aaaccagcgt tgccggcgagg gcgcgcccgg gtccctcggcc 300
 tgctgcggcg acagcagccc gttggtgtgc ggcacgctgc ggtccgtacc cggcccgggg 360
 cccgcgcccg cggccgggtg gaagcggggc ttggcgtagt tgctcacgaa ctggtcctgc 420
 aggaaagagc cggccatggc gtagcggggc ccgggcacga tctgcgagcg cggcgagtcg 480
 ttgggcgagg gggtcaggcg gtccatgtca cagc 514

<210> 38
 <211> 608
 <212> DNA
 <213> Homo sapiens 3.C.01

<400> 38
 gcggccgcgg cgcagcggag gggctgcggg cccggaaccc aggcgggtca gcgtgtaagc 60
 gcccagccg gccgggctcc gtgggggggtc agctccctga cccctacagc gcggtagcgc 120
 ctctccgaga gctccgggac cagcggcccc gccgccccca aagccagcct ccctctccct 180
 tccccgcacc gggatcccag accagggagg gggcgcacgt ccgacggctg aggaatagca 240
 gggcgcgagc cggcccggca ggtgcccatc gtcgccctct gggaccccgg tggcgcgctc 300
 tgtcctccgc gccacgctca gccaccaccc cggctgtttg ggacccggca cccagccgag 360

WO 02/060318

PCT/US02/03077

cgcgccgccc cctcggggac ccgctgggag gggctgagcg aggcttggag tgcgggagaa 420
 gggacgtggg gcgaaccggg ggcgctgcgc caccctgggt gtctccagcg gagaccggcg 480
 ccctcgcccc ccgtctccgt tcattgtgct gtattcatcc agcagatttt gaaacaattc 540
 tcgtgtaaaa aggcatttta ctccgcgcgt cttccttaca gccatttagt tgggagtttg 600
 cggtgggc 608

<210> 39
 <211> 1025
 <212> DNA
 <213> Homo sapiens 3.C.16

<400> 39
 gatatcctcg ctgggagccg ggggctgcag ctgctctgc tgctgctgct ggtagaagtt 60
 ctctcctcg tcgcagtaga aatmcgsctg caccgagtcg tagtcgaggt catagttcct 120
 gttggtgaag ctaacgttga ggggcatcgt cgcgaggagc tgctggagcg gggcacacaa 180
 agcgggaggg agtcttgagt taaaggggtc ttggtgcgra aacctggcgc agcgcgcagt 240
 gcgcgccaca gtcccgaacc tctccccttg cagagctatc ccctaaagcg gctgggtggg 300
 cttggtgggg gaataaaggg agcacccttt caccctcttt ggacagtccc ctgctatctc 360
 ggagacgcac ttagtgaacc agcggcttgg tgcccgccga gcccgcgctc ccccgaggagc 420
 ccggagcgca aagcccggga gtcggccccg cagcggcaga ggaatcgaaa tcggccctgg 480
 cgcccttaag aagccgcggg aggtggcggg gaggaaaaca atttgccaaa atccaaggca 540
 caaagttttg cgccacctga aggagaaggc gagaggcgcc tgggcgctag cggctgcgtg 600
 aaccccgctc cgcgccgggg cccctccgct gcggctgttc ccactcgcgc cctagccgct 660
 ctctacccc cgccggcacc gcagcccctc ccaaccttcc ytytccaccg scccgtccc 720
 caccctcagt accgcccccg tccaacactc cttttgccag cttttcttct ttctctcgcc 780
 ggctggagtg gcgagctcag ccgcggggctt taacaccctt ccataaatac arggggggtg 840
 tcaaataata ataggggcac ctcccttcgc actcaatacg gagatgcaac tgcgccagag 900
 accccgctgc gatacctccc ccggagccac cccaccaagg gtagcagctg ttctggaacc 960
 gccagagcc ccgctcctcg cagttcctyc gcctctcggg cgcgaggaca cccgaggcg 1020
 gccgc 1025

<210> 40
 <211> 1010
 <212> DNA
 <213> Homo sapiens 3.C.17

<220>
 <221> n
 <222> (829) .. (829)
 <223> a or g or c or t

<220>

WO 02/060318

PCT/US02/03077

<221> n
 <222> (875) .. (875)
 <223> a or g or c or t

<220>
 <221> n
 <222> (906) .. (906)
 <223> a or g or c or t

<400> 40
 gcggccgcgg accgacttcc ttcgccggcc accggaggga gggggcgccc ctaccccggg 60
 agggggctgg gcgagccggg agacggtcaa gttggggctcg ggggagcgcg ggcgctccgc 120
 actctggggc acgcggggac gagcccggcc gcattgtctg cgcggcctcg gaacaagcac 180
 ggccggcggt ggcaccggcg ggcgcgggga ggagttgccg tcccctttcg ccgccgcgcg 240
 ccaccgcgtt ctttgtgtgt ctctcgccgc cctccagccg cttcgccgct cgccctgacag 300
 ctgatgggct cacgcgcgcg ggtcccgcgt cctctcggcc gcagccggcg gagcccggcc 360
 cggcaggagg aggaggggag aagaggagcg ttgacagatg ctgtcttgga gcgggcaccg 420
 ccgggggaaa agtctggact gcctcggcga gaagcggccg gtaggcaacc ggccccagcc 480
 tcgcattcgc ctcaaagacc ccaattggct aggagccctt ccctccgcag cggctcgcgc 540
 agctccgctc ttgcgccccg cgcccggctc agcggacgga ctagcgcgcc cggtaagaa 600
 tcctggggaa cccgctccgc cccctggctc cagcgccctc caatggatgt cggcgtacag 660
 aggggctggt ccgcccattc aggtgtcggg aagcccagcc agtccccggg gagtgtagcc 720
 aatagaaggc gacttcggca cacaccgcgc ctgatccact aggacaaacc gctcgagccg 780
 ggggtgggtga ccgatcctga ggcagatcag ccagtcgcgc aaactgtgng caagtagatc 840
 tgagacggtc cgtgttaatg actatatcta agagntggat gggaacgggg cgcccaattt 900
 tccctngtat acgcttttgg caagttgggt tgaaaactga caacctgagc tgttaatgag 960
 gcttctttaa ctgtttatgc tatacgccca gtggctcaga caacgttttt 1010

<210> 41
 <211> 413
 <212> DNA
 <213> Homo sapiens 3.C.30

<400> 41
 gcggccgcgg taaagcgcg atgcgcggcg tggccacgcc ccttcagtgc ttgtgacgca 60
 ggcgccctgg gcttttttgg cgcgaaaaag aagcagtcct gggttgtacc cggcgcagct 120
 gggagcggct gcttcctccg gggtcgtatc tccgcccggc atggggctgc tggacctttg 180
 cgaggaagtg ttcggcaccg ccgaccttta ccgggtgctg ggcgtgcgac gcgaggcctc 240
 cgacggcgag gtccgacgag gctaccacaa ggtgtccctg caggtacacc cggaccgggt 300
 gggtgagggc gacaaggagg acgccacccg ccgcttccag gtatgcaggg acccgccccg 360
 aagacgaccg gctgcgcggg cctcccccta gacttttggc tacggggccc cgc 413

WO 02/060318

PCT/US02/03077

<210> 42
 <211> 927
 <212> DNA
 <213> Homo sapiens 3.C.35

<220>
 <221> n
 <222> (595) .. (595)
 <223> a or g or c or t

<400> 42
 gcggccgccc ctcccttgcc gaccgcttgc tccccgccc cccgcccgcc gggttgtcgg 60
 cgcgggggcca ctggcgggtc gtgatgagca ctgcctcgcg cccccgcacg cacacgcgaa 120
 acccgggccc gcccgcgcgc cgcggccgcc tctcgcactc ccggagctcg cccaccggcc 180
 gcgctggctc acactctccc tcacagcacg ccggccgagg gaggaagggg gcggtccggg 240
 ctcccgaggg gtggggaggg ctgtttatatt tggggggagg aggggcgcga ggcaggaacg 300
 agctgactgg ccgggatcct ccgaccgcc actgtggcag caccgggaag gcggggagag 360
 agaaagaggg agggagggag ggaccgggat gtagaactcc agcccgcgcg ggaggctacg 420
 gcgagggggg cgggtggcgg ccgcgggggg ggcggtgcca ggccccctcg gcaatctccg 480
 tagtctcctc gctggctgcc cgagggaggg cgggaagcga tcggggaagc tcgggaatct 540
 ccggcacggg cctgggattg tcctggaggg acagcgcggc tggagtgcgg ggcanccgcg 600
 gggggggcgg gtctgtctcc tttctgggcg gggccgtatc ctgaagcagg cggggcttga 660
 gagaccgaa agccacggag tggctcctgc ttgcggtact agttggacag agtaaagtcc 720
 tggagttacc tcgcctgagc accctggttt cccgagaggg aatgggcact ctgtgagagg 780
 caagctatatt gcctgctttc cctccgcaga agaaaaaagg ctcaattgga aggtggagga 840
 tgaagccacc ctctatggtc accccaatct gagagcttta ctttatataa ctacattcta 900
 aggagtagta aaataccccg ggtggaa 927

<210> 43
 <211> 1365
 <212> DNA
 <213> Homo sapiens 3.C.64

<400> 43
 gcggccgcaa ggaccggctg agarmtgkgg gscsctgtgc tgggggcs g arggagrcgg 60
 ccytraggac tgcscscccc ccacaccggg gcccgggcgg gacacacgcc caacgggacc 120
 cctgagcccc caggctgggg accggcaggg gctccgggga ggctggtagg gccaggacgg 180
 agccgccycc acgcgtagcc gtgaagcggg aggtacgcgg cccctggag ctgccccgac 240
 tgcagccgag ggcgcgacct gtggtgcaa ccgcctgacc ctgcttggcc gccgccgcct 300
 gcggtctcc agcaggtccc accccacgcg cccgcggggc ccgctccaga ggctcctcca 360
 aggccgctgc agaggcgcgg ccaggctccc atttctgcgc atccctggcg ctcagacacg 420

gcctgagccg ggtacccggc gactcccttc ggccctccacc gcctcctggg gagggaccgc 480
gcgctgctcc cacgcggggc cgggggtctc cgcagccctg gcctgggtgc gtccgtcggg 540
ctgctcggct cggagcacc cccgccccgc cgcaccacca gcgcctytyc ggagcgctca 600
ccccgcccc gactcgtgtt gttgttgctt gggttttttc tctaattctc cggagttact 660
cttttggtgc caattgtttc tatgcccgga ggccacgctg taaatgagat gttacatctg 720
caccgagcta agtaaactt ttataaatga ataaataagt gaataaataa cgaaatcgtc 780
atctcggggc ggcccggtc ccagggtcc ggccgcccgc ctgcgggggt ctgtgtggtc 840
ccgggccctg ccttgggggc ggggagggc cgggaggggc cgtttcccag ccgtgtccct 900
accctgacc catcttcctt cctctcccaa atcatcctc agactctggg cgtttgggtc 960
ccagatgtcg tgtgggattc gtggcttcca cccaccgctt ctcaaacaaa aacgggttgt 1020
caccgcggtc cttaaccctg ggcgagccac ggagcggttc ttcccgggat cgggatcggg 1080
ccgcggctcg aaccggcatc tgcagaagga agaccgggc ctgtaggccg ccgcccgcgc 1140
aggaccggac tgggtggcctc tccacgtcgt gtccggacc cgcwcatcgc ctccaacgcs 1200
aacaacgga agcagcggag cctccgcctc cmasscykgc cyctgyscgs yswgmcmggc 1260
gcattsragt gcwcsakkym sgcyaatym mgagagckct gracktkca aytatcwgg 1320
actarsrrsr rcawwtkmww argsactcay tgagtaactg atatac 1365

<210> 44
<211> 608
<212> DNA
<213> Homo sapiens 3.D.21

<400> 44
gcggccgcac tgccttggcc gccacgctcc gcgcctgcgc cgcgcacctc aggggcccgc 60
cgagagggcg gggaggtgac gaggtgaggt gggggcaggg agcgggctgc gcgaacgcac 120
cgcacacgcg gcctgggagg gaccaccggc ccgcagcccc gggggaggcc cagcggcccc 180
cgccccctgc cggaggcctt gcgcgcgcgc agtctccctc tgggcgggga agagccccctc 240
ccgagccccg agggcgatcc caccctctag gattactcca cgcagggcgg ccagcgaatt 300
tatcccgccc gcctccaccg ccccttcaag ccctggggaa ctgggagaaa cgtggcgcg 360
agcggcacct ttcccacgct gctcctcaag ggaaaggacg cgagtgggtc tggccagggtt 420
aggcaaggca gatggcatct cagaccccga agtgtgccag ccgcctgttg gggacagaga 480
ggccgaggac ctcgtcacgg ttttactgag gccacaccag agaaccacct agggctagga 540
tgctgcctc agggcaagag ggtgaaacct gaagactgcg agtcgttggt gagtttcacc 600
cgattcct 608

<210> 45
<211> 1947
<212> DNA

<213> Homo sapiens 3.D.24

<220>

<221> n

<222> (748) .. (748)

<223> a or g or c or t

<400> 45

gatatcatct atttttaaag acatatgtaa aacccaaccc ttaagaaagg attcctatca	60
ctgttcccca caggcatcct cctcagtctt acacctttcc acccccacaa acaaatcatt	120
cagcatatct atttcatact gtaatatagg aaatagctat ttttttagact ttttatatta	180
ttagcactga tcatacaaac atggaataga aattccttat gttttatctg gatttaaggt	240
gatacataat ggaatatatt tctatcaagc cgtacacatt agagataatg aaatcacttg	300
tgttctagtt taaacattat ggggaatttca gaactgcaac ataacaaata atcctcggat	360
gaaaactaaa tctctcctct ggtcaggcat ctatgtgcat cagwgatgag aagacaggga	420
ctgtggaagg gaaaacagcg agtcaggaag gactgtggcc acgtccattc cctggtcctt	480
caagtaatta aatcctgacc tcctctaccc cagtctgtcc tggggaatgg ccaacactgg	540
cctttcacaa ctgtgtgtta ctagaaatgc aacagaaacc cagctgaatc ccctcctctg	600
cccttctcaa aggaaagatc tgtcccagga ccatttgttc caacattttc aattatgaga	660
actgggaaga taaagttatt ttacattta taaagaaaca catatttatt cacmctcatt	720
wcaagraagg tcaagaatct atmcaaanac caagaggaat tttttaaata ccataatwcc	780
accatcaaaa gagccacact tagcatgttg gtccacaggc ttcttttagca ccctcttyyg	840
ttggtgtatg cacaaaatgc acaatcacat tctgtctaca ttttataatt tgctgtttg	900
ttgattamca ctatatattg aacaattttt aagacctgca acatatgttg acaacattac	960
ttccaaacaa tgtattttaca aataaatgca cacacacact atctgtctta tatacaacgt	1020
gtcttacttt ctaattctcc actcttgaag atttaggttt ttccaacttt ttcttaatat	1080
attcaccagg agtcagcaac ttttttccat aaaaggccaa agagtaggcc gggcgagtg	1140
gctcacgcct gtaatcccag catthttggga ggccaaggcg ggcagatcac gaggtcagga	1200
gatccagacc atgctggcta acacgggtgaa accctgtctc tactaaaaac acaaaaaatt	1260
agctgggtgt ggtgagtgtg gcggcggaca cctgtagtcc cagctactcg ggaggctgag	1320
gcaggagaat ggcgtgaacc cgggaggcag aggttgcagt gagccaagat cgcaccactg	1380
cactccagcc tgggcgacag agcaagactc tgtcacaaaa gmaaagaaaa aaaaaaggcc	1440
aaagagtaga tatttttaaac tctgcaggcc ataggtttct gttgcaacac tcaactctgc	1500
tgttgcaggg aaagaagcca tacacaattt gtaaataaat gggcatgact gtgttcttcc	1560
cgacatgggt tgccagcccc tgatgtataa cactacagag gatgctgtta gaatgaaawt	1620
tctttacata tctctgatga tctccttagg actaattact agacatgaca tcatggtagc	1680
tgtgggtcaa agggcatgca tgctctggga tgtacattcc cagattgctc atcatgagcc	1740

tttctcatgt caaaatgttt tgtgaccacc agaaaggctg gttctgcttt tawtaccat 1800
 ggawtgagga atagaaatga catggcatgg cccttcccca cagcaccacg gcttctcttc 1860
 ctcagcacgg cgacaggggc ttcccccttg ccgccgccgc ccgccaagct ccgccgccgc 1920
 cggccaagct ccgccgccgc cgcggcc 1947

<210> 46
 <211> 1637
 <212> DNA
 <213> Homo sapiens 3.D.35

<220>
 <221> n
 <222> (612)..(612)
 <223> a or g or c or t

<220>
 <221> n
 <222> (715)..(715)
 <223> a or g or c or t

<220>
 <221> n
 <222> (1014)..(1014)
 <223> a or g or c or t

<220>
 <221> n
 <222> (1265)..(1265)
 <223> a or g or c or t

<400> 46
 gatatcttct gataaagaac caatctgcct gggagtttca aatctgaaaa agcaaatacat 60
 agtttactgg agtaaactgc tgttttaaaaa taaaagagaa aggaaaaaaa aaagaatgtt 120
 tcctagttcc agaactgaca actagagcct aaataaatac ctggacaagg gtaaataatga 180
 cctcaaattt ataaccgccc tgaacgcaga acatcaaccg cgacagctgt ggcatcagcg 240
 gcgacagtaa ttttctccct ggcatccaac cagagggcag ttggactgtg caccgactgc 300
 actagtgggtg ggtagccaaa gctagcctcc aaagtgaacc acggtctggg gcctgggtccc 360
 gtttgaccga aaatgctatc cagaacmccc wycgagactg caggcccttc ttcctgattg 420
 agctagaggt gagtgaagac agggctctggg gtagggaggg gcgtccacgc cagcttgccc 480
 attacctgcc ggccttggtg atgatcatct cagtgcctat ctcatgaaag cgcttccaga 540
 gctcggctcc ctgcagatcc acccgcgggg cctgcggcga gggcagaggg gtcccgggcc 600
 gggccaggga gncgcgccgg agacccttg ggggaagcct cccggtgacg ccagagggga 660
 agctccytgc tggaagccgt cctcacagcc gcctggacag caaaggacag agaanaggra 720
 actggtgagg gaaaacagag gggaagcmag ccgcggagac ggsccacct ggtggctgag 780

```

aagargaaaa tgaccgggag aaaaggggaa gctttggtgc catcagggtcc tcctaaagaa      840
caagccagtc gatagacacc cacattctgc ctgtcgaagg ggcgcattca gagctccagt      900
gtggcctgct tggccccaa gtcccaagcc cggrakaggc gygcggsmag cgtccacmcc      960
accccgctgk gcctccgcag gkcsarggcm cmasmaraaa aggcttcacg ccgnccgccg     1020
gggtctggga cgcttgcccg acggagtcag agragctccc sggtcmagag tccacagtgc     1080
aaactycgac gcaacctgcg ccttgaarcg caagcagcaa aagcgcccs g cactctgktc     1140
ccaagagcyt gggcctcctt aagccataag cgtytgccgc gcctcgcttt kggccttctt     1200
ttgggccggg ccggaggmat cttctagaar gctcttyaga acmccgcttt ygycaaactm     1260
ycggnccgcc tgcgcttcca rccarcaga agaaaagtgt gaaaagcaag cccgcggtcg     1320
ccgtcggcct tggcagagaa atcaagagga gaagggaagg gaaccgctca actacccttc     1380
gggaaaccaa gtttccaaat atgccgccct cttcctgggt tgcacaaacg gtttagggca     1440
ttcgttccgg tttcagggtg gggatatgcc tgcgtcccct cttccccgcc ctgtgctttt     1500
aaaagttagg aaacaaaaaa gagcaccat tggctggaac cccaaggag gcagatgcag     1560
gaagcacaga gctgcaccgc taggcgcagc aaacagccgc ggccgaaggc gcgggtcgcc     1620
gagtgggcgg cggccgc .                                         1637

```

```

<210> 47
<211> 900
<212> DNA
<213> Homo sapiens 3.D.40

```

```

<220>
<221> n
<222> (671) .. (671)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (702) .. (702)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (739) .. (739)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (746) .. (746)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (752) .. (752)
<223> a or g or c or t

```

WO 02/060318

PCT/US02/03077

<220>
 <221> n
 <222> (762) .. (762)
 <223> a or g or c or t

<220>
 <221> n
 <222> (782) .. (782)
 <223> a or g or c or t

<220>
 <221> n
 <222> (816) .. (816)
 <223> a or g or c or t

<220>
 <221> n
 <222> (837) .. (837)
 <223> a or g or c or t

<220>
 <221> n
 <222> (867) .. (867)
 <223> a or g or c or t

<220>
 <221> n
 <222> (874) .. (874)
 <223> a or g or c or t

<220>
 <221> n
 <222> (879) .. (879)
 <223> a or g or c or t

<400> 47
 gcggccgcgg cccggaccag ccgctccac ccgccccagc tactacggcg cggcgcgacc 60
 gcgggctccg gccccagccc aggcacgtgc gccagggccg cggggaggcg ccggcgcctc 120
 ccggaacgcg ctcttggcct gcgagtgtg cccgctcagt ctccgggtgg gaagtgcgct 180
 cgccccggac cgaggggaaa gcccaacatc cccgggatgg aacagagagg cggccaccgc 240
 tgagtgggcg tgaccattg gttcccttgc gcagcatctg tggagaatta ggctttcccc 300
 tcctctcttg ccagccgttg ttcctaatt tgtctttttt aaggaggaa agcaggagaa 360
 ctcatgacac tttgtatcac aggaaatcaa gttggtggag agagggtttg ctgacctctc 420
 ccgtcccttc tcagggtccc taggagaatt tttgaagaag taatcggcag caaggagatg 480
 ggggcaatag agagtctcag actcgcaggg acccatgttc gtccccagcg ccactacttt 540
 caaacgtta tccctcagag ctgtttcctc acctccacaa caactctccc gggttcgatg 600
 acactatata tcccaccagt tcattcttgg acaggccaaa aggttaattca aaaagcgaaa 660
 cgaatctcat nttctgacct gtgccctcgg taaagtcccc angtttccac cccaagtaca 720

cttgaagcc agggccctnc acacangctg ancaccacct tncacaaact gaaaacaaag 780
 anaatccctt ggtttcaaag ttagaatagg gatacngcgt gagtgggggtg aattgcnatt 840
 ggggtcaagga aaaaaaaaaa gtaaatnaat taanttttnt tgacctcctg cgctgcccac 900

<210> 48
 <211> 1511
 <212> DNA
 <213> Homo sapiens 3.D.44

<400> 48
 cgggcgcggc gagccccact ttctcccggc aggaaggggg gagggcgaga gcatttcctg 60
 ttgtgcagct gagccctgcg gagacgtcat tgcattcatg ctccctcggg tgtcagcgga 120
 cgggggggcca aagttcaagc cgcgtccagg gcaggcagcg cgcggcgggcg cggcggcgcg 180
 gggcggggcg ccagggtcc cctctccgc tggcgctccc ggcgcctccg tccccggccg 240
 gcccagcgct gctaccggag gccagccctg gggctccgcg gggaagagct gctcttcctc 300
 ccggaggaaa ccgagctcgc aagcccagcg ctcccagccg cagactgcag agctccagta 360
 aggtgaaagt aggcaagaag gccccctgag acgttttctaa aagcatattc tatatgtttt 420
 cattatgaaa acacccactg cactcctttt atttattagg accttaagtt atcctatctc 480
 aactaatact tttaacaatc agaatctctt aagaatcttt caatcttata cttatccact 540
 ttaatagcca aaaaaacctt tagccagagt gttttaaaat ggaaattacc tgttcatggt 600
 tcttaaagat ttttaaagtc tccttctaaa tttccagcct tccatttagt ttcaagccat 660
 aaaccagatt ataacaatgt gtaattgtag agaagctgtg gcttacgggt aataacgatt 720
 aaaaataagg ccataaggta ttttatgatc attttgaaat aaaaattga aatagtttaa 780
 tttcagcttg tgcagtttga gacagatcgt caactacaaa acaaattgta gattctgttc 840
 tcatggtgaa caaacattac agatgtttta ctgtgtcaac atctctaaca tttgaactaa 900
 gcaatgtttc acatcagaac atgaattaaa acaatgtaaa ctatggacct ggggtgacca 960
 tgatgtgtcg atgtagggtc ttggattata acaaatgtac cactctagcg caagacttcg 1020
 atagtggagg aggctgtgtg tatgtgggga caggaagtac atgggaaatc totgtacctt 1080
 ccgctggatt ttgctgagaa gctaaaacta ccctaaaaat ataaactcta tttttaaaca 1140
 tatgttttagg gttttatgag tatcctgata cttaaaatgt gcattgcatt gtaacctatg 1200
 aattgacaag aaattaatct taagaattgg cacagaaatc atctcgatgt tttcatgaag 1260
 ttcacctcgc gttctactgc ttcttgataa acaagtttca tgtttagaag gttactgaaa 1320
 tttttttata tggtaaaggc acatcaaaga ctttaccatt taatatatat tagttgtcct 1380
 atccagtcac gtactattta aggcaatatt aaaggtaact tagatttccc cacttacagt 1440
 gatgcaaagc ccttcaataa tattctgttg tcttatttcc taaacatctg aataatacaa 1500
 ctttatcaca t 1511

WO 02/060318

PCT/US02/03077

<210> 49
 <211> 835
 <212> DNA
 <213> Homo sapiens 3.D.60

<220>
 <221> n
 <222> (607) .. (607)
 <223> a or g or c or t

<220>
 <221> n
 <222> (675) .. (675)
 <223> a or g or c or t

<220>
 <221> n
 <222> (716) .. (716)
 <223> a or g or c or t

<220>
 <221> n
 <222> (731) .. (731)
 <223> a or g or c or t

<220>
 <221> n
 <222> (732) .. (732)
 <223> a or g or c or t

<220>
 <221> n
 <222> (741) .. (741)
 <223> a or g or c or t

<220>
 <221> n
 <222> (778) .. (778)
 <223> a or g or c or t

<220>
 <221> n
 <222> (805) .. (805)
 <223> a or g or c or t

<220>
 <221> n
 <222> (806) .. (806)
 <223> a or g or c or t

<400> 49
 gcggccgccc cggagccggc gtccgcagcg gctgcgcata tcgggcctgc agcggggcgc 60
 ttggcgggcg ggggccgggg gagagcctgt ttgocagta ccccgagg gcggaaggcc 120
 gccgaggtaa gagccgggac tcggccaggt gggagtgggc accttgggcc gggcctgcag 180

ggcgggtcccc gagcgtcccc gggtaggggtg ggctccctgg ggacgatgcc caggggccccg 240
 gccgcgctcc ggtcgcgccc cacccegggt gcagcgcggc cttggggcgc tgctggcctc 300
 gccgcggggg tgggagcggt cgcggcctgg agcagctccg ggcgggcccc aggctctggg 360
 gccagggcca gctgcgcgca ggggtgagtg agcagccccc gggccctcaa gtgagccctc 420
 gtccgctccc caccttgcac ttctcctctc cgcagtgggc gtggcgcccc ttgctgtat 480
 agggggcgcc ccaaattgaa gaaggctggg ggggagaacg cataaacagg tgtttagggg 540
 gccaggcct gtgcgccaag ggttgaagaa taaagagtaa ttcttttttc ccccttttta 600
 agggggncgg gagtccccct ccccccggc cgtggttaagg gccccccctt gctccgtaag 660
 gggccctcct ttggnaaaac aactcctttt ttcttttttt attttgtccc ccccnccca 720
 ataatttaaa nncctccctg ntgcgccccg cccccgctt tttttttttt tttttctnaa 780
 acccccacc ccccccccc cccttnnttt gtttcgctt ttattccaag aaaat 835

<210> 50
 <211> 645
 <212> DNA
 <213> Homo sapiens 3.E.04

<400> 50
 gcggccgccc gcttgacgtg tacggcgctg atcacctacg cttgctgggg gcagctgccg 60
 ccgctgccct gggcgctgcc aaccgcgtcg cgaccgggtg gcgtgctgct gtgggtgggag 120
 cccttcgggg ggcgcgatag cgccccgagg ccgccccctg actgccggct gcgcttcaac 180
 atcagcggct gccgcctgct caccgaccgc gcgtcctacg gagaggctca ggccgtgctt 240
 ttccaccacc gcgacctcgt gaaggggccc ccgactggc ccccgccctg gggcatccag 300
 gcgcacactg ccgaggaggt ggatctgcgc gtgttgact acgaggaggc agcggcgggc 360
 gcagaagccc tggcgacctc cagccccagg cccccgggce agcgctgggt ttggatgaac 420
 ttcgagtcgc cctcgcactc cccggggctg cgaagcctgc aagtaacctc ttcaactgga 480
 cgctctccta ccgggcggac tcggacgtct ttgtgcctta tggctacctc taccacagaa 540
 gccaccccg gcgacccgcct cagcctggcc ccgactgtc caggaaacaa gggctgggtg 600
 catgggtggg gagccacttg ggacgagcgc caggcccggg tccgt 645

<210> 51
 <211> 1021
 <212> DNA
 <213> Homo sapiens 3.E.50

<220>
 <221> n
 <222> (744)..(744)
 <223> a or g or c or t

<400> 51
 gcggccgccc gacggggaga tgcggccccg gtattgatgt cgaaaatgat ggataacgcg 60

ggaatggcaa atatactatt tgtctaattg ctcggcaatt aaattcccct gtaaattgacc 120.
 catgcctcat ttcattcctaa tctatggaat tttgattgaa ttctgcagct ctaattgaaa 180
 aatactgcac tttaatgtct gcattgcagt ttcaggacga gagtgggtttt aatgagacag 240
 tgcccccatg acccggaat atttgagact tttattcgga atttaaagcc aggagattgc 300
 tcgactgagc cctgagattt cctctcctgt atccacgtcc atccatctcc agacgcgatt 360
 taataaacgc acttaaggat aaatgcgcc cgcaccctcg cgccaacgtg ttaccccacg 420
 ggcgcccctc ctcggaataa gggacggcgg aggcggggga ggcgggggag ttggggggct 480
 cagaaggctc tggctccctcc ccggcccaag tttccctgcc ctccctgcca ccctgggtccc 540
 caggcactgt cgcggacccc agactccgcc ttccctaggc caaacctagg cgacctccct 600
 ggactaggag gcctggctgc ctgccaccgc cgcaccggaa gaagggactc gcgcactcgg 660
 agaagggggc gggccccgac gcgctttata tgcaaatggc gaggcgaagc catccctgag 720
 aaatagctac ttgctgaagc tatntactag attgaaatga gttaagagaa acattttaagt 780
 cgtgcaacga gataattggg ccgattaact ggggatgttt gctctttcaa aaaaaaaaaa 840
 aaaaaaacgc ccgaggagga gagagcagta agccgcgttg attgagccca ctgtcaagac 900
 cgaattccga tgcgggacgg tcctcgggac tcgaagagac ccacggagga ctgagaggct 960
 ttcgccggcc gcgcatttct tttcaggcat ccaccggcca gggcctagaa gtccgaaagg 1020
 c 1021

<210> 52
 <211> 518
 <212> DNA
 <213> Homo sapiens 3.E.55

<400> 52
 gcggccgcag gaaccacgat gagaggcagg agctgctcct ggctgagggg cttcaaccac 60
 tcgccgagga ggagcagagg gcctaggagg accccgggcg tggaccaccc gccctggcag 120
 ttgaatgggg cggcaattgc ggggcccacc ttagaccgaa ggggaaaacc cgctctctca 180
 ggcgcatgtg ccagttgggg ccccgcggtt agatgccggc aggccttccg gaagaaaaag 240
 agccattggt ttttgtagta ttggggccct ctttttagtga tactggattg gcgttgtttg 300
 tggctgttgc gcacatccct gccctcctac agcactccac cttgggacct gtttagagaa 360
 gccggctctt caaagacaat ggaaactgta ccatacacat tggaaggctc cctaacacac 420
 acagcgggga agctggggcg agtaccttaa tctgccataa agccattctt actcgggcga 480
 cccctttaag tttagaaata attgaaagga aatgtttg 518

<210> 53
 <211> 498
 <212> DNA
 <213> Homo sapiens 3.E.57

<400> 53
 gcggccgccc ccacggctcc accctctcgg cggggccgca gccatctggg gcccctgcca 60
 gtagcggccg ccttccgctc agcctctggt ccagggcgag cctggcgagc cggcgaagca 120
 ccggcgggga ggaggactag aacaggagga ggggcacggc ggattgaagc gagctgggct 180
 gtgagcaagg gacacccaca gcctggagaa acagccccgc tctcttgccg gctgtctgct 240
 ccagccgcta ctgggggctc taagcagcgc gatgctgctt cgcttcttct aggcggcggc 300
 cggcggaggc tttccgcagc cgcttggccg gcgcgggccc ctattccggt ggcaagtccc 360
 ttgtctatcc cggagggcgc acccggacgc tcgagccgga gcgagcgca agtccgaagt 420
 ccgccccag agccgccaac ttccctgtga gcccctctcc ccgcgcagc ctgcgccaga 480
 cctgggagcg atgcgccc 498

<210> 54
 <211> 471
 <212> DNA
 <213> Homo sapiens 3.E.59

<400> 54
 gcggccgccc gggcccgcgg gcggggggat cggcgggggg gaccgcggg gtgaccggcg 60
 gcaggagccg ccaccatgga gttccgccag gaggagtctt ggaagctagc gggtcgtgct 120
 ctcggaagc tgcaccggtg agcctggcgg gggctccggg agaagagtgg gaggatctga 180
 ggaggatgct aattcccacc tgggcgcaga ctgacagatg aacgggcat accccggcat 240
 gggggtccac ccattctgtc agttttctgc cgtgggctcc gacggcgctg ttctccctgg 300
 tcgagccttg tccattatcc tgttcctttt tctgcacccc accccaccgc gctccactct 360
 ctctgggtgct gtaaattgct ctctccggg tctctggctc ctccccacc acttctgggt 420
 ctctgtcccc gtctctttct ggatgtctct gccccttttc tctctgggtc t 471

<210> 55
 <211> 971
 <212> DNA
 <213> Homo sapiens 3.F.16

<220>
 <221> n
 <222> (905) .. (905)
 <223> a or g or c or t

<400> 55
 gcggccgccc tgggcctgca aaacttccaa agtagcagcc tgtttctcct cgtctccctt 60
 ctctgggta ccagcgccc cgccttcccc agaaaggcg aggggtgggg gcagggtccc 120
 ctcgggaggt ggccaagcgc cgggacgcgc tcccagcgtt actcaggaca cttgggattt 180
 ggctgcagc ccccttcccc atccctggcc tggctgcggg gtcccttgct cccctctgct 240
 gctgctcctg ccccatcaag tcgaaaatct gaggggtggga tgggggtgggg gaccaggggg 300
 taccctccca ggccgctccg cagcaggccg aggtggagac cctgcccggg aggcgagtc 360

```

ttgtgcccac agctcggagc cagcagcggg gtagacaaaa agataaagtt ggtgaatgat      420
aaagaccgta ttttccacgc tttgggtgcg ggaccagatg atctagaaaa tgagctgaaa      480
tggattcagc ctccgagcct gttgtgagag cagctgattc ccccatctcg ggccagatgg      540
ctgctgaaca cagatttgca ttcattttcg cttaatatcg tccaaaatag tggggcagct      600
gcatttggtg tcaaaaaggt ttaaaacccc ttttctttct ggggcaggat cgttacctta      660
tgtgatgggc ttatagaact tttttttcct ctttagtcaa cagtatcaga tttagaagga      720
tttgttttta aaccttctaa tttggtaatc agatttaaata cgccttggcg cgtgtaatct      780
gaattaaaga tactgtaaat gattntaagc atgatacttt cgttagcgca aggaaggggc      840
acctctagca caggctggac attttaggaa gtgtgctata aaggagcatt gttcctatct      900
caacttaatc ttccgaaaag gctttggtat tctgcataac gctgctggcg ttgcctggtg      960
agcccgagag t                                                                971

```

```

<210> 56
<211> 550
<212> DNA
<213> Homo sapiens 3.F.2

```

```

<400> 56
gcggccgcac gcgggtgcta atttgcacac atcaagactg aagtgtagtg aggaaacggt      60
gagtttctgt tttcaaacct ttaacttcgt aattagagat ttaacaactt gaaggggggc      120
ggggagaggc gggggaggag gtgggcagaa ggaataaaac tccatctaaa attcctaata      180
gcaattcctt agaattataa actgcgagat gatcagaagt gacatctttg ctttctttga      240
aggctctctt ctctaagtta ctaataatga taatgcacgt tcgggtacag aaatatgagc      300
caagaactca agtctgcaat gaaggagtgg acatgacagc gtaagaggga gcatcattgt      360
ttgatctatt ttaacctttt ccgtctcaaa gatacgatgg tgcttcctcc aggaagaaaa      420
gcctgtaagc tcaaacaaga gctcccctgg aacagaagac actggagacc gtaagagggtg      480
ggagggttga agggggaaaa ggatagaaaa actgcctggt gggtattatg ctcaccacat      540
gggtgacggg                                                                550

```

```

<210> 57
<211> 870
<212> DNA
<213> Homo sapiens 3.F.50

```

```

<220>
<221> n
<222> (667)..(667)
<223> a or g or c or t

```

```

<220>
<221> n
<222> (684)..(684)
<223> a or g or c or t

```

<220>
 <221> n
 <222> (725) .. (725)
 <223> a or g or c or t

<220>
 <221> n
 <222> (758) .. (758)
 <223> a or g or c or t

<220>
 <221> n
 <222> (776) .. (776)
 <223> a or g or c or t

<220>
 <221> n
 <222> (777) .. (777)
 <223> a or g or c or t

<220>
 <221> n
 <222> (789) .. (789)
 <223> a or g or c or t

<220>
 <221> n
 <222> (845) .. (845)
 <223> a or g or c or t

<220>
 <221> n
 <222> (870) .. (870)
 <223> a or g or c or t

<400> 57
 ttagactctc actgggcagg tctgctgtcc cctctgctcc cgcaggactg gagccaccga 60
 gctcgcgcct tcttctcggg gtgcgatttc tctcctcttt tggactcaag atcaatgctt 120
 cccggccggc gcagatcaca cagcaggacc ccaggggaga ctgtggcctt cttcccgcct 180
 cccaattccc caagaccgcc tctagaggct gctgtgtccg gagaactccg agcattttct 240
 ggacacagat tgcctaacag aggaacaggg gttagggtgg gagcggctgg ccggcccaaa 300
 cacagcagcc ccaagctggc tcccaagcct gggctctcca cccccgctcc catectctct 360
 tgagcacagt taggccaac acccctgtcc cccaaaacac ctctaccct ccctcccccc 420
 cagcccccat cttcaggaac atcacagggc tcacactcac taaccgcgga gagcacatgc 480
 aggccggagc cctcagcccg gcagctctcg gaccctgccc agctcgacgc ggactcatgc 540
 agaagaggac attccgcagg taggtacaat ccagcgcctg gggcctgggg cgtccggggg 600
 gcggcctttg agcttccccg ataccgctcg cctgctcccc gagctgttcg gccgacggct 660

WO 02/060318

PCT/US02/03077

gcccggntcg tgcactttca gtangggccc gctgactcta ctgcccttgg gctaggccta 720
 ccgngatgc ccagactcct tgggacgctg gacccgcngc gcgggaggac acgcannagac 780
 tccgctctnc gcccgggaatc gttgagacgg aatctcagcg gatcccgcggt cgccgagcgc 840
 cgggncaggg agaaaggccg tgtggcgctn 870

<210> 58
 <211> 848
 <212> DNA
 <213> Homo sapiens 3.F.72

<400> 58
 gcggccgccc cgctcgccgac gcccggcagg actgagcgca cggagcggcg gaactcctcg 60
 ttctctccacg ttagagagcag cggattgagc gcggacaggg cgcagcacag gagccagctg 120
 gccgcctgca ctccccaggg caccggcagc gagaagccgc tggccaggct caccacacc 180
 agtggctgcg tggccagcag gaagacgcag cagagcagca gcaccgacag gccgctgaga 240
 cgccgctgtg cccgccgcgg gtgcagcgcg ggcggcaggg gctgggcctg cgccgggtgc 300
 gcggcgccac cggggcccgg cgcgctgctgg gcgcccggga aggcggcggc ggcggcggcg 360
 caaccgggca actggtgcaa catgtggaag ttgatcacgc tgaccactt gacacttaca 420
 cacacgcagc gcacgatgcc caaatagcat tgcaacaaca tatctgtctg ctccaacaac 480
 accacagaag ccatcaacac cagataatgg attctcagtg gcacagcacc cagccccagt 540
 gcccaaagcg agaacaacat cactaggccc aaggccagct cccaaaacca caccaacatc 600
 cccccctagt gcacctttta tacaacaccc tgtaaataga caacccccca ataataacca 660
 attaccattt aaagcccccc aacaatttga aaaagaagga caaccgtaat tcccaacccc 720
 acacaccacc ccctaaaaaa aaaataattt tcgccaatac cgtcccaatt tttaaaaaat 780
 ttcccaaaaa cctctaattc aaaaacccca acccgcctt cttctatatt tcaaaaaata 840
 cccaaact 848

<210> 59
 <211> 2770
 <212> DNA
 <213> Homo sapiens 3.F.82

<220>
 <221> n
 <222> (6)..(6)
 <223> a or g or c or t

<220>
 <221> n
 <222> (14)..(14)
 <223> a or g or c or t

<220>
 <221> n

WO 02/060318

PCT/US02/03077

<222> (15) .. (15)
<223> a or g or c or t

<220>
<221> n
<222> (37) .. (37)
<223> a or g or c or t

<220>
<221> n
<222> (38) .. (38)
<223> a or g or c or t

<220>
<221> n
<222> (44) .. (44)
<223> a or g or c or t

<220>
<221> n
<222> (56) .. (56)
<223> a or g or c or t

<220>
<221> n
<222> (76) .. (76)
<223> a or g or c or t

<220>
<221> n
<222> (119) .. (119)
<223> a or g or c or t

<220>
<221> n
<222> (151) .. (151)
<223> a or g or c or t

<220>
<221> n
<222> (170) .. (170)
<223> a or g or c or t

<220>
<221> n
<222> (197) .. (197)
<223> a or g or c or t

<220>
<221> n
<222> (198) .. (198)
<223> a or g or c or t

<220>
<221> n

<222> (236) .. (236)
 <223> a or g or c or t

<220>
 <221> n
 <222> (237) .. (237)
 <223> a or g or c or t

<400> 59
 atccanatat ttttnnaacct ctaacaatga agagtannac acanactcaa ttttanaagg 60
 cacaggacct atgaanacat tttatggtaa aagaaatata aatggccatt tcccacgtna 120
 agatgcatct aacctcaatg gtggtcacag naaaataaat tacaaaaaan aaagttttgt 180
 gtgaccatca gttaggtnaa tttaatgctt cctactaatc ttttcatgat aagtannaac 240
 atactagcca ggcattgggtg ctcatgcctg tattctcagc atgttgggaa gctgaggcag 300
 aaggatacct taagctcagg agtttgaggc tacaatgagc tatgatcatg cactccagcc 360
 tgggtaacag agagtgagac cctgttttcta aataaataaa taaatgagt catgagttaa 420
 catacatata tacatatata cacacgggtt tttacatgtt tatagagagt ataatggcc 480
 aatgaccttt taaggcacia ttagcaaata tgtattgagt ggaaagatgc atgttcttgc 540
 atgcaggatt ctacctcctg aaatgcatct gataacactg cttgaaaatg tgtgtagaaa 600
 tgcccacact agcatgtttg tgggtgggcat ataaataata gcaaaacaaa acaaaggaaa 660
 aagaaaagta catatatgtg aggaaccctt ttgggttatcc tgggtttttg agataatgtt 720
 catagaagga aagcaaataa aatgaagagc aattgagcag gaaacggggg gaaataccct 780
 cagagtaata agattatctc attacactta agttttgctg atgcttcaag tttcctgagt 840
 aagttatgag aagcatcttt ctctgaaaat cttcttgctg cagaacaaac catgtttagt 900
 gtctgtatat gtctcaactt cctgtcccca cctggcggat gggaaaaagg acacggctct 960
 tgcttggtgt ttggagttaa agaagcatta aaggcttgc agactttacc aaggattctc 1020
 ctggtctcat ttcagatcca acttccaact ccaggcagcc tctgtgtttt tctttaatgt 1080
 ataatacagga tgtacttcaa tttggactct attgctgttt ggctgtata tgcagtttca 1140
 agatagcccc atacacctgc ctgcaatgat ccttcaggaa tagaatgggc ttctgagttg 1200
 aggaatttgg gagtatactg agccctttgt gtatttttat taagtttctc tattcatgcc 1260
 aggagaaggc tgtggacaaa aagtaaagga ggagacactg gaattgtgat gtccaaagat 1320
 tccaatgttc aaggattatt tgaacccttc acgcctcttt agccaccgcc gccgacagcg 1380
 aagacgcgga gaaaaaagtt ctgcgccacca aagtccttgg cactgtcaaa tgggtcaacg 1440
 tcagaaatgg atatggattt ataaatcgaa atgacaccaa agaagatcta tttatacatc 1500
 agactgccat caagaagaat aaccacacaga aatatctgag cagtgtagga gatggagaaa 1560
 ctgtagagtt tgatgtggtt taaggagaga aggggtgcaga agcagccagt gtgactggcc 1620
 ggggtggagt tcctgtggag ggcagtcgtt acgcgctgat tggcgccgtt acagacgtgg 1680

ctactatgga aagcgccatg gccctccccg ggattacgct gggaggagga ggaagaaggg 1740
 agcggcagca gtgaaggatt tgacccccct accactgata ggcagttctc tggggcccgg 1800
 aatcggctgc gccgccccca gtatcgcccc cagtacaggc agcagcgggt cccgccttac 1860
 cacgtgggac agacgtttga ccgtcgctca ccggtcttac cccatcccaa cagaatacag 1920
 gctgttgaga ttggagagct gaaggatgga gtcccagaag gagcacaact tcagggacca 1980
 tttcatcgaa atccaactta ccgcccaggg taccatagca ggggacctcc tcgcccacga 2040
 cctgccccag cagttggaga ggctgaagat aaagaaaatc agcaagcctc cagtgggtcca 2100
 aaccagccgc ctgttcgccc tggataccgg cgtccctaca attaccggcg tcgcccacgt 2160
 tctcctaacg ctccctcaca agatggcaaa gagggcacgg caggtgaagc accaactgag 2220
 aaccctgctc catccaccga gcagagcagt gctgagtaac accaggctcc ccaggcacct 2280
 tcaccatcgg cagggtgacc taaagaatta atgaccgttc agaaacaaag caaaaagcag 2340
 gccacagcct taccaacacc aaagaaacat ccaagcaata aagtgggaaga cgaaccaaga 2400
 tttggacatt ggaatgtttg ctgttattct ttaagaaaca actacaaaaa gaaaatgtca 2460
 acaaattttt ccagcaaact gagaacctgg gaattcctgc acagaagaca agagagcagc 2520
 ctccccagtt tcagcaagcg ctaggtttat atttttttcc tggtttttac tgtttgggta 2580
 atagatatgg aaacaagtaa tattaatacc gcatggggag aaccccaacc aaagaaatct 2640
 gaaatataaa ataaatgctt ttttttccgt ttttgttcat tttggatgct ggcgctaagc 2700
 ctccaagtgt catgattaaa aaaaaaatta tgtccttatt tatttctagg atgaggggag 2760
 gataacattt 2770

<210> 60
 <211> 563
 <212> DNA
 <213> Homo sapiens 3.G.46

<400> 60
 gcggccgccc ccttccgcag taatggttgt tcagcgaaca agatccgggc ggaaacagta 60
 gataggcggg tgcagcgggg cagaacatag gttgccttag agagggtccc cgggtgtcccg 120
 acggcgggctc aagtcagagt tgctggggtt tgctcagatt ggtgtgggaa gagcctgcct 180
 gtggggagcg gccactccat actgctgagg cctcaggact gctgctcagc ttgcccgtta 240
 cctgaagagg cggcggagcc gggcccctga ccggtcacca tgtgggcctt ctcggaattg 300
 cccatgccgc tgctgatcaa tttgatcgtc tcgctgctgg gatttgtggc cacagtcacc 360
 ctcatccccg ccttccgggg ccacttcatt gctgcgcgcc tctgtgggtca ggacctcaac 420
 aaaaccagcc gacagcagat gtgagcagcg gcacacgggt ccgggcaggg ggcaagggtc 480
 aaggaaggag tggctagggc aggggcggga accgggggtgc ttgaccacac gtgaagactc 540
 agaactaacc caggcagcct gga 563

<210> 61
 <211> 4104
 <212> DNA
 <213> Homo sapiens 3.G.78

<400> 61
 gatatctctc tccaagcccc cttcccaact ccatttctgt aggaaagtac agcccctgga 60
 attgggttct ggttttcgctt tgggctggag gtgggtggat gggggtcaga gagagaatga 120
 ggtggggggg acttcaaggt tctgtccac cgaccagagt ctgaagacta ttcgcctttc 180
 ccaacacgga cctccgcccc tccaggcccc ggactatccc ttcgcggtgt agcggcagcc 240
 ggagacctgg ctgaggaggc aaccgcgtag acacctccct gcttagaaaa caaacactga 300
 accagaccga tcccagttgg agggttcgaa aatgttccag acagcctgtc gggagggggt 360
 gttgttgctg ttggactaaa tagctattcc tgattggtca tgtatagggt tttttaaggc 420
 ggggtggggg aggagggggt agaggaaagg ctccaaacac ctgcagggtg ggggcggaaa 480
 gctgtttgcg attccctgga ctggttggtc ggggacagga ggtaattccc agccattgac 540
 cccattttct ctctctccct ccctcttgcc ctgcctcttt ctctccacce ctatctttcc 600
 tggaaactcg ctttgggccc ggcagatcgc ccaggaccac accgcagcgt aactgcaggc 660
 ctctcagcga aaaaggggga aagcaaagac ccgggtgtgc atcctcttcc tcggcttccg 720
 cccctttccg gcggagtga gatectattc agaggggccc gtctctctaa atatgcccc 780
 ggtgagtttt caggggaatg gtgccggtgg aaacgggtgc taggaaggcc ttgtgttccg 840
 gcctgggggtg aggaaggctc aggacagagg agagccatt ctgagattgg ggggtggggg 900
 aggggaggac cagccagagc ttggaatcgg gatctgactg ctgtagctgc ctctgtggca 960
 ttcagcggct ttttcccttt tccaccaggg gtaaaaccag ctagttggac ttagtcgtcc 1020
 aggcctttcc cattgggtccc gggtctgtgg acgtttccca aggccggtaa ctttggggcg 1080
 gctgtatccg ggtggtacag actgtgcctg gagctcccgc aggaggaagg cggcagcctt 1140
 cctggctagt gcagtcccag ctcgagtggg ccctgatccc aggcctgagg cctaggggtg 1200
 ggaggcagga acacccctct tctccggtag aggcgaggat ggtgggtgctg ttccttggtg 1260
 ggtttggtac ttgtgcaggc ttggggcttc tccagggtgt tgtgctgggtg tgggccaga 1320
 agagagacca gaggctgggt ctaagggcct gaggctgttt tcatctaaga aattctctgt 1380
 atgggggatt ggggtctgct gagacctgtc ccaggaaga atctcctggg gtcttctgtc 1440
 ttgttctggc acaggtggaa atattctggc tgtctggcaa ctgcagatga ggatttctg 1500
 ttgggggcta taagcagggt ctccgtagta caaagagaga ggagctgtag tcgtcaaata 1560
 ctctagaacg attcagtcta aaatctccct cctccttcat tctcccaaa taaaaacaaa 1620
 caaaatctct cgggcgttcc tttctgtaat ccaaatacag tgatgcagct tagtcgcaa 1680
 caaccatcag tgtttgtgag tggcttcttt ggggcatgga cctctggctg gtaatcctaa 1740
 accggcagga ttttcctaaa atgtggggag gagccgggag aggtcctcca cagatcctgg 1800

gatccaatca tatatttctt acaaggaacc ttggcgatgg gatatttata ggtgtctgga 1860
gaggacattt gtggccaggg tcaattcatc tggaatatgt actcccattg cctctcagga 1920
atccaccgct agagcaggag cctaagaatt aattggaggg taaaaatgtg tcataacaga 1980
gcttgagctc agtctgcaac tgcagtgcac actgtcactc ggttagaagc tggggcttaa 2040
gcatggatca ctgggctcac accggtgtgt caggacggag agcagtgagg tagggaacca 2100
ataccttgaa gcttgtatgt ttcccagggg ttggtatatt tctggcacat ttcgctgctg 2160
ctgggagcaa gaggacctgg ctgatatact tctggtgcat ttccagtggc cttggtgtct 2220
tggtggttgc attctatgga tagagaccta ttgtctccac caaaatcata aactcacttc 2280
caatgaagtg tcagggacct actgccttta cagcttgtat acaccaggac ttagggaatt 2340
ttgtggtttc tgtgccagac ctggggggct ggcattccca aagaagggtg acagcagtct 2400
gaatcttgac tctctgtcat cctgggtgtc tagtggcaat tgagccaagc tccagaggag 2460
gctgcagatg atccattctc ccttctgggg tgggagggat ggttcctagg atgactcctg 2520
tccagagcat tgcagtggca gtatgggagc tcaatggctg ctatgtatga tttagatgga 2580
ctctgcatgg gggtaaattg tttttttgta tttgttttct tcttttaaat acccaattat 2640
ataattcaga gagcagaaag cttattttta acaacttatg tggtgttgat catatatgta 2700
caactcacia ctcacaaact ctggcccttg agtctcctga tttttctgtt ttggttcttg 2760
ctggtgcccc gctctatctg gatgaagcca ggtgatggaa gagccccagc acacctgtgg 2820
gaagtagagt ggctgtggtc atctcggagt atgcttgtgg ggtcacaagg tggtttcaact 2880
gctctgggaa tacaggaggg ttgagcaaag tgagattatt gctctggtct ggctctctca 2940
cagataggct gtgagtgact tgacattcgg ccaggcagtt ttctcactgg cccattctcc 3000
ttgttaataa tgtttacttg aacgtttgca cagcactttc aaatgcataa aggaggtatt 3060
cctcccattt cccaaagaac accaaggcag gagatggcgg tgaggggggc tggaagagtt 3120
caagggcctc atgacatcct gtctgtctct tggatgggag tccagacccc actggcctca 3180
gggaaccctt caaatgcccc gctccattct acctcagcca ggcctctctt tgagactcga 3240
cctcacttca gagtccagct gagcagaacg aggtggactg tgcagggagg ttgggccagc 3300
accatcttct tcccttggcg acctctcatc tctgtctgag tgggagtaaa gatccgctgg 3360
gcgggcagag gactcacagt ggatttgctc agtgtagaca gacactccct cactccccag 3420
cgggggcgaa tgtgtgtgtg tgtgtgtgtg gagggagctg gttcctcggg attattctct 3480
gccagctctg gcggagtgga tcccagtcct cgtagcctcc acttttctaat tccctacttc 3540
catccgcacc gggtttctgg gtgtgtgcct gtaggtgggc tgggaatatt gctgagaggc 3600
caagggaggt tcctaaagca acgaaccctt gcctgacaga ttccccgcta aaaccaaaaga 3660
gcacgatccg gaatttgctc cctcctcttc cctttaggcc tgagaaaggg gacagagtaa 3720
tctctttctt gcctccttgt acatttcctt cctcctgatt tcccctctctg tgtttctgtc 3780

gctggctgta ttcccttttct tccgggtgtct ctgtcgtctt cctccatctc tgtcccttttg 3840
gccctcagtc tctgtgtctc ccaggcaccc ctcccttctc ccaatccaga gaccctcttt 3900
ccctcccacc ctagccccaac ccggcctccc gccctagccc cacgtggcgc taactttgtc 3960
tgctctttct cacgtctcgg tgcgtgagtt cctctctctg cccttctccc ctttaccaca 4020
gcccacgtcg gtgggtcagg ggcggtcgtc agagcgggca tccgcttgtc tgtctgtctg 4080
cccacaggat gaccgagcgg ccgc 4104

<210> 62
<211> 570
<212> DNA
<213> Homo sapiens 4.B.44

<400> 62
gcggccgcct gtctgggcgc cgcgctcctg ctccatagcg ccgcgccccg ctccctgcgc 60
ccgggtgagt gccgcgcggc cgagccgcgc accccaacc aaacctggct cctcgcgctt 120
tccaccgcgg cctgacctct cgacagcgcg ggggacacct gttgtctcct tccctggctgg 180
ggctaggggt ggccgggcagg ggcgctggtg cggcacagaa aggctctaga cgcgcccgcg 240
agcaaaggct cttgctcctc ctccggagtt acctccccac tcccagagcg gtgactgttt 300
tgagtcccac agccgggtgcc tggagaccgg ggtcagttgt ggggggtaga ggacaattgg 360
ccaatccggg aaggccatct cccttacctt caccctcttc ccctgcgcac cccacggccc 420
ctggacatga gcgctgctgg gcgcatgcgc ataggagggg aagcttgggc cactcgggtcc 480
ggtcccttgg ttgtcctact gtgcagtggg tgccactccc tgctccaccc tgaaatccac 540
actgggtagg gcttgggact cctgtgcacc 570

<210> 63
<211> 535
<212> DNA
<213> Homo sapiens 4.B.56

<400> 63
gcggccgcgc tttctccatg gccccggcct cggcgcgcct ggctccggct cgggggtccg 60
gcacggcagt ctcaagtgcgc ggtcgccagg cgcgccgtcc caccocggct cggcttgggg 120
gtggccccgc gcctccgccc ccgacgcagc tagctggttt tttaaattgct aatctcatta 180
acggcgcgcc cgtccgagag gcgaggctgg taaatggatg acggcgagcc ccaccccgcc 240
cgatcgtcgc ggccgggaag gcacccgaga ttgcagagga cagggcggag tcccctgggg 300
tcctccggct cggcggggcc tttcttcagg ctgcggaact cctcgaagtg ggcgccctcc 360
ctcggccact cacctgtcat ttatcgagcg cctactgtgt gccaggcatt gtctggggac 420
acggctgtga accacttccc agctccgtct tggagctgac attctggtag agggaaacac 480
ttgaattgga ctgcatgaaa tgccccattt tcaaccattt tttaatttat agaaa 535

WO 02/060318

PCT/US02/03077

<210> 64
 <211> 737
 <212> DNA
 <213> Homo sapiens 4.C.05

<400> 64
 gcggccgccc ggcggggtta aggcctctca gccaaaggccg cggccagctc actgccaggt 60
 cgggtcagcg cctgcgcgcc aggtccggcc ttggataccc tctgccgcca cgcgtcggtc 120
 cggcctctac gcccgcttg ccctctgcgc gcgcgcgcca cggcgcaggt ccgggcctcg 180
 gtgactgccg gaggggcgcg gcgccccgcc tcctgtcacc atggccaccg caacccttc 240
 caccgcctca cggccggccg gcatccaatc acaggcgagc gttaccgatg ccggggcggg 300
 gcaagacagg gagaggaagt cccggaagg agtgcgagg gatgcggcg ttcggcgagc 360
 acccgttgtg tgggaactcc gtctcaagtc gccccattg tacggatgaa ggaatcgaag 420
 ccacgagcca gaatttcctc actcgcaact cgagaataaa ttgcgcctcc ctgagtgtgg 480
 aggattaaat aagtagttta aggcgtgttt aaagagcgct tgtaagttgc caagtcgctg 540
 gagagccagt cccttatccc ttgaaccagg tgatgctgac gtctgatttc aagacagttc 600
 ctaccctcg tggaaggaaa gccccatcgc aagaagtcga tgcctgttaa tttacgttat 660
 aatcttcgca tcataaagat tactcggcag taattggttt cttgactaat tataccagat 720
 gagaattgaa gactatt 737

<210> 65
 <211> 684
 <212> DNA
 <213> Homo sapiens 4.C.25

<400> 65
 gcggccgcca taggaaacac ctggcagtta gttcctcaaa aggttaagcc cagaactccc 60
 gtaagaaccc gcaattccac tccttagtat agacccgaga gaaaacatgc gtccgtccac 120
 gcaaaaatct gcacacgaat gttcacagaa gcatcaggca taacagtcga aatgtagaga 180
 caacccaa atgtccatattg atgaactaac tgtgggtccat ccatgaccgt aatggaacac 240
 gaccataacc aggtgtgaag ttcagctgtg acagggatga ccctcgaaca cggcacgctt 300
 ggtaaaacaa gcccgatgca gaacagcacg attctattta tgcgcctgcc cacaagaggc 360
 acaccccggg aaagaaagca gatcagcact tcccaggaac cgggacgcag ggacgcaggg 420
 agggagggac tgctgaagat gcacggcggt tcttttggga tgaagaacag gttctaaaat 480
 cgactgtggt gatggctgcg taaatcagt aatacactaa aaaccttact gaactgtata 540
 ttattttattt atttattgaa acagagtctc gctttctcgc ccaggctgga gggcaatcgc 600
 accatctcgg ctactgcaa ccttcgcctc ccgggttcaa gggattctcc tgcctctgcc 660
 tcccagagtag ctgggactac aagc 684

<210> 66
 <211> 1012

<212> DNA
 <213> Homo sapiens 4.C.42

<220>
 <221> n
 <222> (793)..(793)
 <223> a or g or c or t

<220>
 <221> n
 <222> (849)..(849)
 <223> a or g or c or t

<220>
 <221> n
 <222> (903)..(903)
 <223> a or g or c or t

<220>
 <221> n
 <222> (921)..(921)
 <223> a or g or c or t

<220>
 <221> n
 <222> (926)..(926)
 <223> a or g or c or t

<220>
 <221> n
 <222> (956)..(956)
 <223> a or g or c or t

<220>
 <221> n
 <222> (1005)..(1005)
 <223> a or g or c or t

<400> 66
 gcggccgcgg cggcagcggc tgccggggagc tccagcagcg gcggcggcgg cggcggcggc 60
 agcggcagcg gcagcagcag cagcgacacg tccagcaccg gcgaggagga aaggatgcgg 120
 cgcctcttcc agacgtgcga cggcgacggg gacggataca tcagcaggta cgcggggagg 180
 tacgaggaaa ccgacaggag cgagatcagt ccctccgcgc gcccttgacc cctgctctgc 240
 cccctcgccc caacttgccg caagttgctc agaagctcgc gggaaaagtt ggccgcgact 300
 ccgagagcgc gtagccggct cggccacgaa ggccgagggg actgctctgt tcgccttgcg 360
 ggggtgccag ttggtccaac ttttcccagc gctgtctttg tctaggcggt gggagacatc 420
 tccttaggat gcgcaactctt ccggggggctc ggagtgttct tccctgtggg aaaaggagtt 480
 ctggccgctt gtcccaggta ggaggggctg cccacagcc tcggggtcct gggcatcaag 540
 atgccgcagc acgggggcagc gatctgcccg gcggcttggt ggacacccca gggccgcacc 600

gggaggagat gagctaagcg acagcctcgg acagggaaat aacctgtgaa gaaactttct 660
 tgtgccgcag aacccatgaa ttccaaactt cagagcccaa gaatgggtat cgtttgccac 720
 ccagtattga tttaaacgca gtagcctgag aggaacgaag cgctcaggag caaactaggg 780
 ctagacccga ctinctacccg gctctgtgcg ctgaccaggt gagcttcggc gtggttccgg 840
 gcgcctcgng cctcactaca acaacttttg ggtgttgctt cgatccccga cttctacaga 900
 gcngattaag cttctgctcc ngctgncaat atactctgcc aattggacta acttgngtga 960
 gaagatccac ttctgatgct ttgatgtgca cgctgaatgg ttccngatga tg 1012

<210> 67
 <211> 595
 <212> DNA
 <213> Homo sapiens 4.C.9

<400> 67.
 gcggccgcct tgaaggcgct ggacgggatg gtgctgaagt cggatgaagga gccccggcag 60
 gtgagctcgc ggcccgccag cccgctgccc acgcagtagt ggaagaggcc gaagtagcca 120
 ggcttggggg tgctcacgct gtcgcccacc cagtagggct ggatgaagac caccacgttg 180
 atgatggcga agcagatggg gaagatggcc cacagcacgc cgatggcccg cgagttccgc 240
 atgtagtgct cgtggtagag cttggaggcc tcctgcgagg gcagcatggg gcccgaggcc 300
 ggggccggcg gcggcgggcg ctggcggggg ccgcccggcc gggacggagc gccgggctgc 360
 cgggcgggag ctggggacgc acgcgagaag cggccctgag tcaaggaacc cgcgagggcg 420
 gggcctgggg cagagctggg ggcgtctggg agctgctaag ggagagagga aggggtcatg 480
 agagtgttga ggccgtgtct agggggactg gcaaaggtct cctactgggg ggcctaggaa 540
 ggggccatga gaaagtggg gggcgccctag gatggggata tgagacctga agtgc 595

<210> 68
 <211> 1955
 <212> DNA
 <213> Homo sapiens 4.D.07

<220>
 <221> n
 <222> (615) .. (615)
 <223> a or g or c or t

<400> 68
 atatctatcc atatctatac ctacatctac ctgtatgtgt gtagtgtata tatatacata 60
 ttatatgtgt gtatatatgt acatatatac atttaaacia aaattttctcc ttcgtcctcg 120
 aagcaaacia accagcacc ctcagtgctc gccaggaggc gcagggggca gcgtgggacc 180
 tgcggtacct ccacggttgt agaggtgtag agggatgccg cagcgacgga accgggcttc 240
 ttttttaaag aatcaatgtg agggaagggt gcagagccgc gttatttcag ggagacattg 300
 tcgcactccc cctcccacgt gtaggtagca tctgggggtgc gtgcgccctg ttcgcagacc 360

ccatggagag acgctggcgg cggcagatgg ggctcctttc acggttgcag ccggcagtaa 420
 cccgaccccc cgggcgcaga gactgaagaa gcgcakggga cagcggcgag ctgcgaacaa 480
 aagcccttgg cgcggggcgg aagcccakga cgcggtgtga gtaaaccggc tcgggtaccg 540
 ggagctgcgg gaacctgggc ggccaggttc tttgcactcc aggagcccac ccactgggat 600
 gctgtggggg aactntcgga gggcacccga rggcgggtat ctgaaccccc actgggggtg 660
 atggtatctt tagcacattc agacttggag gagawycggk gcggtctgag artatccagg 720
 caccttctcc atccccagca aaacamccgg tgggggtggw ggtggggggc gaggcggcgt 780
 gcagagccct cagtaagccc tgccagagct gctggagcaa gaatccatca cccctcccgg 840
 agaggccttt ggggacttct cccagccctt taatcaccgg ggggccttgc gaccgagtct 900
 cctttggcag gggaaatcaa ccataaactt ccttyccytag gcaaattgggg tcccttggga 960
 tgaacaggcc tcttgctttt ttgttcttgc aaagctgcat cccagtagc ccgcctaagc 1020
 taaaaacaaa tacgctaata ctcccgggaa tcctccagcg cctccctctc tagctcctgc 1080
 ctgcacctgg atcttttcat cttaacttgc agcagaaagg ggatgcatct agcgggctag 1140
 gcgcccagag gagcctcgcc acaggcctcc accccgcatt ccgggggctg agggagaccc 1200
 aggctgctct ctgaacacga gtgtccgccc caccctmatc ccsgtyytgg cgctcagcct 1260
 gggctttccg acatcggttt tatgatttac gtyccaccaa agcctctgag cctaatacga 1320
 aagcggatta agttgggatg gggtgactat ggatgaggag gggggaagag ctctcagacg 1380
 tattcctcga tgtccctcct tgtgatctgc agagattcca acaaaggacg gggctcagcc 1440
 atggtggacc cagtgcctga agaagagaag gcaggagcgg aaccggcgga ctctggaggg 1500
 gacgaggccg tggcgtccgt gcccctgat tcccaggggc cacaggagcc cgcagcctcc 1560
 tcggcctcgg cctcggcctc cgcggcggtg ccccgcaagg cagaagtccc atgtgcagcc 1620
 gcagaaggcg ggcggcgggg gcagtccccg ctgctgcacc tcgacctctt caacttcgac 1680
 tgcccagagg cggagggcag ccgctacgtg ctgaccagcc cccgctcgct agaggcctgc 1740
 gcccgctgtg cgggtcaagcc ggtggagctg ctgccacggg ccctggccga cctggtgcga 1800
 gaggtccgg gccgctccat gcgggtggcc accggcctgt atgaggccta cgaggcggag 1860
 cggcgcgcca agctgcagca atgccgggccc gagcgcgacc gcatcatgcg cgaggagaag 1920
 cggcgtcttt tcacgccttt gagccccgcg gccgc 1955

<210> 69

<211> 1888

<212> DNA

<213> Homo sapiens 4.D.08

<400> 69

gcggcgcgcca gctcacaag gatagggagg gatattgctc ttggcatttg atgggaagca 60

tctgctgcat cccattgggg tgttgcccag gatggattgg aaaagagttg gcaggaaggc 120

tgagctctgt gctcacaacc tggcttggtg gtggccgagg agcttggcag gagcagagtg 180

```

caggacctgg gaactggggg ttggtgcatg tgtgcacgca cgtgtgtgtg tgtgtgcgtg      240
cgtgctgggt gggtagggag gaagctgtga aaccacatcc cctcctctct gctgctgtgt      300
tgctgtgtgt ttcagcagca cgtgggtgtc accacacttc ctagcagggtg tcaacctcca      360
agactgttct gggctcttct cccagttggc tgagttggag gtgggagtcc caactgtccc      420
ctgtggcttc cagagtggga ccttgctgtg ggataggctg gccaatgggtg ctccctcccc      480
tgtgaccctt ctgttgggtg ggtcacgagg aaggactgtg ggtgttgccc acagacaggt      540
ggacatgtgg caaggacacc ttgggacctt ctttctgacg ccccttgaag ggggcacttt      600
ctcagctttg agatgagtct ctgtggatgt gggaagttca ctatctcaag agcagcagcc      660
ttggaaaatc caacacagaa ccccgagtag gggcggggag gggtcctgtc ccgctcactg      720
gctgcctggc agagttctgc acaaggaagc gcctgtgttg ctgtgggcgg aggaatggac      780
tgagggctac attcgcttcc tgttgccgct gtaactgctt atcacaaact cagtggctta      840
aagcaacaga ggctccttcc ttacagtgc taagggtcag aagccgatca gtctcaccgg      900
actaaagtca aggtgttggc agaatccatt cctgcctctt ccagctttgg gtgggaggct      960
ctgctggagt tccttggctt gcggctgcat ccctccagcc tctgcctcca tcctcctaca     1020
gcctcctcct tctctgcagt cagatctccc tctgccttcc tctttttttt ttttgagacg     1080
gagtcaccca ggctggagtg cagtggcaca atcttggctc actgcagcct ccgcctcctg     1140
ggttcaagcg attctcctgc ctcagcttcc cgagtagctg ggattacagg catgtgctac     1200
tacacctggc taatttttgt attttttagta gagacagggg tttgccatgt tggccaggct     1260
ggctctgaac tcctgacctc aggtgatctg cctgcctcag cctcccaaag tgctgggatt     1320
gcagccatga gccatcacac ctggcctgcc tccctcttaa aggacgcttg tgatttgggg     1380
cccacctggg taatctcttc atctcaacat cttcagttac atctacagag tccttgttgc     1440
cacatgaggt aacacagttt ggggaaggag agttattcag cctaccctag gggcctgtgg     1500
tgtatctcag ggcccttctg attttaagat ataaagcaag aaaacaaact ggctcaaggg     1560
gaaaaaagga cacgttgaat tctgttgctt taaatgtata tttttttatt gtgctaaaat     1620
gcacagaaca taaaatttgc cattagtaac actgagtaca ttcacagtgt cgtgcaacca     1680
tcagcactgt ctagcgccag aactttttca tcaccccaaa gggaaacccc gtatccatga     1740
aggactcact ccccatctgc cctctccagc ccttggcagc caccagaatg ctttctgtct     1800
ccataaatte atttttaata agtgcaatc tgtgtgactt taaaataaat aaacatgagc     1860
acgatgagtt gcttattgga aggatatc                                     1888

```

```

<210> 70
<211> 994
<212> DNA
<213> Homo sapiens 4.D.12

```

```

<220>

```

<221> n
 <222> (673) .. (673)
 <223> a or g or c or t

<220>
 <221> n
 <222> (686) .. (686)
 <223> a or g or c or t

<220>
 <221> n
 <222> (701) .. (701)
 <223> a or g or c or t

<220>
 <221> n
 <222> (754) .. (754)
 <223> a or g or c or t

<220>
 <221> n
 <222> (764) .. (764)
 <223> a or g or c or t

<220>
 <221> n
 <222> (774) .. (774)
 <223> a or g or c or t

<400> 70
 gcggccgcta ggaaaaggct cagctccggc cgctccgatt agccgtggcc ttgctctgcg 60
 agcagataaa cgtgacctcc gtggcctgtg gccagcctcg gccctctgga ggcggggctg 120
 tgtgcggccc tccccctccc agcagggctg agctcagaag cagcaggcag ccggaagggc 180
 tgggcagtcc ccgcacctgt cctgttgcca gtctggtggg tggtgtgtgt gcaggggtggg 240
 cgtgccggga ccctctggcg tggggctgtc tggcaaaggg cgagggggga gggggctgtg 300
 cttcagcata gaagggaagg gcgtgtccag aagagggaac agaagagggt ccagaggccg 360
 aaccagaaca cgtcccttca ctgatggaaa cttcccaccg cgctcgaatc aattcccaat 420
 tgctcgactc ctgcacctc ccgggaggtc ctgtagaggc agcgctccct cccagcctca 480
 cccgccggcc tgttcctgcc acagggtctt gcccttcctg agctctccgc ccggactctc 540
 atcccggact ctctcccca tctccttcca aagccagttc tttctcatta ctcagggtc 600
 tgctccaatg ccacctctc ggagggggcca cctcctctc tgaacggcgc ccctccctcc 660
 ctcttttctc ggngccagct ccattntccc cttctccttt ntcaccacgc ccacaactta 720
 gaggcgcgtg tcccgtccct agaactgctg cggncacagg actnctggcc cttngcatag 780
 gctggcacgt ggcacgttcg cccagcctc gtacgcattt tgatggagag ttggaccaga 840
 gagggcgcgg agcatgaatc tctgaagagc tgaggagccc aaatcagaag ctggtgagtg 900

agtttaatct gacttggagc atggagttat acgggagctg cttccagaag cccagctctg 960
 cactgctacc atatatggca cggacgcttt agct 994

<210> 71
 <211> 677
 <212> DNA
 <213> Homo sapiens 4.D.13

<220>
 <221> n
 <222> (352)..(352)
 <223> a or g or c or t

<400> 71
 gatatctttg ttgcattgag acaggaaagc tatTTtaaga tgggtgtggtg aaaaaggata 60
 aaagctcctt actcaagctc tagcttatct aactctcagt caataggtaa caaaacaccc 120
 aagaagctgt taactgcaag ctctatTTtc agagggctag ggacttcccc agatccccgc 180
 ctgtacagtt agacttaaac tccaacctac atttaccctt tcttcacttt aatgctaata 240
 attactcctg ggggtggagat ttaaaatgct aatgctacat atgatgtatg aaaaagcata 300
 ttgggccact gtgcaagcac tagaaaaact cctcctatag gtgccctgat gntaaccctc 360
 ccctatagaa agaccctata aaactgaccc acacactatc ctcagagcag tccgttcctt 420
 tgccttttctt ggtgctgact cccttgcgca caagctgaat acactttcct ttgctgctat 480
 gtttggtgat ctctgttaat ctctatcatg ggagatcata agaatccagg gcaacagtaa 540
 cagcttctga gttttttaaT taaaaataac agtaataata tctttaaatt tttaaaatgt 600
 aggacactaa acaagtaaaa tctaaatcca gagtacatct gacctcaaag ttcattgggt 660
 tctcacttcc ctggcca 677

<210> 72
 <211> 435
 <212> DNA
 <213> Homo sapiens 4.D.47

<220>
 <221> n
 <222> (11)..(11)
 <223> a or g or c or t

<220>
 <221> n
 <222> (24)..(24)
 <223> a or g or c or t

<220>
 <221> n
 <222> (58)..(58)
 <223> a or g or c or t

<220>

WO 02/060318

PCT/US02/03077

<221> n
<222> (59)..(59)
<223> a or g or c or t

<220>
<221> n
<222> (76)..(76)
<223> a or g or c or t

<220>
<221> n
<222> (82)..(82)
<223> a or g or c or t

<220>
<221> n
<222> (110)..(110)
<223> a or g or c or t

<220>
<221> n
<222> (111)..(111)
<223> a or g or c or t

<220>
<221> n
<222> (125)..(125)
<223> a or g or c or t

<220>
<221> n
<222> (147)..(147)
<223> a or g or c or t

<220>
<221> n
<222> (151)..(151)
<223> a or g or c or t

<220>
<221> n
<222> (156)..(156)
<223> a or g or c or t

<220>
<221> n
<222> (163)..(163)
<223> a or g or c or t

<220>
<221> n
<222> (165)..(165)
<223> a or g or c or t

<220>

WO 02/060318

PCT/US02/03077

<221> n
 <222> (177)..(177)
 <223> a or g or c or t

<220>
 <221> n
 <222> (209)..(209)
 <223> a or g or c or t

<220>
 <221> n
 <222> (223)..(223)
 <223> a or g or c or t

<220>
 <221> n
 <222> (226)..(226)
 <223> a or g or c or t

<220>
 <221> n
 <222> (249)..(249)
 <223> a or g or c or t

<220>
 <221> n
 <222> (320)..(320)
 <223> a or g or c or t

<220>
 <221> n
 <222> (395)..(395)
 <223> a or g or c or t

<220>
 <221> n
 <222> (396)..(396)
 <223> a or g or c or t

<220>
 <221> n
 <222> (404)..(404)
 <223> a or g or c or t

<400> 72
 gcggccgcgt nccctctcgc ccgnaaagag gactggagaa ggggctgggg tggaggtntt 60
 ctctgtgtgt gtctanggtt gngggcagga gaggttaatt ctattaagan ntcataatc 120
 anccngtgtg cacttttctgc tcgacancgg ntccnctac ttnanagcaa gtctggncca 180
 gctgggatcc gaccagaaac cgcaagcgna ggagacgcat gancgnaggc tgagcgctaa 240
 ctgaaggcnc gacctgagcc ctgcagcctg ctggggagct gcgcaaccac ggacagcagt 300
 tcggcaatac acggcctggg ctgcatggcc cccgtcacca cctcacgtgg gaagccagca 360

ctgctgccgc cagccctgcc gctgccctca gactnncaag gcgnccaggg tcctcccaac 420
gcgcctgccc cacac 435

<210> 73
<211> 2343
<212> DNA
<213> Homo sapiens 4.E53

<400> 73
tggccagggtg aggtcaggct ctgtttcttc cgagctacca tcctctacct gattcctcac 60
acctttttct tgtaggcgc agctaagaga cagagagaga gagagagaga gagagagaga 120
gagagaagcg actgaaacag agagtaaatt ctagtttctc ctttttagtc tcttttcttc 180
tgccctttgc tctgctagtt tatctgcgtc ttttctcttc tcgcgctgca agagtggaaa 240
actcgtgctc agttctaggg aaacattaac cccgggagac gtttccaagc gggagacaaa 300
ctctagagag tgagaagcga gatgcgaggg caccaagggc aagaaggggg ctccgggtac 360
gccacgttgg cgggacgcgc ccgcgcctc cctctgctgc gcggcctgcg ccgggagcct 420
ggtggggggcg gcaagacgac agaccccgcg cccgggcctc ccaccagtga ccacctccct 480
cgcagcttgg gctgacctc cagacagcat gcaacgggtg ggagggaagt cccctgactg 540
ggcggggggac ctagcggctg ctctgaaact ccgaacacct gaagaggagg cgcggaaggt 600
ccagccgccc aagactcgca ctttccctc ctccgcagcc cgggcagggt accgtcctgg 660
gcctgggtga gcgcggagg gatccgggcg ggagctgagc tcggttcccc aggctgaca 720
agtggccgcg tggcacgacc aaccccgggc acagggctgg ggctgctccc caaggtgggg 780
aatttaattc tcacattttc gcactaccct gacggagctg gacgcgggaa gcgggaaaga 840
cccgttcctg tttgcagtgc ccgaggggca ggacacctac cagaagggt ctatcacagt 900
ggtgttaggc cgggcgcagt ggctcacacc tgtaatccca gcactttagg aggccgaggc 960
gggaggatcg cttgaaccca ggaggcagag gttgcagtga gccagatcg cccactgca 1020
ctccatcccg ggcgacagag ctgtcttgaa aaaacacaca aaaaacaaaa aacagtgggtg 1080
ttagagggat gggattatag gtgacatgac tttcgttttg aactttcctt aaccttgca 1140
gggcagccgt gccctgaaaa cgcctgtgat ttggagtaga gggccaggc gcagtgtggt 1200
gagtgacct aggcagggtc ctagttcttt ttcagccttc actgaatcct ctcttacag 1260
gggatgttac cccaggtct ccgtgtcttt caggagaaa ttagttcatg agttagatgg 1320
tgcactatca atcatccttt tattagacag aaacaataag tttgaggaag aggacgtcta 1380
ccttacaggg ggtttaattt tcagcttctt tgagataaaa ttcatgaac ggtgttttac 1440
gtgcgcgcct tttccaacag accccacgcc tattcccagc gccagaggcg gacaaccgct 1500
ttactgagat acagagacag gtacttcctg aggcacttca gtccagttcc actgggttta 1560
ctacaactaa taatgactgt ttctgtttac taggtattag gcgatgtgtt ttaagtaa 1620
gaattgtctc taatcctcac aactctaaag caagttaggc gtcacccgca ttttacaat 1680

catagcgccc tgctcaccat atctggaatc ttgcctcgcc ccgaggggttc taattttcac 1740
 tttagagagc tgagcaagat gattgcccag cgctaactcc gtgaaatccc tgggactgaa 1800
 aatcacaggt aactcgccag agtttttcaa ttttaggcct aggagattat gcaaagattt 1860
 ccttcaagta aacgctgttc tctggggcct ctgggatcta cagtcggaga aggggaataa 1920
 gtcccgggccc ggtgggggat ggggtgggtgc agtttcctaa atagaggaaa gccactttca 1980
 ttcaaagggc tgtggaactc tggctagagg tgggtttctt tgcagttaat catctgcaag 2040
 gctctttgga tgcctgattc cagaaaccca gaactcacac ttaggggtcac aaaatccagg 2100
 gcatttattt gccgagcccc atggatgtta tccctatgga tgcaccccgc ccctgtccgt 2160
 tctccttttg agcagaacga aaccatttcc agagcttttg caggaagtct tcaggccctt 2220
 gcgtccggcc ccttttagaca tcaaagcccc ccctgagagc aaaggacttt gaaagatagg 2280
 aaaagctcag gatccttata gcgtctctgc tccctcccga cctagtcgta aattccgagc 2340
 ctc 2343

<210> 74
 <211> 507
 <212> DNA
 <213> Homo sapiens 4.F.15

<400> 74
 tacgactcac tatagggcga attggagctc cacgcggtgg cggccgcggg cagtgcggac 60
 caggcggggg ccctgtggct gccggccaca tcccggagca acagcagaaa caacggcagc 120
 agcagcagca gcagctgggg cccgggtccc gggctggctc gagcggggac atgagccatg 180
 gcgtgggtgag ggcggcaaag ggtcgaagtc caggaggagg aaggcgagcg ctggcgccacc 240
 ggaggctgcg gactgacctc gcggcagtag ggcgcgcggg gagagcccgg gcagcagggc 300
 gctggatacc gaggtccgcg cggggcgagg ggcttagcgg agcaggcacc cgggcgcgcg 360
 gtccgtgggt accggtggcc cgagcccccg gccagcggtc acagccgtcc ggagcagcgc 420
 agagccgagc cgagcccagag tcggcgcgct gccttggcgg actcgcgctg cgaaagtttg 480
 tagccactg cgcgcccggc ccggctg 507

<210> 75
 <211> 446
 <212> DNA
 <213> Homo sapiens 4.F.17

<400> 75
 gcggccgcac acacgagggc ccgtcgcgcc ccccgccctg cccgcctcg ccctccacgt 60
 ccctgcaccc ccgagtcgca ctaagaaccc agtccccgat cggtttcctc tacgccgtct 120
 gagcagaaga gagtgggaac cgggggtgacg gataaggggg gggcgcccac gcgacgtcgg 180
 ggtgcatggg agcgcgcggg aggcgctagt ggggtgcacgg ggcgtgaggg ggacacagcg 240
 cgggcgtggg gatggccact gcgcggggag ggttctgcct ggagaaggag ggatgggagg 300

aggttggggg agcagggcgc gtggaggagg gaggttggac gtgtgtacag cgcctgggga 360
 cctcgctggc cccttggtgc cccaggact ctgaggcttc tcctttcggc ttgaaatgtt 420
 tttcccttcc tgcttttcaa atctgt 446

<210> 76
 <211> 424
 <212> DNA
 <213> Homo sapiens 4.F.22

<400> 76
 gcgccgcct tgaaggcgt ggacgggatg gtgctgaagt cggatgaagga gccccggcag 60
 gtgagctcgc ggcccgccag cccgctgccc acgcagtagt ggaagaggcc gaagtagcca 120
 ggcttggggg tgctcacgct gtcgcccacc cagtagggct ggatgaagac caccacgttg 180
 atgatggcga agcagatggt gaagatggcc cacagcacgc cgatggcccg cgagttccgc 240
 atgtagtgct cgtggtagag cttggaggcc tcctgcgagg gcagcatggt gcccgaggcc 300
 ggggccggcg gcggcgggcg ctggcggggg ccgccggccc gggacggagc gccgggctgc 360
 cgggcgggag ctggggacgc acgcgagaag cggccctgag tcaaggaacc cgcgagggcg 420
 gggc 424

<210> 77
 <211> 558
 <212> DNA
 <213> Homo sapiens 4.F.6

<220>
 <221> n
 <222> (413)..(413)
 <223> a or g or c or t

<400> 77
 gcgccgcag ctcaccactg gcctagagat gccctttgcg aggcggcagc aactgacaag 60
 atggtcgcgg gtcgccgcgt ccggagccgc ccaccagggt gccaggagga ggcgggagcg 120
 gggatcaagc ttatcgatac cgtcgacctc gagggggggc ccggtaccag cttttgttcc 180
 ctttagtgag ggttaatttc gagcttggcg taatcatggt catagctgtt tcctgtgtga 240
 aattgttata cgctcacaat tccacacaac atacgagccg gaagcataaa gtgtaaagcc 300
 tggggtgcct aatgagtgag ctaactcaca ttaattgcgt tgcgctcact gcccgctttc 360
 cagtcgggaa acctgtcgtg ccagctgcat taatgaatcg gccaacgcgc ggngagaggc 420
 ggtttgcgta ttgggcgctc ttccgcttcc tcgctcactg actcgctgcg ctgggtcgtt 480
 cggctgcggc gagcggatc agctcactca aaggcggtaa tacggttatc cacagaatca 540
 ggggataacg caggaaag 558

<210> 78
 <211> 865

<212> DNA

<213> Homo sapiens 4.F.69

<400> 78

```

gcgggccgcag cgagttttct ggcagcgcta gcgcccgcggg gcctgggttc ccgggttccg      60
gtctccgcgcg gctccgggct cgcggccgcg agttggccgc accgttcccc cgcggcgggg      120
gcagccgctc ctccgggagg ctccggcagg gaccttcgcc ccggcccccg agcggcagtg      180
cgggtccagc tggaggcctg gcccggggaag caaagtgaag ggacagaggc ctcccttcctc      240
gccagccgcc cgcgcgcgct ttcccagctc aggcggcgcg cccgcggcgcg ggaggagcgc      300
aaagagtcgg ggctgcccc ctccaccgcc cgcattctcg ccggccgacc cgggtccgcc      360
ccgggaggcc ccgcgggagg gaaccccccg cccgctgggc gcttccgcac tgacgccttg      420
gggcccgcgcg ccccgcccc ttactaccgc tacaccgctt gggccccga ccccgctccc      480
gggctgctgc cagcgcgctc ttcccccgta gaaacttcgg agacaccggg gaagctgctc      540
tttgaggttg gggaaactta ggaagaatgg gaaaagccga ggaagtcggg gaggaccccg      600
cagttgcctt gccctcggcc gaaattcctg tgcaattgga cgggaagcct gccacgcca      660
gagagccacc cgggtggcacc ccgttgggga cctgcggctg ccctaggctt gagctggcga      720
ccaacggcgc ataccccggg caccctagg ggaccgtgcc cggcccggct tgggggctcc      780
taacgccagg cttgtgagct ataggggtga gagtgggccc gctcttaagg ggaaaaattt      840
gcggcctttt accaggcaca gccag      865

```

<210> 79

<211> 983

<212> DNA

<213> Homo sapiens 5.D.9

<400> 79

```

gcggccgcag ccagcgcgcg ccctcccggc cgggcggggc ccaaaagccc tttctgtcac      60
cgcaccaggg cgcgaccggg tgatgcattt ccacaccagc ccgccccaaac ctccatgggt      120
ttggagctcc cgggcaggcg gtggaaactt ggcgcaccgt gccactctc cggcgccgct      180
ccgacagccc gacgggtccc gcggccagga agccactcgg cgcctctcgc cgtcactcga      240
ccccggccc ctttcggact ccgatcctcc cgtccccagg ccacacggcg cggaaagggg      300
atgccgagcg ggacgcgcac gaccagggcg cccaggacga gggcgctgga ggagactccg      360
ggcagggacc ggggtcccag gggcccgggc cggggctcaa cacccaccg atgggggtgcg      420
ggcccgcagg gggccggggg tgggagtagg ggcggcgggg gcccgcggag gaggagtggg      480
gataggccgc gcagggggtg cccgggaccc cgggcgcaag ctgggaaaga ggcacgcggg      540
ggcggcgcgc cggggccggg acaggcgccc gtccctcacct gccgggcagg tgtcccgcg      600
gcgagtcgcg cgcgttgctt tccgaggtgg aactgtcgtg gtccacggcg catggcgcg      660
tgaaggcagc ggccagcagc ttcataaggt cggcgggcgg gcaggtgccg gggccgggtc      720
ggaggccacg ccggggccct gggctggggg cggggcgact agcgggctgc gagcgggttc      780

```

cacgcgcgcg gttcaacggg ctgcacccgc gccgcaccgt gccaacactt cgggcggggcc 840
 ccgctgaggg tccgggttgc cgcactagga ggcgagggcc cccgcgtgca agccgcccggc 900
 ggcggggccc ggttgccacc ggcgccagcc atgggtgggc tccgggttgc tttccccccc 960
 tgccccctag ggaattgagc cga 983

<210> 80
 <211> 432
 <212> DNA
 <213> Homo sapiens 5.E.2

<400> 80
 gcggccgctg gtgacctccg cccgcgggtca ctgcacgccc agccttggcg cgtttgcgca 60
 actgcttttg tcccagacct tcattctggg cgcagtcccc tctcccagtc cccctgccgc 120
 ggcgcctgga actctcctgg tggctgtaag attttcctac cgtaggtcg tctgtggcga 180
 ccgccaggcc tgccccacat cgctagccgc cctgtctacc cctcagcctc ccagccacta 240
 aactcgctgg acaaccttac gctagtaaca gtttttgagt ctgagactca tctgtgaaag 300
 ggcagtcata tttgaggact ccaaattgggc tgcagtgcgt aaaccacat gcgatatttg 360
 gttgctattg cccacctcag cctgtggcca atgtgtctct gtaggaacag cactagattc 420
 tttggggttt tt 432

<210> 81
 <211> 746
 <212> DNA
 <213> Homo sapiens 5.E.25

<220>
 <221> n
 <222> (695)..(695)
 <223> a or g or c or t

<400> 81
 gcggccgcgg ggcgctcagg tccttgcgcc tcctcctccg gctcttcccc cagcctctgc 60
 ggggcgtcct ctccacctc cggggccac tcctcccccg gagagccccg gggcgcatcc 120
 tcaaaagcat cctcctcacc ctctcatcc gtgtccccag cccctcgac gggggctccg 180
 gccgcttcct cccccggccc ggcctcggga aatgggaaag ccgtggagga gggcgagtct 240
 ttggccgcgg gttgcgctgc cgggagactg ggcgcctcgg agaccgggag gccgccgggg 300
 gacggcggtt gctggggctc ccggggctcg gcggccaggc tctcgggcag gtcggagagc 360
 gcggacagcg cctgctcggg gtccggactg cccggggcct cccagcccc gccgctcggc 420
 cccagcagga accggtccag gccaggaag gccccgggct gaggggagac ggcagtgggg 480
 ggcgctgcag gctcctcggc gccctggagc tgctgctgct gctgctgttg ctggagctgg 540
 agctggagct gctgctgctg ctgctgctgc aggcggatcg cctgctggat gtctgaaagc 600
 aaatcctctt gctccgtagc cgaatggaag ctatagatgt ccgtgtccga gcccgagctg 660

gtcctttgtc catcctgcgc ccctgctgca gtttnacacat cctcggcgat cggccggccc 720
ccgaccctag cctcggcagg cccagg 746

<210> 82
<211> 617
<212> DNA
<213> Homo sapiens 5.e.4

<400> 82
gcggccgcgg gccggtgttt caggcagctc ttgggcgcgc gcgggctcgg ggccggcgcc 60
gtggagggct cggccccaat tctctcgggc tcggcccccg ctctctctc gggctccgtc 120
tccgcttctc tctcgggctc aggcgcgggc cctggggggcc ctttctctc atccgggagc 180
acgggcggcg tcggctccgc ttccttcggg aactgcgtt ctggccccgc gcgagcagag 240
ggcgctctg aggtggcggc ggggtcagtc tcggggggag tcgtgtcccc ctccgggatg 300
gcggtgggaa acgggctcgc gacgtcttcg ggagcacaga ccacctctc cgccttgtcc 360
gtggccgggg cacacggggc tgcggggggc gcctcccat cctgctttcc gccgtcggga 420
ccgggattcg gggggccctc cggcggggac gggggctcca cgcggagagt gggggccgac 480
tcgggctcgg cgagctccgg ggtggccggg cggcttgagg ggtcctcccc ggggacgccc 540
ccctctcca cgctggcgt gagcgcggag gagtgtgca ggccggcgcg tctggcacgg 600
gcccctccgg gtggcgg 617

<210> 83
<211> 1840
<212> DNA
<213> Homo sapiens A.2.F.45

<400> 83
ggcgcgccga ggccgaggcg cggagaggcg cggcgctctt ggggagacgc ggccgagggc 60
atagacgtac gccggcgctt ccccgagggg gaggggtcgc tgggcggggc ggagtgaggc 120
gcggcgccgg cgcagagacg cacgtcgtc ggctgagggt ggccggggagt gttgcagtcg 180
tacattcgcg cgcgcgggg cggggagcgc ggggggtggc cgggtgcaggc gcagagacac 240
acgtacccgg cggcgagag acgagtggaa cctgagtaat ctgaaaagcc cgtttcgggc 300
gcccgtgct tgcagccggg cactacagga ccagcttgcc cacgggtgctc tgccattgcg 360
ccccctactg gcgactagga caactacagg gccctcttgc ttacagtgt gtccagcgcc 420
ccctgctggc gccggggcac ggcagggtc tcttgctcgc agtatagtgg tggcatgccg 480
cctgctggca gctaggaaca ttgcagggcc ctcttctca cattgtagtg gcagcacacc 540
cgcctgctgg cagctgggca cactgccggg ccctcttgct cgcattgtcg tggctgcacg 600
ccacatgcag gcacatgggg actacgcagg gccctcttgc tcccgggtgtg acggctggcg 660
tcccatattg gccacctct gcaccactta aagtcagagc gccagttatt aatccccatc 720
agttctgtaa attaaaactg aaaaggagct attactgcgg agagctgatg tcccagttat 780

taacttgga gacagctttt caccaagagg cagtacaaag atggaagata acttcattga 840
 aaagaaatac agtgtaaaga gcttattgta caaaaatagg gaggagtagg ctgatactgc 900
 atgaaaacag cctaagagtc ctgtgcaggg atttttatatt tggacttctt cacattccta 960
 cctctgtctc aagtctccgc ctgttttctt tggttttcct gctactgcct taggtccccg 1020
 acttgcccca cttagccttg tgggacctcc tcacttgatt gaggtacatg tgtggtgate 1080
 aatccgaatc cactctggca ccagcctcct tcccaccata ccaggcaggc tgacagcggc 1140
 cacgtttgta tctactgcag ctgcctcttt tgaatgtctt tctctgcctt aatctgtact 1200
 tatggtgcca ggtttctctt aagaatgtcc cctttgtcct tcttatcagc atgtagctag 1260
 caatattctg acatttttat tgcagaatga atgatgattg gggcttcttt tttttttttt 1320
 tttttgagac ggagtctcac tctgtcacc aggccagact gcggactgca gtggcgcaat 1380
 ctcggctcac tgcaagctcc gcttcccggg ttacgccaat tctcctgcct cagcctcccg 1440
 agtagctggg actacaggcg cccgccaccg cgccagctaa ttttttgtat ttttagtaga 1500
 gacgggggtt caccttggtta gccaggatgg tctcgatctc ctgacctcat gatccaccg 1560
 cctcggcctc ccacagtgtc gggattacag gcgtgagcca ccgcgcccat ccgattgggg 1620
 catcttaaga gaagttctag ggtgtttctg cgtaggtacc tcttctccct cctaaccaca 1680
 attgacaagt gccatccac tccagcacta gagatgctac taatatgtgc atttttggtg 1740
 gtccctccag gtgagccttc acagactttc ccttttccag gagctcccc tctgttcat 1800
 gtctagctag ctatctactc taacagagcc cactatcctg 1840

<210> 84
 <211> 3592
 <212> DNA
 <213> Homo sapiens A.2F.50

<400> 84
 gccgaggagg cggctccgac ccaggctcgtc gcagcagcac aggaagctgt aacacaggta 60
 agtgcaggag agcgagagcg tgaaggcgaa gagcagcctg cgcgccctcc gcggctgagg 120
 tggccccgcg cggcccagga ccctatagga catggctcca tgggccccgc ccgggggtca 180
 tggtttccga gggggcaccg gcggctgagc tgctgtggcc ctgcggctgc ctagagggct 240
 cgcgtggcgc tgccacggcc acgcgggtcg ggcgttgggg gcgcctctt ctccgggggc 300
 tgctgaccag ggtgcgcaca gtgccagggg gtcccggggg cagcggctcc tcggggaaca 360
 ggcggttgca tttccagcat ctcccgtcc taggcgatgg ggctccgggc agccgggcgg 420
 ctccggcgct cccaggctct tacgtgcgcc ggggttcggag cgcgccagc gcccgagcc 480
 ccattcctga tctcggagc gccgtcacg aaacgctcgg cggcggcgcg gctgtgcggg 540
 ctggcggggtg gaccggacgg tggcgctggc gccggccgcg atctggctct tcgggaaatg 600
 ccgagcggag cgcgtgccg gctctattta aggagtggcc tgacgtcagc cgcgcgggtc 660

ccccgagccc gcgcccgcgc cagggacctg gcccgccecc tgcgccccca ctctcttacc 720
cctcccagaa acacagcacg cgggcccctcc ccatgcaggc cactccctac ggagccccag 780
gccagctttg gggcggtgaa acgaagggtg caaggcatag tactcctccg ggaggctgga 840
cacccccacc acgctggcct ctgcacatcc agggacacga atccaggctg agatcgcgcc 900
gacatgcaga ccagacagac ccagacgcag acgcaggcac cctgccctga tgcgcgggtcc 960
caccaccctg acccgcacac gcacgcacag gcacagaagc acacgcgccc tagccccggac 1020
acacccccac acccacgcgg ggggtggggag gagaagtccc ctaacctggg cccagataca 1080
ccgacaagga cactcccccc gctctcgaca tctcgccaaa tggacacaca cagccccgaa 1140
tcggacaccg agcgcacgca cgccctggac tgggacacgc gctgtagacg ggatgggtgg 1200
aggagccgag cgtgagttag attccgtgac tattcaccca gcttcttagc cccagcgcg 1260
ctgactcaca ccccggcggc tcgctctgtc tcgcacctat gaggcacgcg cgcaccccaa 1320
cccattgtca cccacctct ccccgggcct gccggagagc gagccccgga gcggcagact 1380
ccgcgtcagg agggttcctc tcttagcagc cgccgcctag cggtagactg ctccccgggg 1440
agctgtccag ggtaccagag ggtcgccgag ggctgagtga ggagggttc ttcacacaga 1500
gacactagga ggaggaaaca gagtacaagg agaacgtatc caggagcaat tccacttcga 1560
atgattccta agtgaatgcc tacaggacag ttctcggtga ccatgtccag aacaggcata 1620
agtgacgac cccagtactt ccctgaggga ccacactggg accttggaac agaaccctgc 1680
atcagaacag gcctaaatgg ccatggctaa gaacacggct gagttgtcct tcaacagcaa 1740
tgccaatgcc aattcaccat gtccgagtgt tcacaagggt agtgccctcc accaccaccc 1800
agccatagaa tgtctagatg accaccatga cccccacct gatcagggtg taactgactt 1860
ccttcctcag gctgtaaact gatcattagg ttctgtggat cttagcccaa accagaaaat 1920
atthtgtccc caaactagtc ccatccctag aaaccttaaa ccaattctac ggcagataat 1980
aataatagct gccaaactttg tatcaagcac ctggcatggg ttaactgatt aaatattcac 2040
aacctatgaa gttgttacca ttaccctggc atcactttgc tgtcttaatt ctaatagtag 2100
ctagcattta ttgagtgcct gttttatggg agttatgcgc taatcacttg acatgcacta 2160
cctcatttat ctttgagat aggtattatt gtaatttcta atctacaggc agtgataaga 2220
agatttaaca aacatataca cagtaactgg cagagctggg attaaaccg ggcagtcttg 2280
actccaagat tcaagctctt agttacagca ctttgcagct tcctaacttc ctttgaccat 2340
tattcatata attccatcct aggtcctct cctggatgta agctaatttg tctatgtctc 2400
ttctaaaatc tcacacctgg gactgcgcga ggaatttcag atatggattg aaaagttcaa 2460
caggactctc acctctcttt tgtaagttct atttctagta atgccaccta agactccatt 2520
atctttttct tgtggctata tcacactgct gacatctcaa acttgcagcc aagtaacatc 2580
tctaaatgtt tcttacaagt gctgctgatt aaggcacagc taccatatac tgtgcttgta 2640

cagtgggcct ttttggaccc aatgtgtagg tccttataga ttgacttga ttgcatttca 2700
 tcttgtctca tcagttcgct gccctagttt tttttaaatg tctatttgaa gtcaaaccac 2760
 gaggtagctt tcatttatcc aaaaagaaaa agtagaaaga ttgtatccca gctttaccct 2820
 ttattccagg tgtactttgg gcaagtggac cccctttaag cctcagggtc ctcagctgta 2880
 aaatgggacg ctatgattca ccttaaaagt ctctcaaagt ttagatgttg catgattcta 2940
 tgattccatt acccaaagca tgaaccactc acttggcatc atgtaatttc cacagttgat 3000
 cacaatttaa ttaattcctc attctaattg ttaataaaaa tgtcaaaaca aatataactta 3060
 aaggagttct tcttcttctt ttgggtgagg ggaagtgtct cactctgttg accatgctgg 3120
 catgcagtag tgcaatcata gctcatgctg cagcctccac ttctgggct caagggatcc 3180
 tcctgcctca gcctcctgag tagctaggac tacaggcatg tgccaccaca cctagctagt 3240
 tttttaattt tttgtagaga tgaagtctta ctgtgttgcc caagctggtc ttgaactcct 3300
 gagctcaagt gatcctcctg cctcagcttc ccaaagtgtc agaattacag acatgagcca 3360
 caatgcctgg cctggaagga gctcttatat atactttgaa caattattca catcatgaac 3420
 ctgctatttt tgtattccat tgttaaaatt acaaggttaa atgtggagtc atctgctgtg 3480
 atcagtacta tttcccttag aaaataaaac atgaatataa tgatttctca taattctgtg 3540
 cttggcttaa tttttaaata atttttaacc tttgaattca taaactgtga ta 3592

<210> 85
 <211> 2722
 <212> DNA
 <213> Homo sapiens A.2.F.67

<400> 85
 cgccgcccag gacactcggg cgcacacccg ccgcgctggc gtccccacc cccagcccaa 60
 acaaaagaca agccttgggg tcgtggcctc gctgggcccg ggcgccccga gccggccagg 120
 gcgcccctctg gggccagagc tccatggttt gcctaaggca tagcttcttg gcggtaggcc 180
 gcaagcggcg gggagacgcc aggcagggtc gggccgcca gaggtccgaa gatgcctcca 240
 gtcgcccgcc cggggaaggc gcgggcgacc tctgagtgtc ccggtaacgt gtgcctttgt 300
 tccccaaactc aggtgaaaat ctggtttcag aaaaaagat ccaagatcaa gaagatcatg 360
 aaaaacgggg agatgcccc ggagcacagt cccagctcca gcgacccaat ggcgtgtaac 420
 tcgcccagct ctccagcggg gtgggagccc cagggtcgt cccgctcgt cagccaccac 480
 cctcatgccc accctccgac ctccaaccag tccccagcgt ccagctacct ggagaactct 540
 gcacccctgg acacaagtgc agccagctca atcaattccc acctgccgcc gccgggctcc 600
 ttacagcacc cgctggcgct ggcctccggg aactctatt agatgggctg ctctctctta 660
 ctctcttttt tgggactact gtgttttgct gttctagaaa atcataaaga aaggaattca 720
 tatggggaag ttcggaaaac tgaaaaagat tcattgtgta agcttttttt tgcattgtaag 780
 ttattgcatt tcaaaagacc cccctttttt ttacagagga ctttttttgc gcaactgtgg 840

```

acactttcaa tgggtgccttg aaatctatga cctcaacttt tcaaaagact tttttcaatg      900
ttattttagc catgtaaata agtgtagata gaggaattaa actgtatatatt ctggataaat      960
aaaattattht cgaccatgaa aagcggaatg tttctgaaaa atacttcatt ctgcccctct      1020
gataactggc tagtgaagtt ttattgaagg caactaaaga aggacaagct ctgcagagat      1080
ccaacaaggc aaaaaagaaa acagaagtcg gggctctatg catgcagact gtatatgtat      1140
atatgttcaa tgctatactt tgtgtgtgtg tgtgcatata tatatataat atatatggca      1200
tgtttatagt actgccatat ctcataattg tttcaggtag aaagtaatgc tgaaataaaa      1260
atacatccct ctccacctgt atgtgagtta gaaggcaaca gaaatccctc aataaccctt      1320
ctgaattcta agctcaaagc aattatcttg gagaagcgcc cccacccatc agcctctgtg      1380
tagtgccaga gcaattagac aaattaccct tcaaaggag tttccagaga tgagaaaatg      1440
aaaaagaaat ctagcctcac acctattaca ttttttaaaa atctaaaatg tttggagcat      1500
ggcaaatgat agaaccttg actctttgga gtatgattat aaatgtatcg gctcttttcg      1560
agagatgaaa acattgcaga tattgtgaag agggaaacttc agggttgggg aaaggaagga      1620
atgaaagcat tgtggcgccg tgttgatttc attttgtgtg agataatact cttaatattht      1680
cccttcccgc cttcctthtt tcaggaagga gcttctctg ttttgcttht acataaaaaca      1740
gtggcaaaca ggttctaaat gatgcaaaat agaactctgt tactaggatt tctcctttgg      1800
gaagccttct ttgggacaga gaggaaggac ttgctgcagc tgtgccctgt gtcccttctt      1860
tcttcttgca ctctgcatg tagataccaa cagcatgacc agagctatgc actgcaccta      1920
aagaccagc cctgaattgt aggtgtctth ctgtctggcc gtccttcagt gggccagact      1980
ctctthcctt aggatacgaa ggaaaatgtt gggttggaaa ttacaagatg catgtgaaat      2040
atthtacagc taggaagtca gcagcaataa atgtgacaaa agagccttct taaagtgggg      2100
gtagattaga gcataaaaaa ttatatcctg tcaactgagga tttctcagaa ggctcttcca      2160
gggttgggag actagacctg aaaaggcacg ctatgtgcct tgaggggaat ttaccttacc      2220
tacatgttht tctctctgtc tctctctctt ctctctctct tctctcttht tctctcattht      2280
tctctgtctc tctgcctgcc tctctctctt ctctctctcc tactctctt ccacctctt      2340
tattththt gttctcttht cctthtactth tthtctagaa gagttaccag gcccgccagt      2400
gtggaacagc ttgcttcttg gaggaatcag tattthtgacc gctctthtaga catatcccgc      2460
agcctggctc cgaggcagaa ctacgcccgg cagcctggcc tgtgcacccc tctctcggca      2520
ccccagcgg ccgagactca atatthcctg ctccccagtc cgctccagcc gtactthtctc      2580
ggaaggagca ctgggtgcgg ggaagagggg gcaataggaa ggtthtgagg gggcgggggg      2640
gggggcggga agccaaaggg tgccccatth tgtthtctgc gctcacagag aataggggga      2700
ttggggaaga gatgaagata tc      2722

```

<210> 86
 <211> 3366
 <212> DNA
 <213> Homo sapiens A.3.F.38

<400> 86
 ggcgcgccctc cagttccaag gccgagctca ctttcaacag ctctggaaat atgaatgtat 60
 ttttcccccc tttagaagaa gctatacgag gaacaacttt ttgaaatcgg gagtgtgttt 120
 gtagagaagg agataaggat tgcatttcgc ttatttttct acaggtgata gaagtgtttt 180
 gggggtcaga gtatcctctc aaggaaaatg taaaacgtgg gggctcgcat tctctatcta 240
 agcctttgta agtttaatta acaggaccct taaagtattc cttatagcta cagataaaaa 300
 attacaggca atgtttggat aaggggccaa ctctccgtgt ccaaactttt agagaactgc 360
 ctgtgagtgt acaccgttgt aatcttattg ggagcccttt gtcgaattct gtattttact 420
 ttgatgcttt ttgagtacca ttcccattgt ttgggtgtcc ttttaactccg tttacagcaa 480
 tatattaata aagaggatgc atatgtcagc gttatgtatc cacaagaatt tggattcctt 540
 taaaatcaaa cggcttggtg agcaggcaag cactcaaaac ccaacagtct caaacagcaa 600
 taataatgtc agcaaacggc tgccatgcct ctttttctcc aaatgctgtt tattctaaaa 660
 tcaataagtt aggagataca ttgcagagaa acagtcatta gtggttcagg gttggcaggt 720
 ttgtttttca ggtgtagatg ttcttgagta atacctctcc actgtggact aaatattagt 780
 agattgtcgt tgtcattttt ctaatttaat gcggcagcct cagggaaagta ctcatccaga 840
 caattatggg gtatcgattt ttaactttta gattaaaaaa ataccatatt tcacttgcct 900
 tgggactact tttcttgata aaaatatatc tgggaagatg attttagggc catgttagcg 960
 taggggaggg gaattaaggc acaaatggtg gttggttaag gaaattttat gaaagaaaat 1020
 aaagaaaaca tgtcagaata aatcaatcag aggcacaagt gagttagagg aatctgagga 1080
 caaccagcat cttggggatt cttctgttcc cgcggttctc agatatagga ataagggtct 1140
 gagttatgcc cagaatacat tcgtctggta ctggatgtcc cagtccctta gctgttccac 1200
 gtaatgaaga agctctaatt cccgagaact ttggggctta tttttaccat cattgagtct 1260
 gccagggctc agctctctta caaaggata aatctgaaat tcatgtatta atttgaatcc 1320
 ccaagatccg agttatgaga aagggcaagg gcaggctcta ctctatttt gtttactttc 1380
 accgagttac tgtgaagtga ttggaaactt tcttaacggg cagagagaga atacacggaa 1440
 actcggatgc agtaataaag ttgacatagg agtcggaaca gggggctctt tttggatctc 1500
 acctttactg gggcttgagg ttgtggaatg ggtggaagag taattaactg aatgaagaat 1560
 ttttaacgttg aaaacagagc ccacagtatt tttggttata gtggtgtggt ctctgcctcg 1620
 gcaaagaaac aaacaccccc acccatctt cgcagttctc ctctctgctg tagcgacgcc 1680
 aggcgctgct ttccgccggg taaattagcg gcgagcctcg ccagacgctt tcctccttgc 1740
 cttctttcgc cgaaaggggg cgcgctcctc ccaggctgcg ctggtacctt tcctgccttc 1800

```

aaaaatttct gggttcctgc aggacagaca gtaacaaaac gtgggaaata atagtttgat 1860
gacacttcag ggactatagg aatataaggt gcacacacat gcatcttaat ggaaacatgt 1920
agacacctgg caggagcatt ggctgcctgc ctctcctcct ttcaaatgag ggtgggtcggg 1980
gttccagggg ggcaggaggg gagtggggcc agatgaccgt ggatggaatt ggtgggtgct 2040
aggactgacg cctgggttcc atggcggagg agagggtttg tccccatgga gctgtgtgga 2100
cttttctgca tatgtacttg aggtcttcaa agaaagaagg gcagatctga gaaatggaga 2160
agtggctggg attagtgaga tgttgaaaaa ctgccacaga agccctcaca gtgcctggag 2220
tgtaagaca gaagagaaaa cctggcacca tagagtttta ggccctggga tcagggtaac 2280
ctttcctcct cacgaaagaa caataactgc cccaaatctt gtgtgagcct gcaacttggg 2340
tacctaaagc catttccaat ctgcaaactt gactcctggc ctccactgat cctccatttt 2400
tgggcaagag tttcaagaga ctcacaggac agatgaggat aaatttttaa ccccttctgt 2460
aaatttaggg attttcgact tcttaccact cctgacaat ggggggtcaac aaatcaaggc 2520
acggtgagag taacaaactg gaataatata tattttgtct tcatagcata gatgatgggt 2580
aatacatact ttccaagata atctgagctg gagtggtcac tagaaacagg agcacaaggc 2640
cagaactgta aggcaaattg ctttcccaca aacgtttgtc tgagaataag aacattcacc 2700
ccattcactt aatttctcat catcagtcac gtcattatat tttcaaggac ctcacagtgc 2760
tggaagtgg tgtagttata aataagcata aaaacagatg ggtgatccca gtcctctaaa 2820
tataatcggg gatgccaaat cttttcaaag agaattcata tatacaactt aaaggccaag 2880
gagcccaatt caatcaaaat ttgagccagg atatgctaag ttcaatcagc ttgaatatgg 2940
gcaaagtgta agacctagcc agcacttcag atatatacag agaaccacat tttctcaagt 3000
ttccattggt attttccaca caaatttagt gttagtcttc aaagggttg ttagatttgg 3060
tttgggccgg gaggggtggg agagtcagtg cccagggctc ctgtccttgt ctactcccct 3120
ttctttggta ctctctctgc ttcagcagtt tgccgaaaat ctgtgttgca gagaaaattg 3180
acacctagag gccacagagg tctcctaaat gctgttttct aggatcctca gaaaacaaga 3240
ggaccgctga gctcaattat atgtaatata cctggatatc ttatgtattt ttcttttctg 3300
ctaattcatt ttataatagc taagttagag acttcttgga gatttaggtt ttggggactg 3360
gatatc 3366

```

```

<210> 87
<211> 638
<212> DNA
<213> Homo sapiens A.4.D.30

```

```

<400> 87
ggcgcgcctc gcccgagatg cccctgcgtc cgctggcca ggcctggggg ttacccgacc 60
cgggttctcc cttcgctggc tttgcgcccc ttcacacctc tgcgggtggg acggagctgc 120
cgagacaagc agagtgcgaa ctggagaaag cccagagctc agagctccca ggagcccacc 180

```

gtgccccacg gctaggcggt ctcttggtgt ggacggctag cgggtgtcatt acttcttaca 240
 aaagtttatt ttgaaagct tctcccttcc ttctttcttc ccttcccttc ttttcttcct 300
 tttttctttg ttttgagtca ggttctcact ctgtcgccca ggcaggagcg cagtggcgct 360
 atctcagctc acggagcctc cacctattgg gctcaagcga tcctcccacc tcagcctccc 420
 gagtagctgg gaccacagtc gcacgccacc acgtccggct aattatTTTT tttcgTTTT 480
 cgtagagagg gagtgtcgtt atgtgcccc ggctggtttc aaactcctgg cctcaagcga 540
 tcctcccacc tccggcttcc caaagtgtg ggattcgggg tgtagccac tgtcccgga 600
 tacttctttt ttatcctgtc agaaaaacta tccatgtt 638

<210> 88
 <211> 1860
 <212> DNA
 <213> Homo sapiens A.4.D.36

<220>
 <221> n
 <222> (33)..(33)
 <223> a or g or c or t

<220>
 <221> n
 <222> (49)..(49)
 <223> a or g or c or t

<400> 88
 ggcgcgcctg tccccaccta atgccacgat ccnccccctcc cccaccctnc cgcactgcct 60
 cccttgccgcg tgtaggggag atccctgacc ttgtctgccc agctgcaggc cacttgccca 120
 ggcggccccct cccttggtgc cacctcccgc ccagctcacc aggagcgtgt gccctggtgc 180
 tactggcaac tgccctgtgc taaagctcag cccccaaact ggcttaatgc tgattgatgg 240
 tcagaaatag gatattttct ggaacagagc ggagcgctgg tgcaaggccc tctctgctgc 300
 tgagtcctag ggacctcccg ggtggcaggc ctctctctc ctctcctttt ggccccaccc 360
 accctacact acccctcaga gaccaacggg ctcttcggac atcctcatct caggttaagt 420
 gctgagccag caagccagtg ttcgctttct tgctgagtaa caggcagcca ccccggaatt 480
 tctctttctta tccttgaggc ttctgagttt tatgaatgag gcccggtgtg ctggacgcta 540
 ccacttccct ttttatcttc atccccacta acttgttcac tcgttctctc ctcttatac 600
 ataggtacct aaaatagact acccctctag taaccagaac tattcctgca aacgcttaca 660
 agagcatttt ccagaaataa atcatttcat atcagtatcc ctctctcagt catttcccg 720
 ctctcatgcca cctccctcct aagacacaga attgggtcatt tccaccactt taaagacaca 780
 gtctagataa aaagcctgca ttataatgt tctttgcagg agtagctttt gcctatcttg 840
 tggggggtttt gtttggtttt tgttttctgt ttgatactcc ctctcaaact gcagcctccc 900

ttcccttttc tgggatggca gcctccttct ctgagccatc ctggactaac attttctgga 960
 ctaataaatt tctgcacctg tctctactcc ttctccttcc cagtctgact gtaaaggacc 1020
 agatttcatt atcaaatcaa ttctcttttag aagaactttg ttctgtagca tttctttcca 1080
 ggaccccaat atttttggca gagtattttc attatttaaa ttgtcgtact tagcttcttt 1140
 ttgcctatgg acattacttt ggaaaaccat gtgatgtttc tgagtcactg atttgttcct 1200
 ccaaacaaaa cttccttcag aggcctccat atgttgggca ccattgtagg ccccgggggg 1260
 tgggaatgga gcaaagacaa gacccaaatg ggtttcagca ttttaaagcc cccattacag 1320
 ctggtttatg gttattgcta tgatggttaa tgtgataaca gcacactaca tttgactagg 1380
 actttacagt ttacaaaagg ctttcaaaga cattatctcc attaatccca gcagcaggaa 1440
 ttttaaatag caaggattcc accaaaaggc ccagtaatgc tcaccaatcc tgcttaacca 1500
 aaaagaaaaa tattgcaaatt catcctaaca gctgatggag ctttaaaaca cagaataaac 1560
 aattcataag aagcttctga agcttagtta ctggaatgta acttggagaa gataagtga 1620
 atgcacgtaa catgtatatt accagaaggg tgtcttggag agaaactcca tcctggggct 1680
 tcagtggcct ggtgaactgc tggaggtgga ggctttccag ggctctggac tattgcctta 1740
 tcctaggatc taaaatggga tgaaagtgtt agcacaaagt tgctgggaga ctagcaaatt 1800
 aagcaaaatg agtaggcaat gatgttactt tcttttagcta caaagcattc ttgagatatt 1860

<210> 89
 <211> 2107
 <212> DNA
 <213> Homo sapiens A.4.E.32

<400> 89
 ggcgcgccac aaggccgtgg tgctgcgctg ccacgctgtg ctgctggcgc ggcgcacaa 60
 ggcgcgcgcc ctggcccgcg tgctccgcca gaccgcgctg gcggccttca gcgacttcaa 120
 gcgcctgcag cgccagagcg acgcgcgcca cgtgcgccag cagcatctcc gcgctggggg 180
 cgccgcgcgc tcggtgcccc gcgccccact gcgcgcctg ctcaatgcca agtgcgccta 240
 ccggccgcgc ccgagcgagc gcagccgcgg ggcgcgcgc ctcagcagca tccatgagga 300
 ggacgaggag gaggaggagg acgacgcgga ggagcaagag ggaggagtcc cccagcgcca 360
 gcggccggag gtgctcagcc tggcccgga gctgaggacg tgcagcctgc ggggcgcccc 420
 ggcgcccccg ccgcccgcgc agccccgcgc ctggaaggcc ggccccaggg agcgggcggg 480
 ccaggcgcgc tgagagccga aggacaggac tcgcagcccc aggcccgacc cgccagactc 540
 acagcctcca accccggccc tgcccgttcc ggctgccccg gccccggccc cgtgtctccc 600
 ccgtgggtctc cgtgttgtcc gccccgcgc ctcatcttgg ctcaagggtga tgcctgatac 660
 gcccttggtt attggggggg gttcctctct cccacacccc ggagtttccc gggcctgcca 720
 ttgtggaccc gcccctatg ctttacacct agtctctttg cccacagacc tcctcattcc 780
 ctcccaaac atcctctcaa gagaaggag gagaagtctc aagaaatcag gaggggtggg 840

```

tttggaccct gggcaggggtg gaggcagtga ccttgccctt ggtccctcta gccttcttcc 900
ctgtgcaaaa aaaaatgacc ctggagaggc attctttag tagcggccgg 960
ggagaattgg ggccggggccg gcggtgggca gagtccgctg ctatacacac agggaggaat 1020
tctcacgccc aagccccgcc tctctacgcc ttggaggact cctgtgactt cactgctctg 1080
cctctggaga aactggggag agtcctaccg acgttcaaac aacagggttag gccaggtaac 1140
agccctgcac caggccgctg cccacgcctc tgccctggca ccccagggg attccttgcc 1200
catcccatct ctctgcagac ggatgtgtgt ggccccctcc taggtgcccc acaaccagga 1260
ccaagatggg gctcccaaag gaggtaagga gaacctttgg cagggtgctta ggacactgac 1320
tacctagaaa gtagacgcag cagagttgct cccaagtcga ggctcctcag agcagggtggg 1380
tcctgacagc agtggattct cccagcagga tgaggaagga ggggtgtgtta accaaccaag 1440
ggagtggggc cccacccag gtgtctccgc aagaccacaa aaagcccaaa gatctatgtg 1500
tactgatca ttgtaaataa agtggacctg cttttacagc cctgtcacta ctctgtgtt 1560
gtgtttaatg ccaggcctgc tgggggtgaa aaaatggatt gaagatcaga taagccacag 1620
gtgagcctgt atagctcccc ctggttacca tcagaaacct gaaagtagtt cttttgagca 1680
gccagagcca accccaggat taggacggga tctggggact gctgccagga agctgttcct 1740
taatgtcaga gaaggaggca gtaacttatg ccttgtctga aaatcacatg tgccaggctc 1800
cctggaggga cgtcggctgt ctgtctcagc ctcccaggat gtctgtacgc ctgggcactc 1860
agatgcagggt gtctgggaca tttggcaggg agggagcact gggctggggg cttctcataa 1920
gcatgtattc atatctctga gaaggttcat gtgtatttca gagcatatgg tatagactgt 1980
gtgtgtgctc tcagggatga gtgcgagcag gttgtaagag aatgtgggtga gcagcccagt 2040
tttctttcag aggctctgga aaaacctgtc cagaccctgt ggcagtgtga gtcttcagct 2100
ggatatc 2107

```

```

<210> 90
<211> 498
<212> DNA
<213> Homo sapiens A.5.E.28

```

```

<400> 90
ggcgcgccgg agttcgggct gccggctcct tagccgcggg gcgggggaga cgctcgggga 60
aggggagagg cgcgggcggg tgggaacggg cgggagacga gcggggacgg ggagacgcgc 120
cggaggcccc gagcccgcgc atgctcagtg cgcggccgga ggaggcgagc gctggggacg 180
cagcacctgc cccgcgcggc cgagaggcgg cagccccagg tccccagcgc gcgaaattag 240
taaagggcgc ctggccccgat tctcaggcaa gaggagatta tcagccggat tcccgtagcg 300
ggacgtaggg gttgcgttgt tcagcggcca gggatgcgcc gaggcgatgt ctctccctt 360
tacaaccgga gtatcggggc acgaggaggc gcgaccttcc tgggtaccca aacctctggc 420

```

WO 02/060318

PCT/US02/03077

ctccgggaga cgcggaattc gggggatcgt taaggcgccc tggccaggga aacagatgct 480
tctgcgtctg ggctgaaa 498

CLAIMS

What is claimed is:

1. A method of identifying CpG islands which are preferentially methylated in malignant cells contained within a tumor or neoplasm, comprising:
 - 5 a) digesting genomic DNA obtained from the malignant cells with an infrequently-cutting, methylation-sensitive, restriction enzyme to provide a set of malignant cell restriction fragments;
 - b) digesting genomic DNA obtained from non-malignant, control cells with an infrequently-cutting, methylation-sensitive, restriction enzyme to provide a set of control cell
10 restriction fragments;
 - c) attaching a detectable label to the ends of the malignant cell restriction fragments and the control restriction fragments;
 - d) digesting the labeled malignant cell and control cell restriction fragments with a second restriction enzyme;
 - 15 e) separating the labeled malignant cell restriction fragments and the labeled control cell restriction fragments, wherein the malignant cell restriction fragments and the control cell restriction fragments are separated by electrophoresis on two different gels;
 - f) digesting the restriction fragments in each of said gels with a third restriction enzyme;
 - 20 g) electrophoresing the restriction fragments in each of said gels in a direction perpendicular to the first direction to provide a first pattern of detectable malignant cell restriction fragments and a second pattern of detectable control cell restriction fragments; and
 - h) comparing the first pattern to the second pattern to identify diagnostic control
25 cell restriction fragments in said second pattern which are absent or exhibit a decreased intensity in the first pattern, wherein said diagnostic control cell restriction fragments comprise a CpG island that is unmethylated in the DNA of the control cells and methylated in the DNA of the malignant cells.
2. The method of claim 1 further comprising the step of determining the sequence of at
30 least a portion of a diagnostic control cell restriction fragment, wherein said portion is located at or near an end of the fragment.
3. The method of claim 1 further comprising the step of obtaining a clone from a DNA library which comprises a diagnostic control cell restriction fragment.
4. A method of preparing a polynucleotide or oligonucleotide for characterizing tissue

obtained from a subject suspected of having cancer, comprising:

synthesizing a polynucleotide or oligonucleotide which comprises a sequence which is identical to or substantially complementary to a target sequence on one of the strands of a diagnostic control fragment identified according to the method of claim 2, wherein said target sequence comprises at least two CpG dinucleotides, wherein said oligonucleotide is from 15 to 34 nucleotides in length, and wherein said polynucleotide is from 35 to 2000 nucleotides in length.

5. The method of claim 4 wherein said target sequence is located at or near the control restriction fragment end which was cleaved by the methylation-sensitive, restriction enzyme.

10 6. The method of claim 4 wherein the target sequence is located from about 100 nucleotides to about 500 nucleotides downstream of the control restriction fragment end that was cleaved by the methylation-sensitive, restriction enzyme.

7. The method of claim 4 wherein the control restriction fragment comprises a sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.:12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:15, SEQ. ID. NO.:16, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.:19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23, SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:26, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:39, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44, SEQ. ID. NO.:45, SEQ. ID. NO.:46, SEQ. ID. NO.:47, SEQ. ID. NO.:48, SEQ. ID. NO.:49, SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54, SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:57, SEQ. ID. NO.:58, SEQ. ID. NO.:59, SEQ. ID. NO.:60, SEQ. ID. NO.:61, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64, SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:68, SEQ. ID. NO.:69, SEQ. ID. NO.:70, SEQ. ID. NO.:71, SEQ. ID. NO.:72, SEQ. ID. NO.:73, SEQ. ID. NO.:74, SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79, SEQ. ID. NO.:80, SEQ. ID. NO.:81, SEQ. ID. NO.:82, SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID. NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93.

8. An isolated polynucleotide or oligonucleotide for characterizing cells that are obtained from a subject suspected of having a cancer which is associated with methylation of

one or a plurality of CpG islands in the genomic DNA of malignant cells, wherein said polynucleotide or oligonucleotide comprises a sequence which is identical to or complementary to a target sequence on one of the strands of a diagnostic control fragment identified according to the method of claim 2, wherein said target sequence comprises at least two CpG dinucleotides, wherein said oligonucleotide is from 15 to 34 nucleotides in length; and wherein said polynucleotide is from 35 to 3000 nucleotides in length.

9. The isolated polynucleotide or oligonucleotide of claim 8 wherein said target sequence is located at or near the control restriction fragment end which was cleaved by the methylation sensitive restriction enzyme.

10. The isolated polynucleotide or oligonucleotide of claim 8 wherein the target sequence is located from about 100 nucleotides to about 500 nucleotides downstream of the control restriction fragment end that was cleaved by the methylation-sensitive, restriction enzyme.

11. An isolated polynucleotide or oligonucleotide for characterizing cells which are obtained from a subject suspected of having a cancer which is associated with methylation of one or a plurality of CpG islands in the genomic DNA of malignant cells, wherein said polynucleotide or oligonucleotide comprises a sequence which is identical to or complementary to a modified target sequence on one of the strands of a diagnostic control fragment identified according to the method of claim 2, wherein said modified target sequence is derived from a target sequence that has been modified by treatment with sodium bisulfite, wherein said modified target sequence lacks cytosines and comprises at least two UpG dinucleotides, wherein said oligonucleotide is from 15 to 34 nucleotides in length; and wherein said polynucleotide is from 35 to 3000 nucleotides in length.

12. The isolated polynucleotide or oligonucleotide of claim 11 wherein the modified target sequence is derived from a target sequence located at or near the control restriction fragment end that was cleaved by the methylation sensitive restriction enzyme.

13. The isolated polynucleotide or oligonucleotide of claim 11 wherein the modified target sequence is derived from a target sequence that is located from about 100 nucleotides to about 500 nucleotides downstream of the control restriction fragment end that was cleaved by the methylation-sensitive restriction enzyme.

14. An isolated polynucleotide for characterizing cells which are obtained from a subject suspected of having a cancer selected from the group consisting of glioma, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, breast cancer, colon cancer, head and neck cancer, testicular cancer and lung cancer; wherein said polynucleotide is from 35 to

3000 nucleotides in length and comprises at least two CpG dinucleotides, and wherein said polynucleotide comprise a sequence which is identical to or complementary to a target sequence located within a sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.:12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:15, SEQ. ID. NO.:16, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.:19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23, SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:26, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:39, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44, SEQ. ID. NO.:45, SEQ. ID. NO.:46, SEQ. ID. NO.:47, SEQ. ID. NO.:48, SEQ. ID. NO.:49, SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54, SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:57, SEQ. ID. NO.:58, SEQ. ID. NO.:59, SEQ. ID. NO.:60, SEQ. ID. NO.:61, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64, SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:68, SEQ. ID. NO.:69, SEQ. ID. NO.:70, SEQ. ID. NO.:71, SEQ. ID. NO.:72, SEQ. ID. NO.:73, SEQ. ID. NO.:74, SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79, SEQ. ID. NO.:80, SEQ. ID. NO.:81, SEQ. ID. NO.:82, SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID. NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93.

15. The isolated polynucleotide of claim 14 wherein said subject is suspected of having glioma and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within SEQ. ID.NO. 78, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:22, SEQ ID NO:82, SEQ ID NO:27, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:72, SEQ ID NO:70, SEQ ID NO:26, SEQ ID NO:54, or SEQ ID NO:69.

16. The isolated polynucleotide of claim 14 wherein said subject is suspected of having acute myeloid leukemia and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within SEQ ID NO:10, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:58, SEQ ID NO:73, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:56, SEQ ID NO:68, SEQ ID

NO:76, SEQ ID NO:17, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:26, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:72, SEQ ID NO:16, SEQ ID NO:55, SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:70.

17. The isolated polynucleotide of claim 14 wherein said subject is suspected of having a primitive neuroectodermal tumor of childhood and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:4, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:72, SEQ ID NO:26, SEQ ID NO:15, SEQ ID NO:19, or SEQ ID NO:61.

18. The isolated polynucleotide of claim 14 wherein said subject is suspected of having breast cancer and said polynucleotide comprises a sequence identical or complementary to a target sequence which is located within SEQ ID NO:21, SEQ ID NO:28, SEQ ID NO:41, SEQ ID NO:80, SEQ ID NO:37, SEQ ID NO:63, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:22, SEQ ID NO:82, SEQ ID NO:12, SEQ ID NO:23, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:43, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:77.

19. The isolated polynucleotide of claim 14 wherein said subject is suspected of having colon cancer and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within SEQ ID NO:11, SEQ ID NO:40, SEQ ID NO:74, SEQ ID NO:81, SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:76, SEQ ID NO:17, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:37, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:27, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, or SEQ ID NO:46.

20. The isolated polynucleotide of claim 14 wherein said subject is suspected of head and neck cancer and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within in SEQ ID NO:1, SEQ ID NO. 79, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:76, SEQ ID NO:8, or SEQ ID NO:13.

21. The isolated polynucleotide of claim 14 wherein said subject is suspected of testicular cancer and said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located within in SEQ ID NO. 29, SEQ ID NO:33, SEQ

ID NO:56, SEQ ID NO:68, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:70, SEQ ID NO:54, or SEQ ID NO:69

22. The isolated polynucleotide of claim 14 wherein said subject is suspected of having a lung cancer and said polynucleotide comprises a sequence which is identical to or
5 complementary to a target sequence located within SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID. NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93.

23. An isolated CpG diagnostic oligonucleotide for characterizing cells which are obtained from a subject suspected of having a cancer selected from the group consisting of
10 glioma, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, breast cancer, colon cancer, head and neck cancer, testicular cancer and lung cancer; wherein said oligonucleotide is from 15 to 34 nucleotides in length and comprises at least two CpG dinucleotides, and wherein said oligonucleotide comprise a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 of
15 a sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.: 12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:15, SEQ. ID. NO.: 16, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.: 19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23,
20 SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:26, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:39, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44, SEQ. ID. NO.:45, SEQ. ID. NO.:46, SEQ. ID. NO.:47, SEQ. ID. NO.:48,
25 SEQ. ID. NO.:49, SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54, SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:57, SEQ. ID. NO.:58, SEQ. ID. NO.:59, SEQ. ID. NO.:60, SEQ. ID. NO.:61, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64, SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:68, SEQ. ID. NO.:69, SEQ. ID. NO.:70, SEQ. ID. NO.:71, SEQ. ID. NO.:72, SEQ. ID. NO.:73,
30 SEQ. ID. NO.:74, SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79, SEQ. ID. NO.:80, SEQ. ID. NO.:81, SEQ. ID. NO.:82; SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID. NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93; or a sequence which is the reverse complement of a target sequence located in a region

extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

24. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having glioma and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 in SEQ ID 78,
5 SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:22, SEQ ID NO:82, SEQ ID NO:27, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:72, SEQ ID NO:70, SEQ ID NO:26, SEQ ID NO:54, or SEQ ID NO:69, or said oligonucleotide comprises a sequence which is the reverse
10 complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

25. The isolated oligonucleotide of claim 23 wherein the subject is suspected of having acute myeloid leukemia; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99
15 SEQ ID NO:10, SEQ ID NO:44, SEQ ID NO:48, SEQ ID NO:58, SEQ ID NO:73, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:33, SEQ ID NO:56, SEQ ID NO:68, SEQ ID NO:76, SEQ ID NO:17, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:26, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59,
20 SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:20, SEQ ID NO:30, SEQ ID NO:45, SEQ ID NO:72, SEQ ID NO:16, SEQ ID NO:55, SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:70, or said oligonucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

26. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having primitive neuroectodermal tumors of childhood; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 of SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:50, SEQ ID NO:9, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:37, SEQ ID NO:4, SEQ ID NO:36,
30 SEQ ID NO:46, SEQ ID NO:72, SEQ ID NO:26, SEQ ID NO:15, SEQ ID NO:19, or SEQ ID NO:61, or said nucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

27. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having

breast cancer; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 of SEQ ID NO:21, SEQ ID NO:28, SEQ ID NO:41, SEQ ID NO:80, SEQ ID NO:37, SEQ ID NO:63, SEQ ID NO:71, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:22, SEQ ID NO:82, SEQ ID NO:12, SEQ ID NO:23, SEQ ID NO:31, SEQ ID NO:34, SEQ ID NO:43, SEQ ID NO:60, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:77, or said oligonucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

28. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having colon cancer; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 of SEQ ID NO:11, SEQ ID NO:40, SEQ ID NO:74, SEQ ID NO:81, SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:76, SEQ ID NO:17, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:37, SEQ ID NO:75, SEQ ID NO:18, SEQ ID NO:4, SEQ ID NO:27, SEQ ID NO:38, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:59, SEQ ID NO:36, SEQ ID NO:46 or said oligonucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

29. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having head and neck cancer; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 in SEQ ID NO:1, SEQ ID NO. 79, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:62, SEQ ID NO:76, SEQ ID NO:8, or SEQ ID NO:13., or said nucleotide a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

30. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having testicular cancer; and said oligonucleotide comprises a sequence which is identical to a target sequence located within a region extending from nucleotide 1 through nucleotide 99 in SEQ ID NO. 29, SEQ ID NO:33, SEQ ID NO:56, SEQ ID NO:68, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:70, SEQ ID NO:54, or SEQ ID NO:69, or said oligonucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

31. The isolated oligonucleotide of claim 23 wherein said subject is suspected of having lung cancer; and said oligonucleotide comprises a sequence which is identical to a target

sequence located within a region extending from nucleotide 1 through nucleotide 99 of SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, and SEQ ID NO: 93, or said oligonucleotide comprises a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

32. A method for determining whether cells obtained from a subject suspected of having a cancer are malignant or non-malignant, comprising:

- a) digesting DNA which has been isolated from the cells with a methylation-sensitive restriction enzyme to provide a set of restriction fragments;
- b) hybridizing said restriction fragments with a CpG diagnostic polynucleotide comprising a sequence which is identical to or complementary to a target sequence on one of the strands of a diagnostic control fragment identified according to the method of claim 2, wherein said method employed said methylation-sensitive restriction enzyme, wherein said target sequence comprises at least two CpG dinucleotides, wherein said polynucleotide is from 35 to 3000 nucleotides in length, and wherein said reaction is conducted under stringent hybridization conditions; and
- c) assaying the reaction products of step b to determine the size or the sequence of the restriction fragment to which the CpG diagnostic polynucleotide has hybridized.

33. The method of claim 32 wherein said subject is suspected of having a cancer selected from the group consisting of glioma, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, breast cancer, colon cancer, head and neck cancer, and testicular cancer;

wherein said DNA sample is digested with NotI; and wherein said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located in SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.:12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:15, SEQ. ID. NO.:16, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.:19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23, SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:26, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:39, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44,

SEQ. ID. NO.:45, SEQ. ID. NO.:46, SEQ. ID. NO.:47, SEQ. ID. NO.:48, SEQ. ID. NO.:49,
 SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54,
 SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:57, SEQ. ID. NO.:58, SEQ. ID. NO.:59,
 SEQ. ID. NO.:60, SEQ. ID. NO.:61, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64,
 5 SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:68, SEQ. ID. NO.:69,
 SEQ. ID. NO.:70, SEQ. ID. NO.:71, SEQ. ID. NO.:72, SEQ. ID. NO.:73, SEQ. ID. NO.:74,
 SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79,
 SEQ. ID. NO.:80, SEQ. ID. NO.:81, and SEQ. ID. NO.:82.

34. The method of claim 32 wherein the subject is suspected of having lung cancer;
 10 wherein the DNA is digested with *AscI*;

and wherein said polynucleotide comprises a sequence which is identical to or
 complementary to a target sequence located in , SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID.
 NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID.
 NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93.

15 35. A method of determining whether cells contained within a tissue sample obtained
 from a subject suspected of having cancer are malignant, comprising:

a) treating DNA isolated from the tissue sample with a compound which
 converts non-methylated cytosines to a different nucleotide base;

b) reacting a portion of the treated DNA with a CpG diagnostic oligonucleotide
 20 which is complementary to a target sequence which comprises CpG islands that are
 preferentially methylated in malignant cells of subjects known to have said cancer;

c) reacting a portion of the treated DNA with a modified CpG diagnostic
 oligonucleotide which is complementary to a modified target sequence in which the cytosines
 in said target sequence are replaced with the different nucleotide base; and

25 d) assaying the reaction products of step b and step c to determine whether the
 treated DNA has hybridized with the CpG diagnostic oligonucleotide or the modified CpG
 diagnostic oligonucleotide; wherein hybridization of the treated DNA with the CpG
 diagnostic oligonucleotide as opposed to the modified CpG diagnostic oligonucleotide
 indicates that the DNA has been obtained from malignant cells.

30 36. The method of claim 35 wherein the chemical compound is sodium bisulfite and the
 non-methylated cytosines are converted to uracil.

37. The method of claim 35 wherein the assay is a polymerase chain reaction,
 wherein a portion of the treated DNA is reacted with a first primer set which
 comprises two diagnostic CpG oligonucleotides; and

wherein a portion of the treated DNA is reacted with a second primer set which comprises two modified diagnostic CpG oligonucleotides.

38. The method of claim 35 wherein the subject is suspected of having a cancer selected from the group consisting of glioma, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, breast cancer, colon cancer, head and neck cancer, testicular cancer and lung cancer; and

wherein the CpG diagnostic oligonucleotide comprises a sequence which is identical to a target sequence located between nucleotide 1 and 100 in a sequence selected from the group consisting said polynucleotide comprises a sequence which is identical to or complementary to a target sequence located in SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.:12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:15, SEQ. ID. NO.:16, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.:19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23, SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:26, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:39, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44, SEQ. ID. NO.:45, SEQ. ID. NO.:46, SEQ. ID. NO.:47, SEQ. ID. NO.:48, SEQ. ID. NO.:49, SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54, SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:57, SEQ. ID. NO.:58, SEQ. ID. NO.:59, SEQ. ID. NO.:60, SEQ. ID. NO.:61, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64, SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:68, SEQ. ID. NO.:69, SEQ. ID. NO.:70, SEQ. ID. NO.:71, SEQ. ID. NO.:72, SEQ. ID. NO.:73, SEQ. ID. NO.:74, SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79, SEQ. ID. NO.:80, SEQ. ID. NO.:81, SEQ. ID. NO.:82, SEQ ID NO: 83, SEQ ID NO. 84, SEQ ID. NO. 85, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93; or a sequence which is the reverse complement of a target sequence located in a region extending from about nucleotide 100 through nucleotide 500 in said SEQ ID NO.

39. An isolated polynucleotide for characterizing cells which are obtained from a subject suspected of having a cancer selected from the group consisting of glioma, acute myeloid leukemia, primitive neuroectodermal tumors of childhood, breast cancer, colon cancer, head and neck cancer, testicular cancer and lung cancer; wherein said polynucleotide is from 35 to

1000 nucleotides in length and comprises at least two CpG dinucleotides, and wherein said polynucleotide comprise a sequence which is identical to or complementary to a target sequence which originates between nucleotide 1 and nucleotide 15 of SEQ. ID. NO.:1, SEQ. ID. NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:5, SEQ. ID. NO.:6, SEQ. ID. NO.:7, SEQ. ID. NO.:8, SEQ. ID. NO.:9, SEQ. ID. NO.:10, SEQ. ID. NO.:11, SEQ. ID. NO.:12, SEQ. ID. NO.:13, SEQ. ID. NO.:14, SEQ. ID. NO.:17, SEQ. ID. NO.:18, SEQ. ID. NO.:19, SEQ. ID. NO.:20, SEQ. ID. NO.:21, SEQ. ID. NO.:22, SEQ. ID. NO.:23, SEQ. ID. NO.:24, SEQ. ID. NO.:25, SEQ. ID. NO.:27, SEQ. ID. NO.:28, SEQ. ID. NO.:29, SEQ. ID. NO.:30, SEQ. ID. NO.:31, SEQ. ID. NO.:32, SEQ. ID. NO.:33, SEQ. ID. NO.:34, SEQ. ID. NO.:35, SEQ. ID. NO.:36, SEQ. ID. NO.:37, SEQ. ID. NO.:38, SEQ. ID. NO.:40, SEQ. ID. NO.:41, SEQ. ID. NO.:42, SEQ. ID. NO.:43, SEQ. ID. NO.:44, SEQ. ID. NO.:45, SEQ. ID. NO.:47, SEQ. ID. NO.:48, SEQ. ID. NO.:49, SEQ. ID. NO.:50, SEQ. ID. NO.:51, SEQ. ID. NO.:52, SEQ. ID. NO.:53, SEQ. ID. NO.:54, SEQ. ID. NO.:55, SEQ. ID. NO.:56, SEQ. ID. NO.:58, SEQ. ID. NO.:60, SEQ. ID. NO.:62, , SEQ. ID. NO.:63, SEQ. ID. NO.:64, SEQ. ID. NO.:65, SEQ. ID. NO.:66, SEQ. ID. NO.:67, SEQ. ID. NO.:69, SEQ. ID. NO.:70, SEQ. ID. NO.:72, SEQ. ID. NO.:73, , SEQ. ID. NO.:75, SEQ. ID. NO.:76, SEQ. ID. NO.:77, SEQ. ID. NO.:78, SEQ. ID. NO.:79, SEQ. ID. NO.:80, SEQ. ID. NO.:81, SEQ. ID. NO.:82, SEQ ID NO: 83, SEQ. ID. NO. 86, SEQ. ID. NO. 87, SEQ. ID. NO. 88, SEQ. ID. NO. 89, SEQ. ID. NO. 90, SEQ. ID. NO. 91, SEQ ID. NO. 92, and SEQ. ID. NO. 93.

RLGS




Fig. 1A




Fig. 1B

Section D2




Fig. 1C




Fig. 1D




Fig. 2A





Fig. 2B






Fig. 3




Fig. 4A




Fig. 4B